

# VANCOUVER

Sheraton Vancouver Wall Centre Hotel February 27 février – March 1 mars 2008

WHERE CANADA'S EXPERTS IN CLINICAL  
MICROBIOLOGY AND INFECTIOUS DISEASES MEET  
POINT DE RENCONTRE DES EXPERTS CANADIENS  
EN MICROBIOLOGIE MÉDICALE ET INFECTIOLOGIE



## Annual Conference 2008 Conférence annuelle

### Final Program Programme final

This educational event is approved as an Accredited Group Learning Activity, Section 1, as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

*Cette activité est une activité de formation collective agréée aux termes de la section 1 du programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada.*

# WELCOME BIENVENUE

Dear Colleagues,

It is our pleasure to welcome you to the AMMI Canada – CACMID Annual Conference 2008 in Vancouver, B.C.

The challenges faced by healthcare professionals in infectious diseases and medical microbiology today require members of this community to look at innovative trends in the diagnosis, prevention and control of infections. The past several years have brought new approaches and technologies to many aspects of clinical microbiology and infectious diseases.

Thanks to the collaborative efforts of the planning and scientific committees, the 2008 Annual Conference program will bring together the knowledge and skills of some of the most dedicated microbiology and infectious disease experts from across Canada and the US to share knowledge and build support for infectious disease diagnosis, treatment and care. To bring you the most important and relevant information, we have invited an expert Canadian and international faculty to address those issues within plenaries, symposia and workshops.

This year's program offers you cutting edge updates on new and emerging issues such as resistant tuberculosis, discussions on the recent trends and controversies in tick and mosquito-borne infections, as well as reviews related to longstanding issues of concern as the increased resistance of microbes to diverse therapeutics and antibiotic misuse. Also, we would encourage you to join us at this year's new state-of-the-art clinical session lectures where we will hear about current insights in our understanding of clinical treatment and management of infectious disease entities

As every year, this exciting event is made possible with the extraordinary and continuous support of our sponsors. Don't miss out on what's in the Exhibit Hall for you! Take a glimpse at the industry's innovative tools exhibited throughout our conference, there will always be a representative to answer your questions.

We hope this year's educational offerings, combined with our social activities program, and all what Vancouver city has to offer, will provide you with a memorable experience.



Michel Laverdière, MD  
President, AMMI Canada



Graham Tipples, PhD  
President, CACMID

Chers collègues,

Il nous fait plaisir de vous accueillir à la conférence annuelle de l'AMMI Canada - CACMID 2008 à Vancouver, C-B.

Les défis auxquels font face de nos jours les experts en infectiologie et en microbiologie médicale, exigent de se tourner vers des moyens innovateurs en matière de diagnostic, de prévention et de contrôle des infections. Au cours des dernières années, de nouvelles approches et des technologies d'avant-garde furent appliquées dans plusieurs domaines de la microbiologie clinique et de l'infectiologie.

C'est grâce aux efforts du comité de planification et au travail impressionnant du comité scientifique, que nous pouvons vous offrir à nouveau cette année, une conférence de grand calibre. Notre programme regroupe des infectiologues et des microbiologistes renommés au Canada et aux Etats-Unis, et vise à partager avec vous de nouvelles stratégies susceptibles de provoquer des bénéfices importants au niveau de la prévention, du diagnostic, et du traitement des infections. Cette conférence annuelle vous apportera les informations les plus récentes en infectiologie et en microbiologie clinique présentées par des experts canadiens et internationaux à l'occasion de nos différentes sessions plénières, de nos colloques et de nos ateliers.

Cette année, nous discuteront entre autre des plus récentes données au sujet de la résistance dans la tuberculose, ainsi que des tendances et polémiques actuelles dans les infections transmises par les moustiques et les tiques. L'on discutera de la résistance sans cesse croissante des microbes aux antibiotiques et de la mauvaise utilisation de ces derniers. En outre, nous vous encourageons cette année à participer aux nouvelles présentations cliniques, où l'on présentera des mises à jour en matière de traitement et de gestion de différentes infections.

Comme à chaque année, cet événement scientifique est rendu possible grâce au support extraordinaire et soutenu de nos commanditaires. Ne manquez pas de les visiter dans le hall d'exposition. Les différents représentants sont là pour répondre à vos questions.

Nous espérons que notre programme éducatif, que les activités sociales prévues au programme et que les charmes que vous offre la ville de Vancouver, feront de cette conférence l'une des plus mémorables.

Bonne conférence à tous!

# OBJECTIVES

THE 2008 ANNUAL CONFERENCE PROGRAM IS designed to address the needs of health care professionals specializing in the areas of clinical and medical microbiology and infectious diseases. The program includes a selection of symposia, plenary sessions, clinical vignettes and presentations, both in short oral and poster formats. New for 2008, "State of the Art Clinical" lectures that will address issues that are important in the practice of clinical infectious diseases. These formats will allow ample opportunity for presentation of innovative scientific research with practical applications on contemporary issues. In addition, this year's conference will provide delegates the chance to network, and to share current information and ideas.

## The 2008 Annual Conference offers an educational forum which will address:

- New findings from the research of basic microbiology related to human disease;
- Updates for medical professionals on diagnosis and therapeutics;
- The most recent trends in prevention and control of infections;
- New findings on pathogenesis and epidemiology of established and newly recognized microbes;
- Analysis of the increased resistance of pathogens to diverse therapeutics.

Dear Delegates and Exhibitors,

On behalf of Tourism Vancouver and our community, we would like to extend a warm West Coast welcome to all delegates attending the *AMMI Canada-CACMID Annual Conference 2008*. Vancouver is extremely proud and thrilled to be the host city for this prestigious conference. This is an exciting time for Vancouver as we move forward to host the 2010 Olympic and Paralympic Winter Games, and we are delighted that you will have an opportunity to share this time with us.

We hope that while attending the various symposiums and meetings during the conference, you are able to take a moment or two to enjoy what Vancouver has to offer. The Vancouver area is surrounded by some of the most stunning natural beauty in the world. Mountains. Ocean.

Rainforest. Parks. Beaches. This is a city like no other! With endless options for cuisine, activities, sights and attractions, Vancouver is a city to explore and you won't want to miss a thing. It doesn't matter what time of day or what time of year - whether you want to be indoors or out, active or a spectator - Vancouver has it all and it is just waiting for you!

Enjoy your visit.

Sincerely,



Rick Antonson  
President, CEO



# TABLE OF CONTENTS

<b>AMMI Canada Council 2007-2008</b>	<b>4</b>
<b>CACMID Board</b>	<b>5</b>
<b>Association and Committee Meetings</b>	<b>6</b>
<b>State of the Art Clinical Lectures</b>	<b>7</b>
<b>Special Lecture</b>	<b>8</b>
<b>Mini-Symposia</b>	<b>9</b>
<b>Social Activities</b>	<b>10</b>
<b>Educational Sessions</b>	<b>11</b>
<b>Poster Presentations</b>	<b>24</b>
<b>Authors Index</b>	<b>36</b>
<b>Gala Dinner</b>	<b>38</b>
<b>Speakers Bios</b>	<b>39</b>
<b>Invitation to 26th ICC</b>	<b>43</b>
<b>Discover Vancouver</b>	<b>44</b>
<b>Educational Grants</b>	<b>45</b>
<b>Floor Plans</b>	<b>46</b>
<b>Sponsors</b>	<b>OBC</b>

## CENTRAL PLANNING COMMITTEE

## COMITÉ DE PLANIFICATION

### AMMI CANADA

Michel Laverdière, MD  
President  
CPC Co-Chair  
Gerald Evans, MD FRCP  
President Elect

Susan Richardson,  
MD FRCP  
Past President  
Sponsorship Committee

Mark Joffe, MD FRCP  
Scientific Committee  
Co-Chair

Coleman Rotstein,  
MD FRCP FACP  
Sponsorship Committee  
Co-Chair

Baldwin Toye, MD FRCP  
Conference Treasurer

Richard McCoy, CAE  
Executive Director

Riccarda Galioto,  
Office Manager  
Special Events Coordinator

### CACMID

Graham Tipples,  
PhD FCCM D(ABMM)  
President  
CPC Co-Chair

Karam Ramotar, PhD  
Vice-President  
Scientific Committee  
Co-Chair  
Sponsorship Committee  
Co-Chair

Marc Desjardins,  
PhD D(ABMM) FCCM  
Sponsorship Committee

Astrid Petrich, PhD  
Conference Treasurer

Martin Petric, PhD FCCM  
Meeting Secretary

Tim Karnauchow, PhD  
Committee Member

# AMMI CANADA COUNCIL

## PRESIDENT

Michel Laverdière, MD  
Hôpital Maisonneuve –  
Rosemont  
Dépt. de microbiologie -  
Infectiologie  
Montréal, QC

## PRESIDENT – ELECT

Gerald Evans, MD FRCP  
Queen's University  
Medicine/Div. of Infectious  
Diseases  
Kingston, ON

## MEDICAL MICROBIOLOGY SECTION HEAD

Alicia Sarabia, MD FRCP  
Credit Valley Hospital  
Dept. of Laboratory Medicine  
Mississauga, ON

## INFECTIOUS DISEASE SECTION HEAD

Krystyna I. Ostrowska,  
MD FRCP  
Trillium Health Centre  
Mississauga, ON

## PAST PRESIDENT

Susan Richardson, MD FRCP  
The Hospital for Sick Children  
Microbiology  
Toronto, ON

## TREASURER

Baldwin Toye, MD FRCP  
Ottawa Hospital  
(General Campus)  
Division of Microbiology  
Ottawa, ON

## SECRETARY

Joanne Langley, MD FRCP  
IWK Health Centre  
Halifax, NS

## 2 – YEAR COUNCILLORS

Christina Greenaway,  
MD FRCP  
SMBD - Jewish General Hospital  
Division of Infectious  
Diseases/Microbiology  
Montréal, QC

Mel Krajden, MD FRCP  
BC Centre for Disease Control  
Laboratory Services  
Vancouver, BC

Karam Ramotar, PhD  
Ottawa Hospital  
(General Campus)  
Pathology and  
Laboratory Medicine  
Ottawa, ON

Stephen Sanche, MD FRCP  
Royal University Hospital  
Saskatoon, SK

Magdalena Kuhn, MD FRCP  
South-East Health Care Corp.  
Microbiology Lab.  
Moncton, NB

Lynora Saxinger, MD FRCP  
University of Alberta  
Division of Infectious Diseases  
Edmonton, AB

## EX-OFFICIO MEMBERS

Marcel Behr, MD FRCP  
Grants and Awards Committee  
Chair  
Montréal General Hospital  
Montréal, QC

Mark Joffe, MD FRCP  
Program Planning Committee  
Chair  
Royal Alexandra Hospital  
Edmonton, AB

Ray Saginur, MD FRCP  
CFID/FRID President  
Ottawa Hospital (Civic Campus)  
Division of Infectious Diseases  
Ottawa, ON

## IN ASSOCIATION WITH: AVEC LA COLLABORATION DE :



Canadian Society of Microbiologists  
*Société canadienne des  
microbiologistes*



Canadian College of Microbiologists  
*Collège canadien des microbiologistes*



Association of Medical Microbiologists  
of Ontario  
*Association des microbiologistes  
médicaux d'Ontario*



The Association of Microbiologists  
of Quebec  
*L'Association des microbiologistes  
du Québec*



Community and Hospital Infection  
Control Association – Canada  
*Association pour la prévention  
des infections à l'hôpital et dans  
la communauté – Canada*



British Columbia Association of  
Medical Microbiologists  
*Association des microbiologistes  
médicaux de la Colombie-  
Britannique*



L'Association des médecins  
microbiologistes infectiologues  
du Québec



International Society  
of Chemotherapy for  
Infection and Cancer



# CACMID BOARD

## PRESIDENT

Graham Tipples, PhD FCCM D(ABMM)  
Public Health Agency of Canada  
National Microbiology  
Laboratory  
Winnipeg, MB

## VICE PRESIDENT

Karam Ramotar, PhD  
Ottawa Hospital  
(General Campus)  
Pathology and  
Laboratory Medicine  
Ottawa, ON

## COUNCILLORS

Martin Petric, PhD FCCM  
BC Centre for Disease Control  
Laboratory Services  
Vancouver, BC

Kathryn Bernard  
Public Health Agency of Canada  
National Microbiology  
Laboratory  
Winnipeg, MB

Marc Desjardins, PhD  
The Ottawa Hospital  
(General Campus)  
Microbiology  
Ottawa, ON

Susan Poutanen, MD FRCP  
Mount Sinai Hospital  
Microbiology  
Toronto, ON

Tim Karnauchow, PhD  
Children's Hospital of Eastern  
Ontario & The Ottawa Hospital  
Clinical Microbiology  
Laboratory  
Ottawa, ON

Jeff Fuller, PhD FCCM  
University of Alberta Hospital  
Laboratory Medicine and  
Pathology  
Edmonton, AB

## PAST PRESIDENT

Margaret Fearon,  
MD FRCP  
Canadian Blood Services  
Medical Microbiology  
Toronto, ON

## SECRETARY TREASURER

Astrid Petrich, PhD FCCM  
St. Joseph's Hospital  
Lab Medicine  
Hamilton, ON

## INDUSTRY REPRESENTATIVE (EX OFFICIO)

Gerald Moore  
Med-Ox Diagnostics Inc.  
Stittsville, ON

## SCIENTIFIC COMMITTEE

## COMITÉ SCIENTIFIQUE

## AMMI CANADA

Mark Joffe, MD FRCP  
Co-Chair

Richard Lalonde,  
MD FRCP

Michel Laverdière, MD

Nicole Le Saux,  
MD FRCP

David Patrick, MD FRCP

Anita Rachlis, MD FRCP

Susan Richardson,  
MD FRCP

Marc Romney,  
MD FRCP

Alicia Sarabia, MD FRCP

Gary Victor, MB FRCP

## CACMID

Karam Ramotar, PhD  
Co-Chair

Margaret Fearon,  
MD FRCP

Tim Karnauchow, PhD

Martin Petric, PhD FCCM

Astrid Petrich, PhD

Susan Poutanen,  
MD MPH FRCP

Graham Tipples,  
PhD FCCM D(ABMM)

# AT YOUR SERVICE ....

Tourism Vancouver will be on site to offer a Concierge Service for the delegates and families of the AMMI Canada – CACMID Annual Conference. Well trained and knowledgeable staff will help you enjoy the perfect conference experience in the beautiful city of Vancouver and surrounding areas.

## Services include:

- helping you find the perfect restaurant
- helping you book a trip to a famous tourist attraction
- providing maps and vacation guides
- outlining great shopping, outdoor adventures for the whole family to enjoy



**TOURISM  
VANCOUVER**

## CONCIERGE SERVICE

Junior Ballroom Foyer – Level Three – North Tower

Wednesday, February 27 1400 – 1800

Thursday, February 28 1000 – 1400

Friday, February 29 1000 – 1400

TO FIND OUT WHAT VANCOUVER HOLDS IN STORE FOR YOU, VISIT TOURISM  
VANCOUVER AT: [WWW.TOURISMVANCOUVER.COM](http://WWW.TOURISMVANCOUVER.COM)



# ASSOCIATION & COMMITTEE MEETINGS

Our partners are encouraged to use our conference to hold a meeting. Logistics can be arranged by the conference secretariat at [manager@ammi.ca](mailto:manager@ammi.ca) or by calling 613-260-3233 ext 102.

## WEDNESDAY, FEBRUARY 27

- 0800 – 1700 **AMMI Canada Council Meeting**  
Port McNeill – Level Four  
*Chair: Dr. Michel Laverdière*
- 1230 – 1400 **CCM Executive Board Meeting**  
Port Alberni – Level Four  
*Chair: Dr. Martin Petric*
- 1700 – 1800 **Associate Committee Meeting\***  
Junior Ballroom C – Level Three  
*Chair: Dr. Jessica Minion*
- 1730 – 1830 **CACMID Board Meeting**  
Port Alberni – Level Four  
*Chair: Dr. Graham Tipples*
- 2000 – 2130 **ICC 2009 Programme Planning Committee**  
Port McNeill – Level Four  
*Chair: Dr. Mark Joffe*

## THURSDAY, FEBRUARY 28

- 1200 – 1400 **BCAMM Meeting**  
Gulf Island BC – Lower Lobby Level  
*Chair: Dr. Sylvie Champagne*
- 1200 – 1400 **CJIDMM Editorial Board Meeting**  
Parksville Room – Level Three  
*Chair: Dr. Lindsay Nicolle*
- 1530 – 1700 **Antimicrobial Resistance Committee Meeting\***  
Port Hardy – Level Four  
*Chair: Dr. Jim Hutchinson*
- 1700 – 1800 **CCM Annual General Meeting**  
Port Alberni – Level Four  
*Chair: Dr. Martin Petric*
- 1700 – 1800 **AMMI Canada Annual General Meeting and Sections Meeting**  
Port McNeill – Level Four  
*Chair: Dr. Michel Laverdière*

## FRIDAY, FEBRUARY 29

- 0630 – 0800 **CHEC Committee Meeting\***  
Port Alberni – Level Four  
*Co-Chairs: Drs. Elizabeth Bryce and Andrew Simor*
- 1200 – 1400 **RCPSC Specialty Committee in Medical Microbiology Meeting**  
Parksville Room – Level Three  
*Chair: Dr. Fiona Smaill*
- 1300 – 1400 **Guidelines Committee Meeting\***  
Port Hardy – Level Four  
*Chair: Dr. Gerald Evans*
- 1500–1630 **PICNIC Meeting**  
Parksville Room – Level Three  
*Chair: Dr. Upton Allen*
- 1630 – 1730 **OMA - ID Section Meeting**  
Parksville Room – Level Three  
*Chair: Dr. Gary Garber*
- 1630 – 1730 **CACMID Annual General Meeting**  
Port McNeill – Level Four  
*Chair: Dr. Graham Tipples*
- 1745 – 1845 **CFID - FRDID Board Meeting**  
Port Hardy – Level Four  
*Chair: Dr. Raphael Saginur*
- 1745 – 1900 **National Molecular Microbiology Diagnostic User Group Meeting**  
Port Alberni – Level Four  
*Chair: Dr. Astrid Petric*
- 1900 – 2030 **Encephalitis Collaborating User Group Meeting**  
Parksville Room – Level Three  
*Chair: Dr. Graham Tipples*

\* AMMI Canada Committee

# NEW – STATE OF THE ART CLINICAL LECTURES

OUR CONFERENCE CONTINUALLY ENDEAVOURS TO create new ways to fulfill the needs/interests of our varied membership. For the first time, there will be “State of the Art” clinical lectures to address issues that are important in the practice of clinical infectious diseases. They will be scheduled on all three days of the conference in the afternoons and will run concurrently with oral presentation of abstracts.

## THURSDAY, FEBRUARY 28

Port McNeill – Level Four

### 1400 – 1445 **Nosocomial UTI and Urosepsis – What Can We Improve?**

*Professor Kurt G. Naber*  
President, International Society of  
Chemotherapy (ISC)  
Associate Professor of Urology  
Technical University of Munich

### 1445 – 1530 **What To Do With What Lurks Beneath the Bandage: Science or Witchcraft?**

*John Embil, MD FRCPC*  
Associate Professor  
Department Internal Medicine  
Infectious Diseases and Medical Microbiology  
University of Manitoba

## FRIDAY, FEBRUARY 29

Port McNeill – Level Four

### 1400 – 1500 **Respiratory Infections in the Elderly: Current Insights and Recent Twists in our Understanding of Prevention**

*Mark Loeb, MD MSc FRCPC*  
Professor, McMaster University

Royal College of Physicians and  
Surgeons of Canada Gold Medal  
Award in Medicine (2006)



## SATURDAY, MARCH 1

Port McNeill – Level Four

### 1400 – 1500 **Non-Traditional Pulmonary Infections in Cystic Fibrosis: Not Just the Usual Suspects**

*Jane L. Burns, MD*  
Professor, Department of Pediatrics  
University of Washington, School of Medicine  
Division of Infectious Diseases,  
Immunology and Rheumatology  
Clinical Director, Infectious Diseases  
Children's Hospital and Regional  
Medical Center

## Awards Presentation

**Saturday, March 1**

**Pavilion Ballroom, Level Three**

Following this year's Special Lecture which starts at 1515

Come celebrate Microbiology's and Infectious Disease's best and brightest at our Awards Presentation. Featuring awards for excellence in student research, as well as recognizing those who have made a significant contribution in the fields of medical microbiology and/or infectious disease.

This year's presentation ceremony will include:

### AMMI CANADA AWARDS:

#### **Dr. Juan A. Embil Award for Excellence in Infectious Diseases Research Award**

#### **CJIDMM Trainee Review Article Award**

#### **Distinguished Service Award**

#### **Lifetime Achievement Award**

### OTHER AWARDS:

#### **Dr. Lindsay E. Nicolle Editorial Award**

#### **Canadian College of Microbiologists (CCM) Distinguished Service Award**

#### **Student Poster Awards**





## AMMI CANADA – CACMID SPECIAL LECTURE

### TAKING CHARGE OF YOUR HEALTH: WHY LIFESTYLE MATTERS

Saturday, March 1  
1515 – 1600  
Pavilion Ballroom – Level Three

#### DR. ART HISTER

##### Canada's Full-time Media Doctor

- Accomplished radio, television and live host, moderator and speaker
- Authored *Midlife Man* and *Art Hister's Do-It-Yourself-Guide to Your Health* as well as numerous articles for publications.
- Knowledgeable on a variety of medical topics

Sponsored by



Family physician, Dr. Art Hister gave up his practice in 1991 to become a full-time “media doctor.” Dr. Hister currently hosts the call-in show *House Calls with Dr. Art Hister*, heard across Western Canada. Over the years, Dr. Art Hister has become an expert on providing a human and humorous face to the mysteries of medical science and the health industry. Combining humour, common sense and plain language, he helps to make the often frightening and confusing world of medicine understandable to all and accessible to everyone.

**JOIN DR. ART HISTER'S SPECIAL LECTURE TO DEBUNK SOME OF THE MEDICAL MYTHS, AND GET HIS OPINION ON WHAT 'MAKES SENSE' TO LIVE A HEALTHY LIFESTYLE.**

## Meet and Greet Reception

Join all of your colleagues  
for a great opportunity to  
catch-up over a drink and  
great conversation.

**Date:** Wednesday, February 27, 2008  
1830 – 2000

**Location:** Pavilion Ballroom

*Refreshments and hors-d'oeuvres will be served*



# MINI – SYMPOSIA

## THURSDAY, FEBRUARY 28

Pavilion Ballroom – Level Three

### 1200 – 1400 **New Developments in treatment of HIV and Fungal infections**

Lunch will be served

Hosted by Pfizer Canada

*Chair:* Dr. Marc Romney

*Speaker:* Dr. Brian Conway

Dr. Coleman Rotstein

### **New Agents in the Battle Against Candidemia/Invasive Candidiasis**

*Chair/*

*Speaker:* Dr. Coleman Rotstein

### 1830 – 2030 **The Next Stages in Vaccine Design and Application**

Dinner will be served

Hosted by GlaxoSmithKline

*Chair:* Dr. David Scheifele

*Speakers:* Dr. Ripley Ballou

Dr. Shelly McNeill

Dr. Francisco Diaz-Mitoma

## FRIDAY, FEBRUARY 29

Pavilion Ballroom – Level Three

### 1200 – 1400 **Invasive Fungal Infections – Emerging Trends, Future Direction**

Lunch will be served

Hosted by Schering-Plough

*Co-Chairs:* Dr. Michel Laverdière

Dr. Coleman Rotstein

*Speakers:* Dr. Deepali Kumar

Dr. Michel Laverdière

Dr. Donald Sheppard

Dr. Shariq Haider

## SATURDAY, MARCH 1

Pavilion Ballroom – Level Three

### 1200 – 1400 **Collateral Damage: Unintended Consequences of Antimicrobial Use**

Lunch will be served

Hosted by Wyeth

*Chair:* Dr. Jim Hutchinson

*Speakers:* Dr. Daryl Hoban

Dr. Louis Valiquette

**MINI-SYMPOSIA  
ARE HOSTED BY  
OUR PLATINUM  
SPONSORS WHO  
HELP MAKE  
THE ANNUAL  
CONFERENCE  
POSSIBLE.  
INVITATIONS  
TO THE  
MINI-SYMPOSIA  
WILL BE SENT  
OUT IN ADVANCE.**

# GENERAL INFORMATION

## REGISTRATION DESK

Junior Ballroom Foyer – Level Three – North Tower

Wednesday, February 27 1400 – 2000

Thursday, February 28 0700 – 1700

Friday, February 29 0700 – 1700

Saturday, March 1 0700 – 1700

## SPEAKER READY ROOM

Blue Whale – Level Three – South Tower

Wednesday, February 27 0700 – 1700

Thursday, February 28 0700 – 1700

Friday, February 29 0700 – 1700

Saturday, March 1 0700 – 1700

## CONFERENCE SECRETARIAT OFFICE

Orca Room – Level Three – South Tower

Thursday, February 28 –

Saturday, March 1 0800 – 1700

## MEDIA ROOM

Gulf Islands A – Lower Lobby Level – North Tower

Thursday, February 28 –

Saturday, March 1 0800 – 1700

## CME CREDITS

Attendees requiring CME credits must obtain a three-part form from the Conference Secretariat.

## HANDOUTS


Handouts will not be available at the Conference. Presentations will be posted on the AMMI Canada and the CACMID websites, after the conference.

## LOST AND FOUND

Items may be left at the Conference Registration Desk.

## MESSAGES/CONFERENCE UPDATES

A message board will be available by the Conference Registration Desk for posting messages for other delegates and to announce last-minute session changes.



## SOCIAL ACTIVITIES

### MEET AND GREET RECEPTION

Pavilion Ballroom  
Refreshments and hors d'oeuvres will be served

**Wednesday,  
February 27**  
1830 – 2000



### WEDNESDAY, FEBRUARY 27

1830 – 2000 **Meet-and-Greet Reception**  
Pavilion Ballroom

### FRIDAY, FEBRUARY 29

2100 – 0100 **Somagen Diagnostics Event**  
Pavilion Ballroom AB and Foyer

### SATURDAY, MARCH 1

1515 – 1800 **Special Lecture,  
Awards Presentations  
and Clinical Vignettes**  
Pavilion Ballroom – Level Three

1900 – 1930 **Gala Reception**  
Grand Ballroom Foyer

1930 – 2400 **Gala Dinner**  
Grand Ballroom

## Exhibit Hall

Grand Ballroom – Grand Ballroom Level – North Tower

### EXHIBIT HOURS

**Thursday, February 28** 1000 – 1100  
1200 – 1400  
1530 – 1700

**Friday, February 29** 1030 – 1100  
1200 – 1400  
1500 – 1630

**Saturday, March 1** 1130 – 1400

### EXPLORE. LEARN. DISCOVER.

Take a moment to explore our Exhibit Hall and discover the leading edge of business and research in the fields of medical microbiology, infectious disease, medicine, pharmaceuticals and diagnostics.

Educational and informative exhibits will be available for viewing. Approximately **50** exhibitors from various fields will show off their wares with representatives on hand to answer your questions.

Breaks and lunches will be served in the exhibit hall to make sure you don't have to miss a moment of our plenaries and discussions, while still giving you time to interact with exhibitors and poster presenters.

### INTERESTED IN JOINING THE SHOW?

Last year's conference drew more than **350** delegates. Exhibiting your products and services, gives you the opportunity to showcase your advances to Canada's largest gathering of clinical and medical microbiologists and infectious disease specialists.

### For more information about becoming an exhibitor please contact:

AMMI Canada  
101-298 Elgin Street  
Ottawa, ON K2P 1M3  
Tel: 1-866-467-1215 (toll free)  
613-260-3233 x103  
Fax: 613-260-3235  
Email: [icc09@ammi.ca](mailto:icc09@ammi.ca)

or visit our conference websites through:  
**[www.icc-09.com](http://www.icc-09.com)**

## Internet Café

Chartroom – Level Three – North Tower

**Thursday, February 28 to**

**Saturday, March 1 - 0700 - 1800**

Sponsored by



# EDUCATIONAL SESSIONS

## WEDNESDAY, FEBRUARY 27

1400 – 2000 **Conference Registration**  
Junior Ballroom Foyer AB – Level Three

1200 – 1700 **FIFTH ANNUAL TRAINEES' DAY**  
Junior Ballroom C – Level Three

1200 – 1245 **Welcome and Introductions**  
Lunch will be served

*Dr. Jessica Minion*  
ASSOCIATE MEMBER COMMITTEE CHAIR  
UNIVERSITY OF ALBERTA

1245 – 1400 **Community Practice in Infectious Disease and Medical Microbiology**

*Speakers: Dr. Dale Purych*  
MEDICAL MICROBIOLOGY  
ROYAL COLUMBIAN HOSPITAL

*Dr. Dwight Ferris*  
INFECTIOUS DISEASES  
KELOWNA GENERAL HOSPITAL

### Objectives:

- To gain a perspective of what ID/MM practice in a community setting is like;
- How the community practice of ID/MM differs from the academic centers where most of us train;
- Career planning advice for residents intending on working in community settings.

1430 – 1530 **New Diagnostic Technologies**

*Speaker: Dr. Patrick Tang*  
B.C. CENTRE FOR DISEASE CONTROL

### Objectives:

- Description of microarray technology;
- What are some applications of newer diagnostic technologies;
- Types of opportunities available for obtaining training in diagnostic technology.

1530 – 1630 **Surveillance of Infectious Diseases**

*Speaker: Dr. Tim Brewer*  
McGILL MEDICAL SCHOOL  
GLOBAL HEALTH PROGRAM

### Objectives:

- Description of current surveillance initiatives in infectious diseases, including ProMed;
- What are the key aspects of a good surveillance program;
- Opportunities to become involved in infectious disease surveillance.

1630 – 1700 **Closing Remarks and Evaluations**

Canadian College of  
Microbiologists



Collège Canadien des  
Microbiologistes

## CCM Workshop

### THE EMERGENCE OF COMMUNITY-ASSOCIATED MRSA IN CANADA: DIAGNOSTIC APPROACHES TO IDENTIFICATION

JUNIOR BALLROOM D

**Wednesday, February 27, 2008, 0830 – 1200**

Fee: \$70.00 plus GST (5%)

*Moderator: Dr. Michael Noble*

### The CCM Workshop will include three presentations:

The Emergence of Community –  
Associated MRSA in Canada

*Dr. Mike Mulvey*  
NATIONAL MICROBIOLOGY LABORATORY

Tem-PCR as a Novel Method for  
Molecular Differential Diagnosis  
of Infectious Diseases

*Dr. Jian Han*  
HUDSON ALPHA INSTITUTE FOR BIOTECHNOLOGIES

So You Want to do MRSA PCR!  
The Experience of One Hospital

*Dr. Marc Desjardins*  
THE OTTAWA HOSPITAL

Participants will receive a statement for  
four CEU in Continuing Professional  
Development (Category 1, Accredited  
Group Interactive Learning Activities).

## Quality Management Seminar

### DIPPING INTO THE QUALITY TOOLBOX

**Quality Improvement in the Medical Laboratory  
Can be Improved Through Effective Use of Tools  
Found in the Quality Toolbox**

JUNIOR BALLROOM D

*Moderator: Dr. Michael Noble*

**Wednesday, February 27, 2008, 1300 – 1630**

Fee: \$60.00 plus GST (5%)

Principles and Practices in the Modern Medical Laboratory  
*Mr. Michael Cody*

LEAN SPECIALIST - LIFE LABS MEDICAL LABORATORY SERVICES

Quality Improvement for Today's Laboratory

*Mr. Hans Vingtoft*  
SIX SIGMA BLACKBELT - LIFE LABS MEDICAL LABORATORY SERVICES


Stepping into Quality Management

*Dr. Michael Noble*  
PROGRAM OFFICE FOR LABORATORY QUALITY MANAGEMENT, UBC

Applying the Toolbox to Laboratory Improvement

*Ms. Jane Crosby*  
LABORATORY SERVICE DIRECTOR AT PROVIDENCE HEALTH CARE.

The Quality Management  
Seminar is sponsored by



**THE QUALITY  
MANAGEMENT  
SEMINAR AND THE  
CCM WORKSHOP  
ARE THE PERFECT  
COMPLEMENT  
TO THE  
AMMI CANADA –  
CACMID ANNUAL  
CONFERENCE.  
BOTH ARE  
OPTIONAL,  
AND OPEN TO  
EVERYONE  
INTERESTED,  
EVEN IF THEY ARE  
NOT ATTENDING  
THE CONFERENCE.**



# EDUCATIONAL SESSIONS

## THURSDAY, FEBRUARY 28

0700 – 1700 **Conference Registration**  
Junior Ballroom Foyer AB – Level Three

0800 – 0815 **Welcome and Opening Remarks**  
Pavilion Ballroom – Level Three

0815 – 1000 **PLENARY - TICKED OFF AND BUGGED OUT**  
Pavilion Ballroom – Level Three

0815 – 0900 **Lyme Disease: Recent Trends and Controversies**

**Speaker:** *Paul Mead*, MD MPH  
CHIEF, EPIDEMIOLOGY AND SURVEILLANCE ACTIVITY  
BACTERIAL DISEASES BRANCH  
DIVISION OF VECTOR-BORNE INFECTIOUS DISEASES  
CENTRE FOR DISEASE CONTROL (CDC)  
FT. COLLINS, COLORADO

### Objectives:

- To describe the epidemiology of Lyme disease in the United States;
- To discuss the condition “Chronic Lyme Disease” and associated controversy;
- To describe prospects for control and prevention of Lyme disease.

0900 – 0945 **Mosquito-Borne Viral Pathogens: a Canadian Perspective**

**Speaker:** *Michael Drebot*, PhD  
CHIEF, VIRAL ZOOSES  
DIRECTOR, SCIENCE TECHNOLOGY AND CORE SERVICES  
NATIONAL MICROBIOLOGY LABORATORY  
PUBLIC HEALTH AGENCY OF CANADA  
WINNIPEG, MB

### Objectives:

- To give a historical perspective on mosquito-borne viral pathogens in Canada;
- To provide an overview on clinical aspects, epidemiology, and viral ecology of Canadian arboviruses such as West Nile and California serogroup viruses;
- To describe the public health impact of Canadians encountering travel associated arboviruses such as dengue and Chikungunya virus;
- To detail the latest developments in the diagnosis and treatment of arbovirus-associated illness.

0945 – 1000 **Panel Discussion – Q and A**

1000 – 1100 **Student Poster Presentations (SP1 – SP48)**  
Grand Ballroom and Foyer

**Student Poster Presentations (SP49 – SP57)**  
**Posters (P1 – P16)**  
Pavilion Ballroom Foyer

1000 – 1100 **Exhibit Hall Opens**  
Grand Ballroom and Foyer

**Break in Exhibit Hall**  
Sponsored by Inverness Medical



1100 – 1200 **Oral Presentations – Session A**  
Junior Ballroom AB – Level Three

1100 – 1115 **A1**  
**Do Bugs Need Drugs? - Focus on Physicians - Three Evidence-Based Strategies to Limit Your “Resistance Footprint”**  
*D. PATRICK<sup>1,2\*</sup>, E. BLONDEL-HILL<sup>1</sup>, F. MARRA<sup>1,2</sup>, D. PURYCH<sup>3</sup>, S. DOBSON<sup>1</sup>, W. BOWIE<sup>1</sup>, L. VRBOVA<sup>1</sup>, A. CHAU<sup>1</sup>, B. HENRY<sup>1,2</sup>, P. KENDALL<sup>1</sup>, M. CHONG<sup>1,2</sup>, K. DREHER<sup>1,2</sup>, M. CARSON<sup>4</sup>, D. LOW<sup>5</sup>*  
University of British Columbia, Vancouver, BC<sup>1</sup>, British Columbia Centre for Disease Control, Vancouver, BC<sup>2</sup>, Fraser Health Authority, Surrey, BC<sup>3</sup>, Capital Health Authority, Edmonton, AB<sup>4</sup>, University of Toronto, Toronto, ON<sup>5</sup>

1115 – 1130 **A2**  
**Extended-Spectrum  $\beta$ -Lactamase -producing *Escherichia coli* from Canadian ICUs are Susceptible to Mecillinam**  
*P. LAGACÉ-WIENS<sup>1\*</sup>, P. BAUDRY<sup>1</sup>, M. DECORBY<sup>1</sup>, K. NICHOL<sup>2</sup>, D. HOBAN<sup>1,2</sup>, G. ZHANEL<sup>1,2</sup>*  
University of Manitoba, Department of Medical Microbiology, Winnipeg, MB<sup>1</sup>, Clinical Microbiology, Health Sciences Centre, Winnipeg, MB<sup>2</sup>

1130-1145 **A3**  
**Determinants of Regional Variation in Outpatient Antibiotic Consumption in British Columbia**  
*F. MARRA<sup>1,2</sup>, S. MAK<sup>1\*</sup>, M. CHONG<sup>1</sup>, D. PATRICK<sup>1,3</sup>*  
BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, UBC Faculty of Pharmaceutical Sciences, Vancouver, BC<sup>2</sup>, UBC Department of Health Care and Epidemiology, Vancouver, BC<sup>3</sup>

1145 – 1200 **A4**  
**A Real-Time PCR Assay for Detection of Vancomycin Resistance Genes In Enterococci Using BHQplus™ TaqMan Probes and the Spartan DX™ Instrument**  
*N. ARBOUR<sup>1\*</sup>, C. HARDER<sup>1</sup>, B. TOYE<sup>1,2</sup>, K. RAMOTAR<sup>1,2</sup>*  
The Ottawa Hospital Research Institute, Ottawa, ON<sup>1</sup>, The Ottawa Hospital, Ottawa, ON<sup>2</sup>

### 1100 – 1200 Oral Presentations – Session B

Junior Ballroom C – Level Three

#### 1100 – 1115 B1

##### Comparison of Two New DFA Assays to RT-PCR for the Detection of Human Metapneumovirus in Respiratory Specimens

A. PETRICH<sup>1\*</sup>, M. BOOTH<sup>1</sup>, K. LUINSTR<sup>1</sup>, M. ACKERMAN<sup>1</sup>, S. CASTRICIANO<sup>2</sup>, M. SMIEJA<sup>1</sup>, J. MAHONY<sup>1</sup>  
St. Joseph's Healthcare, Hamilton, ON<sup>1</sup>, Copan Italia, Brescia, Italy<sup>2</sup>

#### 1115 – 1130 B2

##### Of Gastro and the Gold Standard: Use of Latent Class Modelling to Estimate Test Performance for a Novel PCR and EIA for Norovirus G1 and G2

D. FISMAN<sup>1,2\*</sup>, G. BROUHANSKI<sup>1</sup>, T. MAZZULLI<sup>1,3</sup>, S. DREWS<sup>1,3</sup>  
Ontario Central Public Health Laboratory, Toronto, ON<sup>1</sup>,  
Research Institute of the Hospital for Sick Children, Toronto, ON<sup>2</sup>,  
Mt. Sinai Hospital, Toronto, ON<sup>3</sup>

#### 1130 – 1145 B3

##### Dual *H influenzae* and Respiratory Syncytial Virus: is Detection of Two Organisms Associated with Increased Severity of Respiratory Illness?

L. SAUVE<sup>1\*</sup>, M. AL-DABBAGH<sup>1</sup>, E. THOMAS<sup>1</sup>, S. DOBSON<sup>1</sup>, J. BRUNSTEIN<sup>1,2</sup>  
University of British Columbia, Vancouver, BC<sup>1</sup>,  
Centre for Translational and Applied Genomics, Vancouver, BC<sup>2</sup>

#### 1145 – 1200 B4

##### Results of a West Nile Virus (WNV) rna Proficiency Panel Sent to Canadian Laboratories

A. PETRICH<sup>1\*</sup>, K. LUINSTR<sup>1</sup>, A. DIBERNARDO<sup>2</sup>, R. LINDSAY<sup>2</sup>, M. DREBOT<sup>2</sup> and NATIONAL MOLECULAR MICROBIOLOGY DIAGNOSTICS USERS GROUP (NMG)  
St. Joseph's Healthcare, McMaster University, Hamilton, ON<sup>1</sup>,  
National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, MB<sup>2</sup>

### 1100 – 1200 Oral Presentations – Session C

Junior Ballroom D – Level Three

#### 1100 – 1115 C1

##### Fungal Identification by Sequencing of the Internal Transcribed Spacer Regions and 5.8S rRNA Subunit

A. MCNABB<sup>1\*</sup>, G. GEDDES<sup>1</sup>, S. MITHANI<sup>1</sup>, L. HOANG<sup>1,2</sup>, D. EISLER<sup>1</sup>, P. TANG<sup>1,2</sup>  
BC Centre for Disease Control Laboratory Services, Vancouver, BC<sup>1</sup>,  
Dept of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC<sup>2</sup>

#### 1115 – 1130 C2

##### Characterization of Two Polyketide Synthase Genes Involved in the Biosynthesis of Penicillic Acid, Asperlactone and Isoasperlactone in *Aspergillus westerdijkiae* NRRL 3174

N. BACHA, H. PHONG DAO, F. MATHIEU, T. LIBOZ, A. LEBRIHI  
Institut National Polytechnique de Toulouse, Toulouse, France

#### 1130 – 1145 C3

##### Caspofungin Etest Endpoint for *Aspergillus* Shows Poor Essential Agreement with the Reference Minimum Effective Concentration (MEC)

A. SCHOFIELD, C. SAND, L. BREITKREUTZ, L. TURNBULL, R. RENNIE, J. FULLER\*  
Division of Medical Microbiology, University of Alberta Hospital, Edmonton, AB

#### 1145 – 1200 C4

##### Withdrawn

### 1200 – 1400 Exhibit Hall Opens

Delegate Lunch  
Grand Ballroom and Foyer

### 1200 – 1400 Student Poster Presentations (SP1 – SP48)

Grand Ballroom and Foyer

### Student Poster Presentations (SP49 – SP57)

Posters Presentations (P1 – P16)  
Pavilion Ballroom Foyer – Level Three

### 1200 – 1400 MINI-SYMPOSIUM

Preventing Viral Entry: A New Strategy to Achieve Treatment Goals

New Developments in treatment of HIV and Fungal infection

Hosted by Pfizer Canada  
Pavilion Ballroom – Level Three

# EDUCATIONAL SESSIONS

## 1400 – 1530 Oral Presentations – Session D Junior Ballroom AB – Level Three

### 1400 – 1415 D1

#### **Sensitive and Specific Detection of a Broad Range of Respiratory Viruses Using the Luminex RVP Assay**

*K. TOKARYK<sup>1</sup>\*, K. PABBARAJU<sup>1</sup>, S. WONG<sup>1</sup>, J. FOX<sup>1,2</sup>*  
Provincial Laboratory for Public Health (ProvLab), Calgary, AB<sup>1</sup>,  
Microbiology & Infectious Diseases, University of Calgary,  
Calgary, AB<sup>2</sup>

### 1415 – 1430 D2

#### **Detection of Norovirus, Rotavirus and Adenovirus in Stool Specimens Using a New Sensitive and Specific Multiplex PCR**

*J. MAHONY\*, S. CHONG*  
McMaster University, St. Joseph's Healthcare, Hamilton, ON

### 1430 – 1445 D3

#### **Early Identification of Influenza A(H5) Viruses with Affinity for the Human Sialic Acid Receptor by MALDI-TOF Based Mutation Detection**

*C. YEA<sup>1</sup>, M. PETRIC<sup>3</sup>, R. TELLIER<sup>1,2\*</sup>*  
Research Institute Hospital for Sick Children, Toronto, ON<sup>1</sup>,  
Division of Microbiology, Hospital for Sick Children, Toronto, ON<sup>2</sup>,  
British Columbia Centre for Disease Control, Vancouver, BC<sup>3</sup>

### 1445 – 1500 D4

#### **Development of a Nucleic Acid Amplification Test on the Luminex Platform for Broad Detection of Arboviruses**

*K. PABBARAJU<sup>1</sup>\*, S. WONG<sup>1</sup>, K. HO<sup>1</sup>, K. L. TOKARYK<sup>1</sup>,  
J. D. FOX<sup>1,2</sup>, P. A. G. TILLEY<sup>1</sup>*  
Provincial Laboratory for Public Health, Calgary, AB<sup>1</sup>, University  
of Calgary, Calgary, AB<sup>2</sup>

### 1500 – 1515 D5

#### **Comparison of the Roche COBAS AmpliPrep/COBAS TaqMan™ HCV and the Versant™ HCV RNA 3.0 Tests for Measurement of Hepatitis C Virus Viral Load**

*W. MEI<sup>3</sup>\*, D. COOK<sup>3</sup>, A. MAK<sup>3</sup>, K. GUNADASA<sup>3</sup>, B. LEUNG<sup>3</sup>,  
M. KRAJEN<sup>1,2</sup>*  
BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of  
British Columbia, Vancouver, BC<sup>2</sup>, PHSA Laboratories,  
Vancouver BC<sup>3</sup>

### 1515 – 1530 D6

#### **Laboratory Diagnosis of Mumps in a Partially Immunized Population**

*T. HATCHETTE<sup>1,2\*</sup>, R. DAVIDSON<sup>1,3</sup>, S. CLAY<sup>5</sup>, J. PETTIPAS<sup>1</sup>,  
J. LEBLANC<sup>6</sup>, S. SARWAL<sup>6</sup>, G. WATSON CREED<sup>4,7</sup>, K. FORWARD<sup>1,2</sup>*  
Department of Pathology and Laboratory Medicine, QEII HSC,  
Halifax, NS<sup>1</sup>, Department of Pathology, Dalhousie University,  
Halifax, NS<sup>2</sup>, Department of Microbiology and Immunology,  
Dalhousie University, Halifax, NS<sup>3</sup>, Community Health and  
Epidemiology, Dalhousie University, Halifax, NS<sup>4</sup>, Canadian Field  
Epidemiology Program, Public Health Agency of Canada,  
Ottawa, ON<sup>5</sup>, Nova Scotia Department of Health, Halifax, NS<sup>6</sup>,  
Nova Scotia Department of Health Promotion and Protection,  
Halifax, NS<sup>7</sup>

## 1400 – 1530 Oral Presentations – Session E Junior Ballroom C – Level Three

### 1400 – 1415 E1

#### **Ovine-associated Q Fever in Nova Scotia; Case Report and Sheep Seroprevalence Study**

*D. WEBSTER<sup>1</sup>\*, D. HAASE<sup>2</sup>, T. J. MARRIE<sup>3</sup>, N. CAMPBELL<sup>2</sup>,  
J. PETTIPAS<sup>2</sup>, R. DAVIDSON<sup>2</sup>, T. HATCHETTE<sup>2</sup>*  
Saint John Regional Hospital, Saint John, NB<sup>1</sup>, Dalhousie  
University, Halifax, NS<sup>3</sup>, University of Alberta, Edmonton, AB<sup>2</sup>

### 1415 – 1430 E2

#### **A Review of Molecular Typing of TB Isolates in Alberta**

*L. CHUP<sup>2</sup>\*, R. LONG<sup>1</sup>, G. TYRRELL<sup>2</sup>, J. PREIKSAITIS<sup>2</sup>,  
D. KUNIMOTO<sup>1</sup>*  
University of Alberta, Edmonton, AB<sup>1</sup>, Provincial Laboratory for  
Public Health, Edmonton, AB<sup>2</sup>

### 1430 – 1445 E3

#### **Seasonal Variation and Environmental Effects in Invasive Meningococcal Disease in Philadelphia, Pennsylvania**

*L. KINLIN<sup>1</sup>\*, V. NG-BRETT<sup>1</sup>, V. SPAIN<sup>3</sup>, C. JOHNSON<sup>3</sup>,  
A. WHITE<sup>1</sup>, D. FISMAN<sup>1,2</sup>*  
Hospital for Sick Children, Toronto, ON<sup>1</sup>, Ontario Central Public  
Health Laboratory, Toronto, ON<sup>2</sup>, Philadelphia Department of  
Public Health, Philadelphia, Pennsylvania, United States<sup>3</sup>

### 1445 -1500 E4

#### **Characterization of *Streptococcus pyogenes* and *Staphylococcus aureus* Isolates Associated with Mixed Skin and Soft Tissue Infections in Northern Saskatchewan**

*R. R. MCDONALD<sup>1</sup>\*, G. R. GOLDING<sup>2</sup>, P. N. LEVETT<sup>1</sup>,  
C. K. YOST<sup>3</sup>, J. IRVINE<sup>4</sup>, G. B. HORSMAN<sup>1</sup>, M. R. MULVEY<sup>2</sup>,  
The Northern Antibiotic Resistance Partnership (NARP)*  
Saskatchewan Disease Control Laboratory, Saskatchewan  
Health, Regina, SK<sup>1</sup>, National Microbiology Laboratory, Public  
Health Agency of Canada, Winnipeg, MB<sup>2</sup>, Department of  
Biology, University of Regina, Regina, SK<sup>3</sup>, Athabasca Health  
Authority, Keewatin Yatthe Health Region, and Mamawetan  
Churchill River Health Region, La Ronge, SK<sup>4</sup>

### 1500 – 1515 E5

#### **Surveillance Systems for Emerging Infectious Diseases: Definitions of Surveillance and Evaluation**

*L. VRBOVA<sup>1</sup>\*, C. STEPHEN<sup>1,2,3</sup>, N. KASMAN<sup>4</sup>, R. BOEHNKE<sup>5</sup>,  
M. DOYLE-WATERS<sup>6</sup>, B. GIBSON<sup>6</sup>, A. CHABLITT-CLARK<sup>6</sup>,  
M. BRAUER<sup>1</sup>, M. FITZGERALD<sup>15,7</sup>, D. PATRICK<sup>1,8</sup>*  
University of British Columbia, Vancouver, BC<sup>1</sup>, University of  
Calgary, Calgary, AB<sup>2</sup>, Centre for Coastal Health, Nanaimo, BC<sup>3</sup>,  
York Region Health Services Dept, Newmarket, ON<sup>4</sup>, Vancouver  
Coastal Health Research Institute, Vancouver, BC<sup>5</sup>, Ontario  
Ministry of Health and Long-Term Care, Toronto, ON<sup>6</sup>, Vancouver  
General Hospital, Vancouver, BC<sup>7</sup>, BC Centre for Disease Control,  
Vancouver, BC<sup>8</sup>



1515 – 1530 E6

**Re-emergence of Pathogenic *Vibrio Vulnificus* on the Pacific Northwest Coast in 2007**

M. BIGHAM<sup>1,3\*</sup>, E. GALANIS<sup>1,2</sup>, R. GUSTAFSON<sup>1,4</sup>, L. HOANG<sup>1,2</sup>, K. LOUIE<sup>3</sup>, A. FAREMO<sup>4</sup>, L. MCINTYRE<sup>2</sup>, J. ISAAC-RENTON<sup>1,2</sup>, P. DALY<sup>1,4</sup>, L. GUSTAFSON<sup>3</sup>, B. WONG<sup>2</sup>, S. CHONG<sup>4</sup>, J. STONE<sup>3</sup>, L. RODRIGUEZ-MAYNEZ<sup>5</sup>

University of British Columbia, Vancouver, BC<sup>1</sup>, British Columbia Centre for Disease Control, Vancouver, BC<sup>2</sup>, Fraser Health Authority, Surrey, BC<sup>3</sup>, Vancouver Coastal Health Authority, Vancouver, BC<sup>4</sup>, Canadian Food Inspection Agency, Vancouver, BC<sup>5</sup>

### 1400 – 1530 Oral Presentations – Session F

Junior Ballroom D – Level Three

1400 – 1415 F1

**Evaluation of the ESwab for MRSA Screening with Real Time PCR, BD GeneOhm and Culture**

S. CASTRICIANO\*, A. GIAMBRA  
Copan Italia, Brescia, Italy

1415 – 1430 F2

**A Guideline for the Molecular Typing of Canadian Epidemic Methicillin-Resistant *Staphylococcus aureus* Using *spa* Typing**

G.R. GOLDING<sup>1</sup>, J.L. CAMPBELL<sup>1</sup>, D.J. SPREITZER<sup>1</sup>, J. VEHYL<sup>2</sup>, K. SURYNICZ<sup>2</sup>, A. SIMOR<sup>3</sup>, M.R. MULVEY<sup>1</sup>

National Microbiology Laboratory, Winnipeg, MB<sup>1</sup>, University of Manitoba, Winnipeg, MB<sup>2</sup>, Sunnybrook Health Sciences Centre, Toronto, ON<sup>3</sup>

1430 – 1445 F3

**Prevalence of invasive Methicillin Resistant *Staphylococcus aureus* (MRSA) with Reduced Susceptibility or Tolerance to Vancomycin (VA) in 2006 from Four Hospital Systems in Ontario: Hamilton Health Sciences (HHS), St. Joseph's Healthcare (StJ), William Osler (WO) and Niagara Health System (NHS)**

D. YAMAMURA<sup>1,2\*</sup>, L. WILCOX<sup>2</sup>, C. RUTHERFORD<sup>2</sup>, P. LYN<sup>2</sup>, D. RICHARDSON<sup>4</sup>, C. MAIN<sup>1,2</sup>, S. DUNNETT<sup>3</sup>, N. MORGAN<sup>1</sup>, L. VAN ZUILEN<sup>3</sup>, G. RICCI<sup>1,2</sup>, C.H. LEE<sup>1,2</sup>

McMaster University, Hamilton, ON<sup>1</sup>, Hamilton Regional Laboratory Medicine Program, Hamilton, ON<sup>2</sup>, LifeLabs, Thorold, ON<sup>3</sup>, William Osler Health Center, Brampton, ON<sup>4</sup>, Niagara Health System, St. Catharines, ON<sup>5</sup>

1445- 1500 F4

**Methicillin-Resistant *Staphylococcus aureus* (MRSA) endocarditis and Daptomycin Resistance de Novo Development During Therapy**

L. TWELE<sup>1,2\*</sup>, E. MOYEN<sup>1,2</sup>, J. KIM<sup>1,2</sup>, B. DALTON<sup>2</sup>, K. ZHANG<sup>1,2,3</sup>, D. CHURCH<sup>1,2,3</sup>, J. CONLY<sup>1,2,3</sup>

University of Calgary, Calgary, AB<sup>1</sup>, Calgary Health Region, Calgary, AB<sup>2</sup>, Calgary Laboratory Services, Calgary, AB<sup>3</sup>

1500 – 1515 F5

**Dissemination of Community-Associated Methicillin-Resistant *Staphylococcus aureus* in Northern Saskatchewan**

J. IRVINE<sup>1</sup>, B. QUINN<sup>1</sup>, D. STOCKDALE<sup>1</sup>, S. WOODS<sup>2</sup>, M. NSUNGU<sup>2</sup>, P. LEVETT<sup>3\*</sup>, R. MCDONALD<sup>3</sup>, G. GOLDING<sup>4</sup>, G. HORSMAN<sup>3</sup>, M. MULVEY<sup>4</sup> and THE NORTHERN ANTIBIOTIC RESISTANCE PARTNERSHIP (NARP)

Population Health Unit, LaRonge, SK<sup>1</sup>, Northern Inter-tribal Health Authority, Prince Albert, SK<sup>2</sup>, Saskatchewan Disease Control Laboratory, Regina, SK<sup>3</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>4</sup>

1515 – 1530 F6

**Evaluation of Outpatient Treatment of CA-MRSA in Skin and Soft Tissue Infections in a Large Health Authority**

T. LEUNG<sup>1</sup>, A. LAKHANI<sup>1</sup>, L. CHENG<sup>3</sup>, Y. ARIKAN<sup>2</sup>, D. PURYCH<sup>2\*</sup>, A. GRUNFELD<sup>1</sup>

Surrey Memorial Hospital, Surrey, BC/Fraser Health Authority<sup>1</sup>, Royal Columbian Hospital, New Westminster, BC/Fraser Health Authority<sup>2</sup>, Burnaby Hospital, Burnaby, BC/Fraser Health Authority<sup>3</sup>

# EDUCATIONAL SESSIONS

## 1400 – 1530 State of the Art Clinical Lectures Port McNeill – Level Four

### 1400 – 1445 Nosocomial UTI and Urosepsis – What Can We Improve?

**Speaker:** *Professor Kurt G. Naber*  
PRESIDENT, INTERNATIONAL SOCIETY  
OF CHEMOTHERAPY (ISC)  
ASSOCIATE PROFESSOR OF UROLOGY  
TECHNICAL UNIVERSITY OF MUNICH

#### Objectives:

- To review the burden, morbidity and risk factors of nosocomial urinary tract infection;
- To define opportunities for intervention to prevent catheter-associated urinary tract infections;
- To optimize management and treatment of urosepsis by interdisciplinary cooperation between intensivist, infectious disease specialists and urologists.

### 1445 – 1530 What To Do With What Lurks Beneath The Bandage: Science Or Witchcraft?

**Speaker:** *John Embil, MD FRCPC*  
ASSOCIATE PROFESSOR DEPARTMENT  
INTERNAL MEDICINE  
INFECTIOUS DISEASES AND  
MEDICAL MICROBIOLOGY  
UNIVERSITY OF MANITOBA  
WINNIPEG, MB

#### Objectives:

- To present an approach to wound assessment;
- To consider a differential diagnosis for various wound types;
- To present an overview of dressing management strategies.

### 1530 – 1700 Student Poster Presentations and Judging (SP1 – SP48) Grand Ballroom and Foyer

### Student Poster Presentations and Judging (SP49 – SP57) Posters Presentations (P1 – P16) Pavilion Ballroom Foyer – Level Three

### 1830 – 2030 MINI SYMPOSIUM The Next Stages in Vaccine Design and Application Hosted by GlaxoSmithKline Pavilion Ballroom Foyer CD – Level Three

## FRIDAY, FEBRUARY 29

### 0700 – 1700 Conference Registration Junior Ballroom Foyer AB – Level Three

### 0800 – 1030 PLENARY – CAN-SUMPTION BE DONE ABOUT GLOBAL TUBERCULOSIS? Pavilion Ballroom – Level Three

### 0800 – 0845 Global Epidemiology of Tuberculosis: from MDR to XDR (via videoconference)

**Speaker:** *Mario C. Ravighione*  
DIRECTOR, STOP TB DEPARTMENT (STB)  
HIV/AIDS, TB & MALARIA CLUSTER (HTM)  
WORLD HEALTH ORGANIZATION  
GENEVA, SWITZERLAND

#### Objectives:

- To discuss the epidemiology of active and latent TB infections;
- To discuss outcomes in MDRTB;
- To discuss the potential impact of extremely drug resistant TB.

### 0845 – 0930 Novel Strategies for Resistance Testing in Tuberculosis (via videoconference)

**Speaker:** *Richard O'Brien, MD*  
HEAD PRODUCT EVALUATION AND  
DEMONSTRATION  
FOUNDATION FOR INNOVATIVE  
NEW DIAGNOSTICS  
GENEVA, SWITZERLAND

#### Objectives:

- To understand the advantages and drawbacks of liquid culture and DST for the diagnosis of M/XDR TB;
- To appreciate how molecular diagnostics may revolutionize the diagnosis of M/XDR TB;
- To provide an update on process for policy guidance and adoption of new M/XDR TB diagnostics.

### 0930 – 1015 New Diagnostics in Tuberculosis: Interferon Gamma Release Assays (IGRA's)

**Speaker:** *Dennis Kunimoto, MD*  
PROFESSOR OF MEDICINE  
UNIVERSITY OF ALBERTA

#### Objectives:

- To discuss the principles of the Assay;
- To discuss applications of the Assay.

### 1015 – 1030 Panel Discussion – Q and A

1030 – 1100 **Poster Presentations (P17 – P62)**  
Grand Ballroom and Foyer

**Poster Presentations (P63 – P81)**  
**Clinical Vignette Poster**  
**Presentations (CVP1 – CVP6)**  
Pavilion Ballroom Foyer – Level Three

1030 -1100 **Exhibit Hall Opens**  
Grand Ballroom and Foyer

**1100 – 1200 Oral Presentations – Session G**  
Junior Ballroom AB – Level Three

1100 – 1115 **G1**  
**Determination of the Complete Genomic Sequence of the Human Parainfluenza Virus 4 (HPIV4)**

C. YEA<sup>1</sup>, R. CHEUNG<sup>2</sup>, C. COLLINS<sup>2</sup>, D. ADACHI<sup>2</sup>,  
J. NISHIKAWA<sup>1</sup>, R. TELLIER<sup>1,2\*</sup>  
Research Institute Hospital for Sick Children, Toronto, ON<sup>1</sup>,  
Division of Microbiology Hospital for Sick Children, Toronto, ON<sup>2</sup>

1115 – 1130 **G2**  
**Mammalian Reassortants Containing the NS Gene from the B Allele Can Transmit Between Mammals; the Mystery of B Allele Restriction Continues**

T. HATCHETTE<sup>1,2\*</sup>, R. WEBBY<sup>3</sup>, P. WILLSON<sup>4</sup>, R. WEBSTER<sup>3,5</sup>  
Department of Pathology and Laboratory Medicine, QEII HSC, Halifax, NS<sup>1</sup>, Department of Pathology Dalhousie University, Halifax, NS<sup>2</sup>, Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States<sup>3</sup>, Canadian Centre for Health and Safety in Agriculture, University of Saskatchewan, Saskatoon, SK<sup>4</sup>, Department of Pathology, University of Tennessee Health Science Center, Memphis, TN, United States<sup>5</sup>

1130 – 1145 **G3**  
**Prevalence of High Risk HPV Genotypes in Ontario Women Determined By AMPLICOR® HPV PCR and Linear Array of SUREPATH® PAP Samples**

M. CHERNESKY<sup>1\*</sup>, D. JANG<sup>1</sup>, E. PORTILLO<sup>1</sup>, M. SMIEJA<sup>1</sup>,  
S. CHONG<sup>1</sup>, S. BURACOND<sup>1</sup>, J. KAPALA<sup>2</sup>, J. PATEL<sup>2</sup>,  
C. DOUCETTE<sup>2</sup>, J. SUMNER<sup>2</sup>  
St. Joseph's Healthcare/McMaster University, Hamilton, ON<sup>1</sup>,  
Gamma-Dynacare Medical Laboratories, Brampton, ON<sup>2</sup>

1145 – 1200 **G4**  
**Peptide Mimetics – A Novel Class of Inhibitor that Blocks Influenza A and B Virus Replication**  
J. MAHONY<sup>\*</sup>, L. LIU  
McMaster University, St. Joseph's Healthcare, Hamilton, ON

**1100 – 1200 Oral Presentations – Session H**  
Junior Ballroom C – Level Three

1100 – 1115 **H1**  
**Risk Factors for Acquisition of Endemic Blastomycosis**

M. CHOPTIANY<sup>1\*</sup>, L. WIEBE<sup>2</sup>, B. LIMERICK<sup>2</sup>, P. SANSFIELD<sup>2</sup>,  
M. CHEANG<sup>1</sup>, B. LIGHT<sup>1</sup>, G. HAMMOND<sup>1</sup>, K. MACDONALD<sup>3</sup>,  
E. TREPMAN<sup>1</sup>, P. PAPPAS<sup>4</sup>, J. EMBIL<sup>1</sup>  
University of Manitoba, Winnipeg, MB<sup>1</sup>, Northwestern Health Unit, Kenora, ON<sup>2</sup>, Lake of the Woods District Hospital, Kenora, ON<sup>3</sup>, University of Abama, Birmingham, Alabama, United States<sup>4</sup>

1115 – 1130 **H2**  
**The Clinical Manifestations and Outcomes of Pediatric Blastomycosis in Children and Youth: A 30 Year Experience**

S. FANELLA, S. SKINNER<sup>\*</sup>, J. EMBIL  
Department of Medical Microbiology, University of Manitoba, Winnipeg, MB

1130 – 1145 **H3**  
**Chylous Ascites: A Late Complication of Intraabdominal *Mycobacterium avium* Complex Immune Reconstitution Syndrome in HIV-infected Patients**

P. PHILLIPS<sup>1\*</sup>, J. LEE<sup>2</sup>, C. WANG<sup>3</sup>, E. YOSHIDA<sup>4</sup>,  
J. MONTANER<sup>5</sup>  
Division of Infectious Diseases, British Columbia Center for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, BC<sup>1</sup>, Department of Medicine, University of British Columbia, Vancouver, BC<sup>2</sup>, Division of Gastroenterology, University of Toronto, Toronto, ON<sup>3</sup>, Division of Gastroenterology, Vancouver General Hospital, Vancouver, BC<sup>4</sup>, Division of AIDS, British Columbia Center for Excellence in HIV/AIDS, St. Paul's Hospital, University of British Columbia, Vancouver, BC<sup>5</sup>

1145 -1200 **H4**  
**Patients with CDAD Due to NAP1-Related Strains of *Clostridium difficile* Had Stool Toxin B Levels that Were High Compared to the Average for NAP1-Unrelated Strains**

M. ALEA<sup>1,3\*</sup>, R. MURRAY<sup>1</sup>, M. MULVEY<sup>1,2</sup>, D. BOYD<sup>2</sup>  
University of Manitoba, Winnipeg, MB<sup>1</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>2</sup>, Diagnostic Services of Manitoba, Winnipeg, MB<sup>3</sup>



# EDUCATIONAL SESSIONS

## 1100 – 1200 Oral Presentations – Session I Junior Ballroom D – Level Three

1100 – 1115 **I1**

**It's All In the Family: A Case Cluster of CA-MRSA Furunculosis, with a Complication of Possible Familial Trimethoprim-Sulfamethoxazole (TMP SMX) Hypersensitivity**

*L. SAXINGER\**

University of Alberta, Edmonton, AB

1115 – 1130 **I2**

**Methicillin-resistant *Staphylococcus aureus* Identified in Hospitalized Patients with No Risk Factors for Healthcare-associated Transmission**

*M. MULVEY\**, *M. OFNER*<sup>2</sup>, *J. CAMPBELL*<sup>1</sup>, *G. GOLDING*<sup>1</sup>, *C. WATT*<sup>3</sup>, *L. LOUIE*<sup>3</sup>, *A. SIMOR*<sup>3</sup>, *M. LOEB*<sup>4</sup>, *A. MCGEER*<sup>5</sup>, *E. BRYCE*<sup>6</sup>, *A. MATLOW*<sup>7</sup> and the CANADIAN NOSOCOMIAL INFECTION SURVEILLANCE PROGRAM (CNISP)

National Microbiology Laboratory, Winnipeg, MB<sup>1</sup>, Public Health Agency of Canada, Ottawa, ON<sup>2</sup>, Sunnybrook Health Sciences Centre, Toronto, ON<sup>3</sup>, McMaster University, Hamilton, ON<sup>4</sup>, Mount Sinai Hospital, Toronto, ON<sup>5</sup>, Vancouver General Hospital, Vancouver, BC<sup>6</sup>, Hospital for Sick Children, Toronto, ON<sup>7</sup>

1130 – 1145 **I3**

**The Diabetic Foot Clinic: Not a Significant Source for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Acquisition**

*P. LAGACÉ-WIENS\**, *D. ORMISTON*<sup>1,2</sup>, *J. EMBIL*<sup>1,2,3</sup>,

*L. NICOLLE*<sup>1,3</sup>, *T. HILDERMAN*<sup>4</sup>

University of Manitoba, Department of Medical Microbiology and Infectious Diseases, Winnipeg, MB<sup>1</sup>, Health Sciences Centre, Infection Prevention and Control, Winnipeg, MB<sup>2</sup>, Health Sciences Centre, Department of Internal Medicine, Winnipeg, MB<sup>3</sup>, Manitoba Health, Winnipeg, MB<sup>4</sup>

1145 – 1200 **I4**

**High Prevalence and Persistence of Methicillin Resistant *Staphylococcus aureus* (MRSA) in a Downtown Vancouver Community**

*M. HULL*<sup>1,2\*</sup>, *E. LLOYD-SMITH*<sup>1</sup>, *S. CHAMPAGNE*<sup>2</sup>, *M. TYNDALL*<sup>1</sup>, *S.H. GOH*<sup>3</sup>, *R. ZHANG*<sup>1</sup>, *P. DALY*<sup>4</sup>, *M. ROMNEY*<sup>2</sup>

BC Centre for Excellence in HIV/AIDS, Vancouver, BC<sup>1</sup>, Providence Health Care, Vancouver, BC<sup>2</sup>, BC Centre for Disease Control, Vancouver, BC<sup>3</sup>, Communicable Disease Division, Vancouver Coastal Health, Vancouver, BC<sup>4</sup>

1200 – 1400 **Exhibit Hall Opens**

Delegate Lunch  
Grand Ballroom and Foyer

1200 – 1400 **Poster Presentations (P17-P62)**

Grand Ballroom and Foyer

**Poster Presentations (P63 – P81)**

**Clinical Vignette Posters  
Presentations (CVP1 – CVP6)**

Pavilion Ballroom Foyer – Level Three

1200 – 1400 **MINI SYMPOSIUM**

**Invasive Fungal Infections –  
Emerging Trends, Future Direction**

Hosted by Schering-Plough  
Pavilion Ballroom – Level Three

## 1400 – 1500 Oral Presentations – Session J Junior Ballroom AB – Level Three

1400 – 1415 **J1**

**Update On Diagnosis of Strongyloidiasis: A Clinician's Perspective**

*M. NDAO*<sup>1\*</sup>, *F. VASQUEZ-CAMARGO*<sup>1</sup>, *R. VARATHARAJALU*<sup>2</sup>, *D. MACLEAN*<sup>1</sup>, *F. NEVA*<sup>2</sup>, *B. WARD*<sup>1</sup>

McGill University/National Reference Centre for Parasitology/Tropical Diseases Centre, Montreal, QC<sup>1</sup>, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States<sup>2</sup>

1415 – 1430 **J2**

**A Longitudinal Study on Sub-populations of *Cryptosporidium* spp. in Sporadic Human Cases in British Columbia, Canada**

*J. LEE*, *C. ONG\**

University of British Columbia, Vancouver, BC

1430 – 1445 **J3**

**Epidemiology of *Staphylococcus aureus* Bloodstream Infections in a Large Canadian Health Region, 2000-2006**

*K. LAUPLAND*<sup>1\*</sup>, *T. ROSS*<sup>2</sup>, *D. GREGSON*<sup>1,2</sup>

Department of Medicine, Calgary, AB<sup>1</sup>, Calgary Laboratory Services, Calgary, AB<sup>2</sup>

1445 – 1500 **J4**

**Withdrawn**

### 1400 – 1500 Oral Presentations – Session K

Junior Ballroom C – Level Three

1400 – 1415 **K1**

#### Validation of Real Time PCR Assays for Detecting and Serogrouping *N. Meningitidis* before Implementation in a Routine Molecular Diagnostic Laboratory

T. CHIU<sup>1</sup>\*, R. MCDONALD<sup>2</sup>, N. ANTONISHYN<sup>2</sup>, G. TYRRELL<sup>1</sup>, L. CHUI<sup>1</sup>

ProvLab, Edmonton, AB<sup>1</sup>, Saskatchewan Disease Control Laboratory, Regina, SK<sup>2</sup>

1415 – 1430 **K2**

#### Dexamethasone (Dex) in *Cryptococcus gattii* Central Nervous System Infection (CgCNS)

P. PHILLIPS<sup>1</sup>\*, K. CHAPMAN<sup>2</sup>, M. SHARP<sup>2</sup>, P. HARRISON<sup>3</sup>, J. VORTEL<sup>4</sup>, T. STEINER<sup>5</sup>, W. BOWIE<sup>5</sup>, E. GALANIS<sup>6</sup>

Division of Infectious Diseases, St. Paul's Hospital, Vancouver, BC<sup>1</sup>, Division of Neurology, St. Paul's Hospital, Vancouver, BC<sup>2</sup>, Department of Radiology, St. Paul's Hospital, Vancouver, BC<sup>3</sup>, Infectious Diseases, Richmond General Hospital, Vancouver, BC<sup>4</sup>, Division of Infectious Diseases, Vancouver General Hospital, Vancouver, BC<sup>5</sup>, British Columbia Centre for Disease Control, Vancouver, BC<sup>6</sup>

1430 -1445 **K3**

#### Are Indirect Immunofluorescence Antibody Assays (IFA) Reliable Tools for the Diagnosis of Cat Scratch Disease?

B. SERHIR<sup>\*</sup>, C. SAUVÉ, S. BEAULIEU, M. PELLETIER, M. COUILLARD

Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC

1445 – 1500 **K4**

#### The Meteoric Rise of MRSA as a Proportion of Staphylococcus Isolates from Skin and Soft Tissue Infections in Two Outpatient IV Clinics, Edmonton, Canada

L. SAXINGER<sup>1</sup>\*, C. PISANI<sup>2</sup>, J. FULLER<sup>1</sup>, U. CHANDRAN<sup>2,1</sup>

University of Alberta, Edmonton, AB<sup>1</sup> Dynacare Kasper Medical Laboratories, Edmonton, AB<sup>2</sup>

### 1400 – 1500 Oral Presentations – Session L

Junior Ballroom D – Level Three

1400 – 1415 **L1**

#### Maintaining Temperature of Blood Culture Specimens During Transport to the Laboratory - A Novel Approach for Cold Climates

K. DIRSE<sup>\*</sup>, M. CARLSON, G. JOHNSTON, P. BROWN

Stratford General Hospital, Stratford, ON

1415 – 1430 **L2**

#### Evaluation of Antimicrobial Activity of the Essential Oil of the Gum of *Pistacia vera* and Its Major Components

J. BEHRAVAN<sup>\*</sup>, B. F. KALALINIA, M. RAMAZANI, A. ASADIPOUR

Biotechnology and Pharmaceutical Research Centers, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran

1430 – 1445 **L3**

#### Bi-Annual Surveillance of *Staphylococcus aureus* Susceptibility to Fusidic Acid in Five Canadian Laboratories

R. RENNIE<sup>1</sup>, C. BROSNIKOFF<sup>2</sup>\*, M. HARRIS<sup>3</sup>, L. TURNBULL<sup>1</sup>, P. KIDSON<sup>2</sup>, D. YAMAMURA<sup>3</sup>, C. BECHARD<sup>3</sup>, M. KELLY<sup>4</sup>, B. WALDRON<sup>4</sup>, B. TA<sup>4</sup>, K. FORWARD<sup>5</sup>, K. LAMBERT<sup>5</sup>, K. HEWITT<sup>5</sup>, M.C. LOCAS<sup>6</sup>, M. LAVERDIERE<sup>6</sup>

University of Alberta Hospital, Edmonton, AB<sup>1</sup>, LEO Pharma, Thornhill, ON<sup>2</sup>, MDS Laboratory Services, Toronto, ON<sup>3</sup>, MDS Metro Laboratory Services, Burnaby, BC<sup>4</sup>, QE II Health Sciences Center, Halifax, NS<sup>5</sup>, Hopital Maisonneuve-Rosemont, Montreal, QC<sup>6</sup>

1445 – 1500 **L4**  
Withdrawn

# EDUCATIONAL SESSIONS

1400 – 1500



## State of the Art Clinical Lecture Port McNeill – Level Four

### Respiratory Infections in the Elderly: Current Insights and Recent Twists in our Understanding of Prevention

The Royal College of Physicians and Surgeons of Canada Gold Medal Award in Medicine (2006)

**Speaker:** *Mark B. Loeb*, MD MSc FRCP  
PROFESSOR, McMASTER UNIVERSITY  
2006 GOLD MEDALIST IN MEDICINE

#### Objectives:

- To outline the epidemiology of viral respiratory infections and pneumonia in the elderly;
- To describe updates in key management strategies;
- To explore recent controversies in vaccine preventable illness.

1500 – 1630

## Exhibit Hall Opens Grand Ballroom and Foyer

1500 – 1630

## Poster Presentations (P17-P62) Grand Ballroom and Foyer

### Poster Presentations (P63 – P81) Clinical Vignette Posters Presentations (CVP1 – CVP6) Pavilion Ballroom Foyer – Level Three

1730 – 1930

## WORKSHOP Business Planning the Executive Way: Ensuring your Initiatives Get Funding BD Diagnostic Systems Canada Junior Ballroom D

1730 – 1930

## WORKSHOP Optimizing HPV Prevention — Taking the Leap Forward Roche Diagnostics Canada/ Merck Frosst Canada Ltd. Junior Ballroom AB

## SATURDAY, MARCH 1

0700 – 1700

## Conference Registration Junior Ballroom Foyer AB – Level Three

0800 – 1130

## PLENARY – WHAT'S NEW AND WHAT'S HOT? Pavilion Ballroom – Level Three

0800 – 0845

## Antibiotic Misuse: A Stewardship Storm is Brewing

**Speaker:** *Jim Hutchinson*, MD FRCP  
CHAIR, CANADIAN COMMITTEE ON  
ANTIBIOTIC RESISTANCE (CCAR)

#### Objectives:

- To understand the definition of Antimicrobial Stewardship;
- To understand the principles of Antimicrobial Utilization measurement;
- To understand the new AMMI Canada Antimicrobial Stewardship and Resistance Committee and its Stewardship curriculum project

0845 – 0930

## Students, Saliva and Swelling: A Perfect Storm for the Sharing of Mumps in Canada

**Speaker:** *Todd Hatchette*, MD FRCP  
DIRECTOR OF VIROLOGY AND IMMUNOLOGY  
DIVISION OF MICROBIOLOGY  
DEPARTMENT OF PATHOLOGY AND  
LABORATORY MEDICINE  
QE II HEALTH SCIENCE CENTRE

#### Objectives:

- To understand the clinical presentation and epidemiology of mumps in Nova Scotia and how it has spread throughout Canada;
- To review possible reasons why mumps outbreaks are occurring now;
- To review the lessons learned during this outbreak including the limitations of diagnostic testing.

0930 – 1000

## Break Pavilion Ballroom Foyer



1000 – 1045

**Hepatitis B, Drug Treatment Calms the Storm**

*Speaker:* **Stephen Shafran**, MD  
PROFESSOR AND DIRECTOR  
DIVISION OF INFECTIOUS DISEASES  
UNIVERSITY OF ALBERTA

**Objectives:**

- To review the Epidemiology and Natural History of Hepatitis B;
- To review new therapeutics for Hepatitis B;
- To consider approaches to patient assessment and treatment as per the new Canadian Consensus Guidelines.

1045 – 1130

**HIV – Sunny Weather on the Way: New Drugs, New Hope**

*Speaker:* **Cécile Tremblay**, MD FRCP  
MICROBIOLOGY  
CHUM, CAMPUS HÔTEL-DIEU DE  
MONTRÉAL

**Objectives:**

- To understand the mechanisms of new classes of antiretrovirals;
- To integrate new clinical data into our clinical practice;
- To establish treatment strategies for ARV-experienced and ARV-naïve HIV infected individuals.

1130 – 1400

**Lunch in Exhibit Hall**  
Grand Ballroom and Foyer

1200 – 1400

**MINI SYMPOSIUM****Collateral Damage: Unintended Consequences of Antimicrobial Use**

Hosted by Wyeth  
Pavilion Ballroom – Level Three

**1400 – 1500 Oral Presentations – Session M**  
Junior Ballroom AB – Level Three1400 – 1415 **M1****Surveillance for Laboratory-Confirmed Influenza in Adults Hospitalized in Canadian Acute-Care Hospitals**

*D. GRAVEL*<sup>1\*</sup>, *A. MCGEER*<sup>2</sup>, *G. TAYLOR*<sup>3</sup>, *J. VAYALUMKAL*<sup>1</sup>,  
*C. FRENETTE*<sup>4</sup>, *A. WONG*<sup>5</sup>, *D. MOORE*<sup>6</sup>, *B. AMIHOD*<sup>7</sup>,  
*S. EDEN*<sup>1</sup>, *C. WEIR*<sup>1</sup>, *CANADIAN NOSOCOMIAL INFECTION  
SURVEILLANCE PROGRAM PUBLIC HEALTH AGENCY  
OF CANADA*<sup>1</sup>

Public Health Agency of Canada, Ottawa, ON<sup>1</sup>, Mount Sinai Hospital, Toronto, ON<sup>2</sup>, University of Alberta Hospital, Edmonton, AB<sup>3</sup>, Hopital Charles LeMoyne, Longueuil, QC<sup>4</sup>, Royal University Hospital, Saskatoon, SK<sup>5</sup>, Montreal Children's Hospital, Montreal, QC<sup>6</sup>, Jewish General Hospital, Montreal, QC<sup>7</sup>

1415 -1430 **M2****Saskatchewan Disease Control Laboratory Pandemic Preparedness Plan: Molecular Testing Strategy for Influenza and Other Respiratory Agents**

*T.A. MAKSYMIV*<sup>1\*</sup>, *N.A. CROZIER*, *A.C.A. OBARIANYK*,  
*T.L. HANSEN*, *C.M. BACALSO*, *R.R. MCDONALD*,  
*N.A. ANTONISHYN*, *P.N. LEVETT*, *G.B. HORSMAN*  
Saskatchewan Disease Control Laboratory, Regina, SK

1430 – 1445 **M3****Defining a Reference Standard and Optimizing Sampling Strategy for Influenza Molecular Diagnostics**

*M. SMIEJA*<sup>1,2\*</sup>, *A. PETRICH*<sup>1,2</sup>, *K. LUINSTR*<sup>1</sup>,  
*S. BURACOND*<sup>1</sup>, *S.A. CHONG*<sup>1</sup>, *J. MAHONY*<sup>1,2</sup>  
St. Joseph's Hospital, Hamilton, ON<sup>1</sup>, McMaster University, Hamilton, ON<sup>2</sup>

1445 – 1500 **M4****Self-Collected Nasal Flocked Swabs: The Next Generation. A Comparison of Self-Collected Nasal Swabs with Staff-collected Nasopharyngeal or Nasal Swabs for Respiratory Tract Sampling in Volunteers**

*S. CASTRICIANO*<sup>\*</sup>, *S. CARRUTHERS*, *S. BURACOND*,  
*G. SO*, *M. SMIEJA*

Department of Pathology and Molecular Medicine,  
McMaster University, Hamilton, ON

# EDUCATIONAL SESSIONS

## 1400 – 1500 Oral Presentations – Session N Junior Ballroom C – Level Three

1400 – 1415 N1

### The HTLV Western Blot Remains a Poor Supplementary Test Compared to PCR and Leads to a High Number of Samples with Indeterminate but Likely Negative Status

L. MALLOCH\*, B. CALDER-KENT, Y. ADONSU-HOYI, K. KADIVAR, J. KIM

National HIV/AIDS Reference Lab, Ottawa, ON

1415 – 1430 N2

### Hepatitis D Virus Infection in Canada: Current Prevalence and HDV Genotypes

K. SWIDINSKY<sup>1,\*</sup>, M. MORBEY<sup>1</sup>, E. GRUDESKI<sup>1</sup>, K. KAITA<sup>3</sup>, A. ANDONOV<sup>1,2</sup>

Public Health Agency of Canada, NML, Winnipeg, MB<sup>1</sup>, Department of Medical Microbiology, University of Manitoba, Winnipeg, MB<sup>2</sup>, Health Sciences Centre, University of Manitoba, Winnipeg, MB<sup>3</sup>

1430 -1445 N3

### DNA Sequence Analysis of HIV-1 non-B Subtypes Highlights the Increasing Genetic Diversity of HIV Entering Canada and Poses a Challenge for the Diagnosis and Quantitation of these Strains

J. KIM\*, Z. CHEN, J. MIHOWICH, J. DESCHATELETS, S. LAVOIE, K. PULIDO

National HIV/AIDS Reference Lab, Ottawa, ON

1445 – 1500 N4

### Validation of an HIV Antibody Avidity Assay for Detection of Recent Sero-conversion for Use in HIV Incidence Estimations

D. TAYLOR<sup>1,\*</sup>, D. COOK<sup>1</sup>, R. CHOW<sup>4</sup>, P. COOK<sup>4</sup>, P. TSANG<sup>4</sup>, M. GILBERT<sup>1,2</sup>, L. BAKER<sup>3</sup>, M. KRAJEN<sup>1,2</sup>

BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of British Columbia, Vancouver, BC<sup>2</sup>, Siemens Medical Solutions Diagnostics, Tarrytown, NY, United States<sup>3</sup>, PHSA Laboratories, Vancouver, BC<sup>4</sup>

## 1400 – 1500 Oral Presentations – Session O Junior Ballroom D – Level Three

1400 – 1415 O1

### *Bordetella holmesii*: How Common is it in British Columbia?

S.H. GOH<sup>1,3,\*</sup>, R. CHEN<sup>2</sup>, D. CHAN<sup>2</sup>, B. AUK<sup>2</sup>, C. CHAND<sup>2</sup>, A. PACCAGNELLA<sup>2</sup>, A. McNABB<sup>2</sup>, L. HOANG<sup>1,3</sup>

University of British Columbia, Vancouver, BC<sup>1</sup>, PHSA Laboratories, Vancouver, BC<sup>2</sup>, University of British Columbia, CDC, Vancouver, BC<sup>3</sup>

1415 – 1430 O2

### A Recent Case of Intestinal (Infant) Botulism in British Columbia (BC) “Where are the *botulinum* Spores Coming from?”

J. FUNG<sup>1,\*</sup>, J. ISAAC-RENTON<sup>1,2</sup>, J. WONG<sup>1</sup>, B. WONG<sup>1</sup>, E. BRODKIN<sup>3</sup>, E. GALANIS<sup>4</sup>

BC Centre for Disease Control Laboratory Services, Vancouver, BC<sup>1</sup>, University of British Columbia, Vancouver, BC<sup>2</sup>, Fraser Health Authority, Surrey, BC<sup>3</sup>, BC Centre for Disease Control Epidemiology Services, Vancouver, BC<sup>4</sup>

1430 -1445 O3

### Comparison of Self-collected Vaginal Swabs to First-void Urine for the Diagnosis of *C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis* using APTIMA® Assays

M. CHERNESKY<sup>1,\*</sup>, D. JANG<sup>1</sup>, E. PORTILLO<sup>1</sup>, M. SMIEJA<sup>1</sup>, C. MACRITCHIE<sup>2</sup>, C. PRITCHARD<sup>3</sup>, D. MACEACHERN<sup>3</sup>, R. EWERT<sup>4</sup>

McMaster University/St. Joseph's Healthcare, Hamilton, ON<sup>1</sup>, Community Health Centre, Hamilton, ON<sup>2</sup>, Youth Centre, Ajax, ON<sup>3</sup>, Evergreen Health Centre, Toronto, ON<sup>4</sup>

1445- 1500 O4

### Quantitative Urine Culture Colony Counts and Interpretation Unchanged by Automated Streaking on Chromogenic Media

P. LAGACÉ-WIENS<sup>1,\*</sup>, M. ALFA<sup>1,2</sup>, O. LARIOS<sup>1</sup>, K. MANICKAM<sup>1,2</sup>, J. KARLOWSKY<sup>1,2</sup>

University of Manitoba, Department of Medical Microbiology and Infectious Diseases, Winnipeg, MB<sup>1</sup>, Diagnostic Services of Manitoba, Winnipeg, MB<sup>2</sup>

1400 – 1500

### State of the Art Clinical Lecture

Port McNeill – Level Four

#### Non-Traditional Pulmonary Infections in Cystic Fibrosis: Not just the Usual Suspects

**Speaker:** *Jane L. Burns, MD*  
PROFESSOR, DEPARTMENT OF PEDIATRICS  
UNIVERSITY OF WASHINGTON  
SCHOOL OF MEDICINE  
DIVISION OF INFECTIOUS DISEASES,  
IMMUNOLOGY AND RHEUMATOLOGY  
CLINICAL DIRECTOR, INFECTIOUS DISEASES  
CHILDREN'S HOSPITAL AND  
REGIONAL MEDICAL CENTRE

#### Objectives:

- To present the clinical manifestations of non-traditional pathogens causing infections in patients with cystic fibrosis including non-tuberculous mycobacteria, MRSA, and small colony variants of selected bacterial pathogens;
- To discuss clinical diagnostic challenges, and management options facing the infectious diseases consultant in evaluating patients with cystic fibrosis pulmonary infections due to less common pathogens.

1515 – 1800

### SPECIAL LECTURE

#### Taking Charge of Your Health:

#### Why Lifestyle Matters

Pavilion Ballroom – Level Three

**Speaker:** *Dr. Art Hister*

Sponsored by Astellas



### AWARDS PRESENTATION

#### CLINICAL VIGNETTES

In this interactive session, some of your colleagues will be presenting their most interesting, difficult, and head-scratching cases. You, as a participant, are asked to help find the right diagnosis and treatment decisions in this lively interactive session.

#### CLOSING REMARKS

AMMI CANADA-CACMID

## Special Lecture, Awards Presentations and Clinical Vignettes

Saturday, March 1, 1515 – 1800

Pavilion Ballroom, Level 3





# POSTER PRESENTATIONS

(Available as of time of printing)

## THURSDAY, FEBRUARY 28

### Student Poster Presentations (SP1-SP48)

Grand Ballroom and Foyer

### Student Poster Presentations (SP49-SP56)

Pavilion Ballroom Foyer

Viewing: 1000 – 1100  
1200 – 1400

Viewing and Judging: 1530 – 1700

### SP1

#### Demographic and Regional Factors Predicting Antimicrobial Susceptibility in *Escherichia coli* from Canadian Intensive Care Units

P. LAGACÉ-WIENS<sup>1\*</sup>, M. DECORBY<sup>1</sup>, P. BAUDRY<sup>1</sup>, D. HOBAN<sup>1,2</sup>, J. KARLOWSKY<sup>1,2</sup>, G. ZHANEL<sup>1,2</sup>

University of Manitoba, Department of Medical Microbiology and Infectious Diseases, Winnipeg, MB<sup>1</sup>, Clinical Microbiology, Health Sciences Centre, Winnipeg, MB<sup>2</sup>

### SP2

#### Evaluation of Etest Compared to the Reference Broth Microdilution Antifungal Susceptibility Testing of Clinical Isolates of *Candida* spp. Against Four Antifungal Agents

R. REYES<sup>1,2\*</sup>, M. JOHN<sup>1,2</sup>, R. LANNIGAN<sup>1,2</sup>, S. MILBURN<sup>1</sup>, M. WITKOWSKA<sup>3</sup>

London Health Sciences Centre, London, ON<sup>1</sup>, Schulich School of Medicine, University of Western Ontario, London, ON<sup>2</sup>, Central Public Health Laboratory, Ontario Ministry of Health and Long-Term Care, Toronto, ON<sup>3</sup>

### SP3

#### *Streptococcus pneumoniae* in Canadian Intensive Care Units: Prevalence and Antibiotic Resistance Results Obtained During 2005 and 2006 Canadian Intensive Care Unit Surveillance Study (CAN-ICU)

G. G. ZHANEL<sup>1,2</sup>, D. J. HOBAN<sup>1,2</sup>, M. DECORBY<sup>1</sup>,

K. NICHOL<sup>2</sup>, A. K. WIERZBOWSKI<sup>1\*</sup>

University of Manitoba, Winnipeg, MB<sup>1</sup>, Health Sciences Centre, Winnipeg, MB<sup>2</sup>

### SP4

#### In Vitro Activity of Tigecycline Against Community and Hospital Strains of Methicillin Resistant *Staphylococcus aureus* (MRSA) at Providence Health Care (PHC)

A. STEFANOVIC<sup>1\*</sup>, S. CHAMPAGNE<sup>2,3</sup>, M. HULL<sup>1</sup>,

R. SEBASTIAN<sup>3</sup>, M. ROMNEY<sup>2,3</sup>

University of British Columbia, Department of Medicine, Division of Infectious Diseases, Vancouver, BC<sup>1</sup>, PHC, Department of Pathology and Laboratory Medicine, Division of Medical Microbiology, Vancouver, BC<sup>2</sup>, PHC, Infection Prevention and Control, Vancouver, BC<sup>3</sup>

### SP5

#### Epidemiology of Invasive Meningococcal Disease with Decreased Penicillin Susceptibility in Ontario 2000-2006

E. BROWN<sup>1\*</sup>, D. FISMAN<sup>1,3</sup>, S. BROWN<sup>1</sup>, P. RAWTE<sup>1</sup>, S. DOLMAN<sup>2</sup>, F. JAMIESON<sup>1</sup>

Ontario Central Public Health Laboratory, Toronto, ON<sup>1</sup>, Ontario Public Health Branch, Toronto, ON<sup>2</sup>, Hospital for Sick Children, Toronto, ON<sup>3</sup>

### SP6

#### Antibacterial Evaluation and Phytochemical Screening of *Anethum graveolens*, *Foeniculum vulgare*, *Trachyspermum ammi*, *Amomum subulatum* and *Elettaria cardamomum*

G.J. KAUR<sup>\*</sup>, D.S. ARORA

Guru Nanak Dev University, Amritsar, Punjab, India

### SP7

#### Multi-Drug Resistant Extended-Spectrum $\beta$ -Lactamase Producing *Escherichia coli* from Patients in Canadian Hospitals: Results from CAN-WARD 2007

P. BAUDRY<sup>1\*</sup>, M. DECORBY<sup>1</sup>, K. NICHOL<sup>2</sup>, P. LAGACE-WIENS<sup>1</sup>, G. G. ZHANEL<sup>1</sup>, D. J. HOBAN<sup>1,2</sup>

University of Manitoba, Winnipeg, MB<sup>1</sup>, Health Sciences Centre, Winnipeg, MB<sup>2</sup>

### SP8

#### Crossing the Threshold: Resistance to First-Line Antibiotics in Uropathogenic *Escherichia coli*

A. CHAU<sup>1,2\*</sup>, D. PURYCH<sup>3,4</sup>, L. VRBOVA<sup>1,2</sup>, D. PATRICK<sup>1,2</sup>

BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of British Columbia, Vancouver, BC<sup>2</sup>, Fraser Health Authority, Surrey, BC<sup>3</sup>, BC Biomedical Laboratories, Surrey, BC<sup>4</sup>

### SP9

#### Activity of Liposomal Antibiotics in Sputum of Cystic Fibrosis Patients

M. ALIPOUR<sup>1\*</sup>, Z. E. SUNTRES<sup>2</sup>, M. HALWANI<sup>1</sup>, A. KUMAR<sup>1</sup>, A. OMRI<sup>1</sup>

Laurentian University, Sudbury, ON<sup>1</sup>, Lakehead University, Thunder Bay, ON<sup>2</sup>

### SP10

#### Antimicrobial Susceptibility of $\beta$ -haemolytic Streptococci in Downtown Vancouver, 2004–2007

K. TAN<sup>1\*</sup>, M. HULL<sup>2,1</sup>, M. ROMNEY<sup>2,1</sup>, S. CHAMPAGNE<sup>2,1</sup>

University of British Columbia, Vancouver, BC<sup>1</sup>, Providence Health Care, Vancouver, BC<sup>2</sup>

### SP11

#### Ciprofloxacin Resistance Among Uroseptic Patients Presenting to the Emergency Department at a Major Tertiary Care Hospital

C. LOWE<sup>1\*</sup>, I. MOMENKHAN<sup>2</sup>, R. REYNOLDS<sup>3</sup>,

D. MCKNIGHT<sup>3</sup>, T. LEE<sup>3</sup>, D. ROSCOE<sup>4</sup>, P. DOYLE<sup>4</sup>

University of British Columbia, Vancouver, BC<sup>1</sup>, Division of Infectious Diseases, Vancouver General Hospital, Vancouver, BC<sup>2</sup>, Department of Emergency Medicine, Vancouver General Hospital, Vancouver, BC<sup>3</sup>, Division of Medical Microbiology and Infection Control, Vancouver General Hospital, Vancouver, BC<sup>4</sup>

**SP12****Broth Microdilution Detection of Inducible Clindamycin Resistance in Methicillin-Resistant *Staphylococcus aureus* (MRSA)**E. SY<sup>2\*</sup>, C. WATT<sup>1</sup>, L. LOUIE<sup>1</sup>, A.E. SIMOR<sup>1,2</sup>Sunnybrook Health Sciences Centre, Toronto, ON<sup>1</sup>, University of Toronto, Toronto, ON<sup>2</sup>**SP13****A Case of Non-Healing Cutaneous Ulcers**

M. ALAWI\*, C. KRAEKER, N. SINGHAL

McMaster, Hamilton, ON

**SP14****Intracranial Tuberculoma Misdiagnosed as En-Plaque Meningioma and Neurosarcoidosis**

J. KANJI\*, P. EL-HELOU

McMaster University, Hamilton, ON

**SP15****Cutaneous Leishmaniasis in Five Canadian Soldiers Returning from Afghanistan Treated with Oral Miltefosine**

O. LARIOS\*, Y. KEYNAN, M. WISEMAN, E. RUBINSTEIN

University of Manitoba, Winnipeg, MB

**SP16****Viral Community Acquired Pneumonia in Adults: Incidence, Organisms, and Outcomes**J. JOHNSTONE<sup>1\*</sup>, S. MAJUMDAR<sup>1</sup>, J. FOX<sup>2,3</sup>, T. MARRIE<sup>1</sup>University of Alberta, Edmonton, AB<sup>1</sup>, Provincial Laboratory for Public Health (Microbiology), Calgary, AB<sup>2</sup>, University of Calgary, Calgary, AB<sup>3</sup>**SP17****Pneumococcal Empyema in Toronto, Ontario (1995-2006)**T. LEE<sup>1\*</sup>, K. GREEN<sup>2</sup>, A. MCGEER<sup>2,1</sup>, D. LOW<sup>2</sup>University of Toronto, Toronto, ON<sup>1</sup>, Mount Sinai Hospital, Toronto, ON<sup>2</sup>**SP18****Beliefs, Attitudes and Opinions Regarding the Shingles Vaccines among Canadians Over 60**

D. SHAW\*, S. MCNEIL

Dalhousie University, Halifax, NS

**SP19****Comparative Genomics Analysis of *Clostridium difficile*: Improving Methods for Detection, Epidemiology, Therapeutics and Understanding Pathogenicity**M. OUGHTON<sup>1\*</sup>, V. FORGETTA<sup>1</sup>, I. BRUKNER<sup>2</sup>,A. VILLENEUVE<sup>1</sup>, G. LEVEQUE<sup>1</sup>, C. NAGY<sup>1</sup>, J. DIAS<sup>1</sup>, V. LOO<sup>3</sup>,V. MAGRINI<sup>4</sup>, M. HICKENBOTHAM<sup>4</sup>, K. HAUB<sup>4</sup>, C. MARKOVIC<sup>4</sup>,J. NELSON<sup>4</sup>, E. MARDIS<sup>4</sup>, A. DASCAL<sup>2</sup>, K. DEWAR<sup>1</sup>McGill University and Genome Quebec Innovation Centre, Montreal, QC<sup>1</sup>, SMBD-Jewish General Hospital, Montreal, QC<sup>2</sup>, McGill University Health Centre, Montreal, QC<sup>3</sup>, Genome Sequencing Centre, Washington University, St. Louis, Missouri, United States<sup>4</sup>**SP20****There is No Way That This is Infectious, or is There??**

T. PAPNEJA\*, M. ALAWI, S. DIXIT, S. HAIDER

McMaster University, Hamilton, ON

**SP21****Unusual Infectious Complications Caused by *Clostridium perfringens***

S. NAYAN\*, C. LEE, N. SINGHAL

McMaster University, Hamilton, ON

**SP22****Evaluation of the Three Dose Schedule of Conjugate Pneumococcal Vaccine**M. LI<sup>1,2\*</sup>, M. ANDERSON<sup>1</sup>, L. MACDOUGALL<sup>1</sup>, R. WONG<sup>1</sup>,C. MCINTYRE<sup>1</sup>, M. MCIVOR<sup>1</sup>, D. PATRICK<sup>1,3</sup>, M. NAUS<sup>1,3</sup>British Columbia Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of British Columbia, Master of Health Administration (MHA) Program, Vancouver, BC<sup>2</sup>, University of British Columbia, Department of Health Care and Epidemiology, Vancouver, BC<sup>3</sup>**SP23****Multi-drug Resistant (MDR) Serotype 19A *Streptococcus pneumoniae* (SPN) Meningitis in a Child in Ontario**W. CICCOTELLI<sup>1,5</sup>, A. OPAVSKY<sup>1,4</sup>, P. COX<sup>1,4</sup>, U. ALLEN<sup>1,4</sup>,M. ALQAHTANI<sup>1,4</sup>, N. RAU<sup>3,4</sup>, D. PILLAI<sup>3,4</sup>, A. MCGEER<sup>3,4</sup>,D. E. LOW<sup>2,3,4</sup>, S. M. POUTANEN<sup>2,3,4</sup>The Hospital for Sick Children, Toronto, ON<sup>1</sup>, University Health Network, Toronto, ON<sup>2</sup>, Mount Sinai Hospital, Toronto, ON<sup>3</sup>, University of Toronto, Toronto, ON<sup>4</sup>, McMaster University, Hamilton, ON<sup>5</sup>**SP24****First Recovery of an Environmental Bacterium, *Aurantimonas altamirensis* from Clinical Material**M. LUONG<sup>1\*</sup>, V. LEUNG<sup>2</sup>, G. AL-RAHAN<sup>2</sup>, D. LAUZON<sup>3</sup>,S. BEKAL<sup>4</sup>, D. VINH<sup>1</sup>, B. NG<sup>5</sup>, A. REIMER<sup>5</sup>, T. BURDZ<sup>5</sup>,D. WIEBE<sup>5</sup>, K. BERNARD<sup>5</sup>McGill University Health Centre, Montreal, QC<sup>1</sup>, Children's & Women's Health Centre of British Columbia, Vancouver, BC<sup>2</sup>, Hopital St-Jean du Haut-Richelieu, St. Jean, QC<sup>3</sup>, Laboratoire de Santé Publique du Québec, INSPQ, Sainte-Anne-de-Bellevue, QC<sup>4</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>5</sup>**SP25*****Mycobacterium haemophilum* Epididymal Abscess in a Renal Transplant Patient**M. KELLER<sup>1</sup>, A. MAK<sup>1\*</sup>, L. THIBERT<sup>2</sup>, P. RENÉ<sup>1</sup>, M. KLEIN<sup>3</sup>Department of Microbiology, McGill University Health Centre, Montreal, QC<sup>1</sup>, Laboratoire de santé publique du Québec, Sainte-Anne-de-Bellevue, QC<sup>2</sup>, Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montreal, QC<sup>3</sup>

**ALL STUDENT  
POSTER  
PRESENTERS,  
WE ENCOURAGE  
YOU TO  
ATTEND THE  
AWARDS  
PRESENTATION.**

**Saturday, March 1**  
Pavilion Ballroom –  
Level Three

**1515 – 1800**

# POSTER PRESENTATIONS

(Available as of time of printing)

## SP26

### Evaluation of Quiki-cult Urine Screening System

A. BELHAJ<sup>1\*</sup>, C. LEE<sup>1,2</sup>, C. MAIN<sup>1,2</sup>, D. YAMAMURA<sup>1,2</sup>,  
L. WILCOX<sup>2</sup>, J. PAGET<sup>2</sup>, K. POWER<sup>2</sup>  
McMaster University, Hamilton, ON<sup>1</sup>, Hamilton Regional  
Laboratory Medicine Program, Hamilton, ON<sup>2</sup>

## SP27

### Changing the Culture of an Institution: Sharps Injuries and the Perception and Attitudes Toward them at a Canadian Centre

J. NADARAJAH<sup>\*</sup>, C. MAIN  
McMaster University, Hamilton, ON

## SP28

### Terminal Gram Stains and Subcultures of Sterile Fluids Submitted in Blood Culture Vials: Is There a Need?

J. CARSON<sup>1\*</sup>, U. CHANDRAN<sup>1,2</sup>  
University of Alberta, Edmonton, AB<sup>1</sup>, Dynacare Kasper Medical  
Laboratories, Edmonton, AB<sup>2</sup>

## SP29

### Withdrawn

## SP30

### Community Acquired Methicillin Resistant *Staphylococcus aureus* in London, Ontario: a 30 Month Retrospective Study

Z. CHAGLA<sup>1\*</sup>, M. SALVADOR<sup>2</sup>, Z. HUSSAIN<sup>2</sup>, Y. CHAGLA<sup>2</sup>,  
M. JOHN<sup>2</sup>  
Queen's University, Kingston, ON<sup>1</sup>, London Health Sciences  
Centre, London, ON<sup>2</sup>

## SP31

### Risk Factors for Community and Hospital-Associated MRSA Infections in Patients Presenting to Emergency Departments with Staphylococcal Soft Tissue Infections in a Major Canadian City

H. ADAM<sup>1</sup>, V. ALLEN<sup>1\*</sup>, B. BORGUNDVAA<sup>2</sup>, A. CURRIE<sup>3</sup>,  
A. MCGEER<sup>2,1</sup>, A. SIMOR<sup>4,1</sup>, S. RICHARDSON<sup>5,1</sup>, L. LOUIE<sup>4</sup>,  
B. WILLEY<sup>2</sup>, K. KATZ<sup>3,1</sup>, EMERGENT WORKING GROUP<sup>1</sup>  
University of Toronto, Toronto, ON<sup>1</sup>, Mount Sinai Hospital,  
Toronto, ON<sup>2</sup>, North York General Hospital, North York, ON<sup>3</sup>,  
Sunnybrook Health Sciences Centre, Toronto, ON<sup>4</sup>, The Hospital  
for Sick Children, Toronto, ON<sup>5</sup>

## SP32

### MRSA Blood Stream Infection: Epidemiologic and Clinical Characteristics in One Institution Over a Seven Year Period

J. MINION<sup>\*</sup>, L. SAXINGER, L. CHUI, J. FULLER, G. TAYLOR  
University of Alberta, Edmonton, AB

## SP33

### Detection of Fusidic Acid Resistance in Methicillin-Resistant *Staphylococcus aureus* (MRSA): Verification of E-test and Disc Diffusion Methodologies

P. GNANASUNTHARAM<sup>1,2\*</sup>, B.M. WILLEY<sup>1,3</sup>, V. PORTER<sup>1</sup>,  
S. MALEK<sup>1</sup>, S. PONG-PORTER<sup>1</sup>, Y. RZAYEV<sup>1</sup>, D.E. LOW<sup>1,2,3,4</sup>,  
S. POUTANEN<sup>1,2,3</sup>  
Mount Sinai Hospital, Toronto, ON<sup>1</sup>, University of Toronto,  
Toronto, ON<sup>2</sup>, University Health Network, Toronto, ON<sup>3</sup>, Central  
Public Health Laboratory, Toronto, ON<sup>4</sup>

## SP34

### Molecular Epidemiology and Antibiotic Susceptibilities of Methicillin-Resistant *Staphylococcus aureus* (MRSA) in Emergency Room (ER) Patients over 6 years

A. ROSTAS<sup>\*</sup>, B.M. WILLEY, E. CUDEK, M. MOUSSA, D.E. LOW  
Mount Sinai Hospital, Toronto, ON

## SP35

### Detection of Low- and High-Level Mupirocin Resistance in Methicillin-Resistant *Staphylococcus aureus* (MRSA): Evaluation of Mupirocin Screen Agars

V. PORTER<sup>1\*</sup>, S.M. POUTANEN<sup>1,2,3</sup>, N. KREISWIRTH<sup>1</sup>,  
E. CUDEK<sup>1,2</sup>, N. NELSON<sup>1,2</sup>, S. MALEK<sup>1,2</sup>, A. MCGEER<sup>1,2,3</sup>,  
D.E. LOW<sup>1,2,3,4</sup>, B.M. WILLEY<sup>1,2</sup>  
Mount Sinai Hospital, Toronto, ON<sup>1</sup>, University Health Network,  
Toronto, ON<sup>2</sup>, University of Toronto, Toronto, ON<sup>3</sup>, Public Health  
Laboratory, Toronto, ON<sup>4</sup>

## SP36

### Detection of Verotoxin-producing *Escherichia coli* by Molecular Approach

C. CHEUNG<sup>1\*</sup>, T. CHIU<sup>1</sup>, B. LEE<sup>1</sup>, R. MCDONALD<sup>2</sup>,  
N. ANTONISHYN<sup>2</sup>, L. CHUI<sup>1</sup>  
Provincial Laboratory for Public Health, Edmonton, AB<sup>1</sup>,  
Saskatchewan Disease Control Laboratory, Regina, SK<sup>2</sup>

## SP37

### Molecular Detection of *Giardia lamblia* in Surface Water: Comparison to Gold-Standard Method

N. PRYSTAJECKY<sup>1,3\*</sup>, P. HUCK<sup>2</sup>, J. ISAAC-RENTON<sup>1,3</sup>  
University of British Columbia, Vancouver, BC<sup>1</sup>, University of  
Waterloo, Waterloo, ON<sup>2</sup>, British Columbia Centre for Disease  
Control, Vancouver, BC<sup>3</sup>

## SP38

### Trends in Incidence of Invasive Pneumococcal Disease (IPD) Following Introduction of the Universal Infant Immunization Program, British Columbia (2002-2006)

N. SHAHIDI<sup>1,3\*</sup>, J. DHALIWAL<sup>1</sup>, G. TYRRELL<sup>2</sup>, L. HOANG<sup>1,3</sup>,  
D. PATRICK<sup>1,3</sup>  
British Columbia Centre of Disease Control, Vancouver, BC<sup>1</sup>,  
National Centre of Streptococcus, Edmonton, AB<sup>2</sup>, University of  
British Columbia, Vancouver, BC<sup>3</sup>



## SP39

**The Impact of Routine Immunization Using Meningococcal C Conjugate Vaccine on Invasive Meningococcal Disease in British Columbia and its Implications for Future Immunization Strategies**

T. SIU<sup>1,2\*</sup>, W. TANG<sup>1</sup>, M. DAWAR<sup>2,3</sup>, D. PATRICK<sup>1,2</sup>

British Columbia Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of British Columbia, Vancouver, BC<sup>2</sup>, Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, ON<sup>3</sup>

## SP40

**Prevalence of Chronic Hepatitis B/Hepatitis C Co-infection and Vaccine Preventable Acute Hepatitis in Individuals with Chronic Hepatitis in British Columbia**

S. PADHI<sup>1\*</sup>, J. A. BUXTON<sup>2</sup>, M. KRAJEN<sup>2</sup>, A. YU<sup>2</sup>

University of Ottawa, Ottawa, ON<sup>1</sup>, British Columbia Centre for Disease Control, Vancouver, BC<sup>2</sup>

## SP41

**Validity of Electronic Surveillance Systems: A Systematic Review**

J. LEAL<sup>1\*</sup>, K. LAUPLAND

University of Calgary, Calgary, AB

## SP42

**Prevalence and Characteristics of Quinolone-Resistant *Neisseria gonorrhoeae* Isolates in Ontario**

K. OTA<sup>1\*</sup>, I. TAMARP<sup>2</sup>, K. JONES<sup>2</sup>, D. FISMAN<sup>1,3</sup>, L.K. NG<sup>4</sup>,

F. JAMIESON<sup>3</sup>, A. DIPRIMA<sup>3</sup>, S. RICHARDSON<sup>1</sup>

The Hospital for Sick Children, Toronto, ON<sup>1</sup>, Hassle Free Mens Clinic, Toronto, ON<sup>2</sup>, Ontario Ministry of Health and Long-Term Care, Toronto, ON<sup>3</sup>, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB<sup>4</sup>

## SP43

**Detection of Class 1, 2 and 3 Integrons in Bacteria Using a Real-time Triplex PCR Amplification and Evaluation of its Methodology**

J.H. XIONG<sup>1\*</sup>, M. BLAIS<sup>2</sup>, N. MESSIER<sup>1</sup>, P.H. ROY<sup>1,2</sup>

Centre de Recherche en Infectiologie, Centre Hospitalier de l'Université Laval, Ste-Foy, QC<sup>1</sup>, Department de Biochimie, l'Université Laval, Ste-Foy, QC<sup>2</sup>

## SP44

**Characterization of Efoxitin-resistant *Escherichia coli* from Water Sources in Canada**

L. MATASEJE<sup>1,3\*</sup>, N. NEUMANN<sup>2</sup>, P. BAUDRY<sup>1</sup>, G. ZHANEL<sup>1</sup>,

M. LOUIE<sup>2</sup>, M. MULVEY<sup>1,3</sup>, ARO Water Study Group<sup>2</sup>

University of Manitoba, Winnipeg, MB<sup>1</sup>, Alberta Provincial Public Health Laboratory, Calgary, AB<sup>2</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>3</sup>

## SP45

**Molecular Characterization of *Escherichia coli* Resistant to Trimethoprim-Sulfamethoxazole Isolated from Urinary Tract Infections in Northern Saskatchewan Communities**

N. C. PERSAUD<sup>1,2\*</sup>, H. NGUYEN<sup>1</sup>, G. R. GOLDING<sup>2</sup>, P. N.

LEVETT<sup>3</sup>, R. R. MCDONALD<sup>3</sup>, J. IRVINE<sup>3</sup>, M. R. MULVEY<sup>3</sup> and

Northern Antimicrobial Resistance Partnership

University of Manitoba, Winnipeg, MB<sup>1</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>2</sup>, Saskatchewan Disease Control Laboratory, Regina, SK<sup>3</sup>

## SP46

**Has Mandatory Reporting of HIV Changed the Probability of Newly Diagnosed People Being Early in Their Illness?**

D. TAYLOR<sup>1,5\*</sup>, M. KRAJEN<sup>1,5</sup>, D. COOK<sup>1</sup>, J. KIM<sup>3</sup>, E. WONG<sup>2</sup>,

M. TYNDALL<sup>4,5</sup>, G. OGILVIE<sup>1,5</sup>, M. REKART<sup>1,5</sup>, D. PATRICK<sup>1,5</sup>

BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, Public Health Agency of Canada, Ottawa, ON<sup>2</sup>, National HIV Reference Lab, PHAC, Ottawa, ON<sup>3</sup>, BC Centre for Excellence in HIV/AIDS, Vancouver, BC<sup>4</sup>, University of British Columbia, Vancouver, BC<sup>5</sup>

## SP47

**Novel Mutation in *Mycobacterium tuberculosis* Conferring Rifampin Monoresistance in a Cluster of HIV Positive Patients**

S. MALHOTRA<sup>1\*</sup>, V. COOK<sup>1,2</sup>, J. WOLFE<sup>3</sup>, P. TANG<sup>1,2</sup>,

K. ELWOOD<sup>1,2</sup>, M. SHARMA<sup>3,4</sup>

University of British Columbia, Vancouver, BC<sup>1</sup>, British Columbia Centre for Disease Control, Vancouver, BC<sup>2</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>3</sup>, University of Manitoba, Winnipeg, MB<sup>4</sup>

## SP48

**Antimicrobial Resistance in Gonorrhea: the Influence of Epidemiologic and Laboratory Surveillance Data on Provincial Treatment Guidelines in Alberta, 2001 to 2007**

C. BOYINGTON<sup>1\*</sup>, A.E. SINGH, S. PLITT, K. SUTHERLAND,

M. LOVGREN, P. TILLEY, G. TYRRELL

University of Alberta, Edmonton, AB

## SP49

**Cost Effectiveness of a Publicly Funded Hepatitis B Vaccination Program for Blood Donors in British Columbia**

S. WATERS<sup>1,2\*</sup>, J. BUXTON<sup>1,2</sup>, M. BIGHAM<sup>3,4</sup>

Health Care and Epidemiology, University of British Columbia, Vancouver, BC<sup>1</sup>, BC Centre for Disease Control, Vancouver, BC<sup>2</sup>, Canadian Blood Services, Vancouver, BC<sup>3</sup>, Fraser Health Authority, BC<sup>4</sup>

## SP50

**Rapid SNP Profiling of Cryptosporidium Isolates from Sporadic Cases; a 5 Continent Study**

J. WILLIAMSON<sup>1\*</sup>, C. ONG

University of British Columbia, Vancouver, BC

# POSTER PRESENTATIONS

(Available as of time of printing)

## SP51

### Candidemia: Epidemiology, Risk Factors, and Incidence of Mixed Candidemia

G. AL-RAWAHI\*, D. ROSCOE<sup>2</sup>

British Columbia Children's and Women's Hospital, Vancouver, BC<sup>1</sup>, Vancouver General Hospital, Vancouver, BC<sup>2</sup>

## SP52

### Crystal Structure of the F Plasmid TraD-TraM Complex Reveals a Potential Drug Target for Controlling Transmission of the Multi-drug Resistance Mediated by F-like R Factors

J. LU\*, J. WONG, R. EDWARDS, J. MANCHAK, L. FROST, J. GLOVER

University of Alberta, Edmonton, AB

## SP53

### Validation of Pyrrolidonyl Arylamidase (PYR) in Combination with Ornithine Decarboxylase (ODC) for Identification of *Staphylococcus lugdunensis* (LUG)

D.H.S. TAN<sup>1,3\*</sup>, B.M. WILLEY<sup>1,2</sup>, P. AKHAVAN<sup>1</sup>, L. STOAKES<sup>3</sup>, S. ABOOD<sup>1</sup>, L. MAZZULLI<sup>1</sup>, G. SMALL<sup>1,2</sup>, S.M. POUTANEN<sup>1,2,3</sup>  
Mount Sinai Hospital, Toronto, ON<sup>1</sup>, University Health Network, Toronto, ON<sup>2</sup>, University of Toronto, Toronto, ON<sup>3</sup>, London Health Sciences Centre, London, ON<sup>4</sup>

## SP54

Withdrawn

## SP55

### Mediastinitis Despite Appropriate Prophylaxis in Cardiac Surgery: What Else Should We Be Doing to Prevent Infection?

R.A. HARRISON\*, L.M. SAXINGER, G. TAYLOR

University of Alberta, Edmonton, AB

## SP56

### Implementation of a Human Papillomavirus Neutralizing Antibody Assay Based on Pseudovirions

S. SO<sup>1\*</sup>, K. KARUNAKARAN<sup>1</sup>, J. PALEFSKY<sup>3</sup>, M. KRAJDEN<sup>1,2</sup>, M. PETRIC<sup>1,2</sup>

BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of British Columbia, Vancouver, BC<sup>2</sup>, University of California San Francisco, San Francisco, CA, United States<sup>3</sup>

## THURSDAY, FEBRUARY 28

### Poster Presentations

Pavilion Ballroom Foyer

Viewing: 1000 – 1100  
1200 – 1400  
1500 – 1630

## P1

### Identification of Nutritionally Variant Streptococci and Aerobic Actinomycetes as Putative Targets for Verification by 16s rDNA Sequencing Methodologies

S. J. DREWS<sup>1,2,4\*</sup>, C. DELIMA<sup>4</sup>, P. RAWTE<sup>4</sup>, S. BROWN<sup>4</sup>, S. RICHARDSON<sup>1,2,4</sup>, F. JAMIESON<sup>1,2,3</sup>

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON<sup>1</sup>, Mount Sinai Hospital, Toronto, ON<sup>2</sup>, Hospital for Sick Children, Toronto, ON<sup>3</sup>, Ontario Public Health Laboratories, Toronto, ON<sup>4</sup>

## P2

### Biofilm Formation Potential of Staphylococci on Polymer Surface and its Co-relation with Methicillin Susceptibility

A. CHAUDHURY\*, A. GURURAJKUMAR

SV Institute of Medical Sciences, Tirupati, Andhra Pradesh, India

## P3

### Impact of 7-Valent Pneumococcal Conjugate Vaccine (PCV7) on Serotype Distribution of *Streptococcus pneumoniae* (SPN) Clinical Isolates in Canada

J. GUBBAY<sup>2\*</sup>, A. MCGEER<sup>1</sup>, K. GREEN<sup>1</sup>, S. PONG-PORTER<sup>1</sup>, D. LOW<sup>1</sup>

Canadian Bacterial Surveillance Network (CBSN), Mount Sinai Hospital, Toronto, ON<sup>1</sup>, Ontario Public Health Laboratories, Toronto, ON<sup>2</sup>

## P4

### Evolution of *parC* and *gyrA* Quinolone-Resistance Determining Region (QRDR) Mutations in Fluoroquinolone Resistant (FQR) *Streptococcus pneumoniae* (SPN) Following Introduction of Moxifloxacin (Moxi) in Canada

J. GUBBAY<sup>2\*</sup>, A. MCGEER<sup>1</sup>, K. GREEN<sup>1</sup>, R. MELANO<sup>2</sup>, C. SEAH<sup>2</sup>, C. DUNCAN<sup>1</sup>, S. PONG-PORTER<sup>1</sup>, S. DREWS<sup>2</sup>, D. LOW<sup>1,2</sup>

Canadian Bacterial Surveillance Network, Mount Sinai Hospital, Toronto, ON<sup>1</sup>, Ontario Public Health Laboratories, Toronto, ON<sup>2</sup>

## P5

### Selection of High Level Telithromycin Resistance in Erythromycin Resistant Group A (GAS) and Group B (GBS) Streptococcus

S.-B. HARVEY<sup>1,2\*</sup>, K. RAMOTAR<sup>1,2</sup>, M. DESJARDINS<sup>1,2</sup>

The Ottawa Hospital, Ottawa, ON<sup>1</sup>, The Ottawa Hospital Research Institute, Ottawa, ON<sup>2</sup>

## P6

### Comparison of Culture Media and Methods Used for the Detection of Group B Streptococcus (GBS) from Pre-Natal Vaginal/Rectal Specimens

P. KORNHERR\*, K. CAMPBELL, D. DOWHANIUK, D. RAYMONDO, A. HOSSELET, S. VALUPADAS, D. MCLEAN  
Gamma-Dynacare Laboratories, Ottawa, ON

## P7

### Development of a Novel Chimeric Anthrax Serology Standard

C. CORBETT<sup>1,2\*</sup>, L. SCHMIDT<sup>1</sup>, V. SEMENOVA<sup>3</sup>, J. SCHIFFER<sup>3</sup>, D. BOESE<sup>2</sup>, C. QUINN<sup>3</sup>, J. BERRY<sup>1,2</sup>  
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB<sup>1</sup>, Department of Medical Microbiology and Infectious Disease University of Manitoba, Winnipeg, MB<sup>2</sup>, Centers for Disease Control and Prevention, Atlanta, GA, United States<sup>3</sup>

## P8

### LightCycler Detection of Mumps RNA by Real-Time One-Step Reverse-Transcriptase PCR (RT-PCR)

J. LEBLANC\*, J. PETTIPAS, S. CAMPBELL, R. DAVIDSON, T. HATCHETTE  
QE II Health Sciences Centre, Halifax, NS

## P9

### Granulomatous Cervicofacial Lymphadenitis – Not That Many?

K.C. THOON\*, C.Y. CHONG, N.W.S. TEE  
KK Women's and Children's Hospital, Singapore, Singapore

## P10

### Hospital-Acquired Pneumococcal Bloodstream Infection

C. PIENAAR<sup>1\*</sup>, S.W. SMITH<sup>2</sup>, G.J. TYRRELL<sup>3</sup>, M. LOVGREN<sup>3</sup>, G.D. TAYLOR<sup>2</sup>  
LifeLabs, Burnaby, BC<sup>1</sup>, Department of Medicine, University of Alberta, Edmonton, AB<sup>2</sup>, National Centre for Streptococcus, Provincial Laboratory for Public Health, Edmonton, AB<sup>3</sup>

## P11

### Evaluation of the Spectral RapidWN™ Test for the Detection of West Nile Virus IgM Antibodies in Patients' Sera Suspected of West Nile Virus Infection

C. CLAESSENS<sup>1\*</sup>, S. DERAPS<sup>1</sup>, N. SHAIKH<sup>2</sup>  
INSPQ/LSPQ, Sainte-Anne-de Bellevue, QC<sup>1</sup>, Spectral Diagnostics Inc., Toronto, ON<sup>2</sup>

## P12

### Detection of Human Herpesvirus-6B in Respiratory Tract Samples from Children with Respiratory Tract Infection

D. AL-NAKHLI\*, K. LUINSTRAS<sup>2</sup>, A. PETRICH<sup>1,2</sup>, M. SMIEJA<sup>1,2</sup>  
McMaster University, Hamilton, ON<sup>1</sup>, St. Joseph's Healthcare, Hamilton, ON<sup>2</sup>

## P13

### Community Outbreak of *Cyclospora cayentensis* Linked to Organic Basil, British Columbia, 2007

L. SHAH<sup>1,2\*</sup>, L. MACDOUGALL<sup>2</sup>, A. ELLIS<sup>3</sup>, C. ONG<sup>4</sup>, S. SHYNG<sup>5</sup>, L. LEBLANC<sup>6</sup>, *Cyclospora Investigation Team Affiliations*<sup>7, 8, 9, 10</sup>

Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, ON<sup>1</sup>, Epidemiology Services, British Columbia Centre for Disease Control, Vancouver, BC<sup>2</sup>, Foodborne, Waterborne, Zoonotics Infections Division, Public Health Agency of Canada, Guelph, ON<sup>3</sup>, Laboratory Services, British Columbia Centre for Disease Control, Vancouver, BC<sup>4</sup>, BC Food Protection, British Columbia Centre for Disease Control, Vancouver, BC<sup>5</sup>, Canadian Food Inspection Agency, Ottawa, ON<sup>6</sup>, Interior Health Authority, Kelowna, BC<sup>7</sup>, Fraser Health Authority, Surrey, BC<sup>8</sup>, Vancouver Island Health Authority, Victoria, BC<sup>9</sup>, Vancouver Coastal Health Authority, Vancouver, BC<sup>10</sup>

## P14

### Using a Lean Systems Approach (LSA) to Improve Time to Reporting of Positive Blood Cultures (BC)

D. ROSCOE\*, A. WHITLEY, H. GARCHA, S. NAMOCATCAT, J. REID, R. WALKER  
Vancouver General Hospital, Vancouver, BC

## P15

### A Novel Approach for Developing an Internal Positive Control Using Chimeric DNA for Molecular Tests

M.-K. LEE<sup>1\*</sup>, D. EISLER<sup>1</sup>, D. JORGENSEN<sup>1</sup>, Q. WONG<sup>1</sup>, M. MORSHED<sup>1,2</sup>  
BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of British Columbia, Vancouver, BC<sup>2</sup>

## P16

### Evaluation of Extraction Methods for the Detection of Neurotropic Viruses in Cerebrospinal Fluid

H. Z. JOHNSON<sup>1\*</sup>, V. KHURANA<sup>1</sup>, G. APPELYARD<sup>1</sup>, J. FOX<sup>1,2</sup>  
Provincial Laboratory for Public Health (Microbiology), Calgary, AB<sup>1</sup>, Microbiology & Infectious Diseases, University of Calgary, Calgary, AB<sup>2</sup>



# POSTER PRESENTATIONS

(Available as of time of printing)

## FRIDAY, FEBRUARY 29

### Poster Presentations (P17-P62)

Grand Ballroom – Exhibit hall

Viewing: 1030 – 1100  
1200 – 1400  
1500 – 1630

#### P17

### An Albertan VISA? A Clinical and Microbiologic Story of a Vancomycin Intermediate *Staphylococcus aureus*

R.A. HARRISON<sup>1</sup>\*, J. AHMED-BENTLEY<sup>2</sup>, J. FULLER<sup>3</sup>,  
L.M. SAXINGER<sup>1</sup>

University of Alberta Hospital, Edmonton, AB<sup>1</sup>, Dynacare Kasper Medical Laboratories, Edmonton, AB<sup>2</sup>, Provincial Laboratory Alberta, Edmonton, AB<sup>3</sup>

#### P18

### Daptomycin (DAP) Activity Tested Against Gram-Positive (GP) Cocci Isolated in Canadian Medical Centers (2004-2007)

D.L. ROSCOE<sup>1</sup>\*, D.J. HOBAN<sup>1,2</sup>, M.A. DESJARDINS<sup>1,3</sup>,  
K.R. FORWARD<sup>1,4</sup>, R. RENNIE<sup>1,5</sup>, H. SADER<sup>1,6</sup>

Vancouver General Hospital, Vancouver, BC<sup>1</sup>, Health Sciences Centre, Winnipeg, MB<sup>2</sup>, Ottawa Hospital, General Campus, Ottawa, ON<sup>3</sup>, Queen Elizabeth II Health Sciences Centre, Halifax, NS<sup>4</sup>, University of Alberta Hospital, Edmonton, AB<sup>5</sup>, JMI Laboratories, North Liberty, IA, United States<sup>6</sup>

#### P19

### Comparison of Oxoid MIC Evaluator (MICETM) Device with Broth Micro-Dilution (BMD) and Etest® Device from AB Biodisk for Antimicrobial Susceptibility Testing of Enterobacteriaceae

R. RENNIE\*, L. TURNBULL, C. BROSNIKOFF  
University of Alberta Hospital, Edmonton, AB

#### P20

### Antimicrobial Activity and Safety of Coencapsulated Gentamicin and Gallium into Liposomal Formulation

M. HALWANI\*, B. YEBIO<sup>1</sup>, M. ALIPOUR<sup>1</sup>, Z. E. SUNTRES<sup>2</sup>,  
A. KUMAR<sup>1</sup>, A. OMRI<sup>1</sup>

Laurentian University, Sudbury, ON<sup>1</sup>, Lakehead University, Thunder Bay, ON<sup>2</sup>

#### P21

### Antimicrobial Resistance in Pathogens Isolated from Canadian Hospital Outpatient Clinics (C), Emergency Rooms (ER), Medical/Surgical Wards (W) and Intensive Care Units (ICU): Results of the CANWARD 2007 Study

M. DECORBY<sup>1</sup>\*, B. WESHNOWESKI<sup>2</sup>, R. VASHISHT<sup>1</sup>,  
N. LAING<sup>1</sup>, F. TAILOR<sup>1</sup>, N. CHIU<sup>1</sup>, K.A. NICHOL<sup>2</sup>, P. BAUDRY<sup>1</sup>,  
A. WIERZBOWSKI<sup>1</sup>, M. MCCracken<sup>3</sup>, M. MULVEY<sup>1,3</sup>,  
P. LAGACE-WIENS<sup>1</sup>, A. WALKTY<sup>1</sup>, D.J. HOBAN<sup>1,2</sup>, G.G. ZHANEL<sup>1</sup>

University of Manitoba, Winnipeg, MB<sup>1</sup>, Health Sciences Centre/Diagnostic Services of Manitoba, Winnipeg, MB<sup>2</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>3</sup>

#### P22

### Development of Novel SYBR Green Real-Time PCR Assays for the Detection of *Mycoplasma hominis* and *Ureaplasma urealyticum*

A. LUM<sup>1</sup>\*, E. THOMAS<sup>2</sup>, J. BRUNSTEIN<sup>1,2</sup>

Centre for Translational and Applied Genomics, PHSA Labs, Vancouver, BC<sup>1</sup>, Department of Pathology and Laboratory Medicine, Children's and Women's Health Centre of BC, PHSA Labs, Vancouver, BC<sup>2</sup>

#### P23

### Phenotypic and Genotypic Analysis of *Bordetella pertussis* Strains Isolated in Ontario, Canada

M. SILL<sup>1</sup>\*, I. MARTIN<sup>1</sup>, J. STOLTZ<sup>1</sup>, F. JAMIESON<sup>2</sup>, S. BROWN<sup>2</sup>,  
P. TANG<sup>2</sup>, A. CHAGLA<sup>2</sup>, A. MAJURY<sup>2</sup>, J. JESSOP<sup>2</sup>, R. TSANG<sup>1</sup>

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB<sup>1</sup>, Ontario Public Health Laboratory, Ministry of Health and Long Term Care, Toronto, ON<sup>2</sup>

#### P24

### Accuracy of ESBL Detection By The BD Phoenix Analyser

L. BORYCHESKI\*, A. SARABIA

The Credit Valley Hospital, Mississauga, ON

#### P25

### Evaluation of chromID VRE Agar for Isolation and Differentiation of Vancomycin-Resistant Enterococcus

R. WOOLVEN\*, F. PAPADOPOULOS, L. SEXSMITH, H. LUNDY  
Quinte Health Care, Belleville, ON

#### P26

### Evaluation of Rapid Assays to Detect *Giardia* and *Cryptosporidium*

M. ALAWI\*, M. SMIEJA, R. MCQUEEN  
McMaster Hospital, Hamilton, Canada

#### P27

### Validation of Strep B Carrot Broth Using a Prospective Double Swab Comparison Method

M. MILLER<sup>1</sup>\*, L. TOMALTY<sup>1,2</sup>, R. LIAO<sup>1,2</sup>, D. ZOUTMAN<sup>1,2</sup>

Kingston General Hospital, Kingston, ON<sup>1</sup>, Queens University, Kingston, ON<sup>2</sup>

#### P28

### Clinical Evaluation of a Preservative Impregnated Sponge for Transport of Urine Samples for Microbiological Culture

L. TURNBULL\*, C. BROSNIKOFF, R. RENNIE

University of Alberta Hospitals Medical Microbiology Department, Edmonton, AB

#### P29

### Evaluation of 3 Chromogenic Agars for the Rapid Identification of *Candida* Species

H. ADAM\*, S. BOROUHANDI\*, M. ROSCOE<sup>1</sup>, M. GRIS<sup>1</sup>,  
S. RICHARDSON<sup>1,2</sup>, Y. YAU<sup>1,2</sup>

Hospital for Sick Children, Toronto, ON<sup>1</sup>, University of Toronto, Toronto, ON<sup>2</sup>

**P30****Evaluation of a New Process for the Detection and Reporting of Group B Streptococcus from Vagino-rectal Specimens**

E. THOMAS, C. BARTH, K. HEGGLIN\*, D. BRUNDAGE  
Regina Qu'Appelle Health Region, Regina, SK

**P31****Pattern of MRSA Colonization in Families of Children with MRSA Infection**

S. WOOTTON<sup>1</sup>\*, S. DOBSON<sup>1</sup>, E. THOMAS<sup>1</sup>, L. JANZ<sup>2</sup>,  
A. PACCAGNELLA<sup>2</sup>, S. GOH<sup>2,1</sup>, L. HOANG<sup>2</sup>  
University of British Columbia, Vancouver, BC<sup>1</sup>,  
BC Centre for Disease Control, Vancouver, BC<sup>2</sup>

**P32****Characterization of Community-Associated Methicillin-Resistant and -Sensitive *Staphylococcus aureus* Infections in Three Northern Saskatchewan Communities**

G.R. GOLDING<sup>1</sup>\*, M.R. MULVEY<sup>1</sup>, P.N. LEVETT<sup>3</sup>,  
R.R. McDONALD<sup>2</sup>, J. IRVINE<sup>3</sup>  
National Microbiology Laboratory, Winnipeg, MB<sup>1</sup>, Saskatchewan  
Disease Control Laboratory, Regina, SK<sup>2</sup>, Population Health Unit,  
LaRonge, SK<sup>3</sup> and The Northern Antibiotic Resistance Partnership

**P33****Comparison of Community-Associated Methicillin-Resistant *Staphylococcus aureus* (CA-MRSA) and Hospital-Associated MRSA (HA-MRSA) in Canada: Results from CANWARD 2007**

K.A. NICHOL<sup>1</sup>\*, M.R. DECORBY<sup>2</sup>, P.R.S. LAGACE-WIENS<sup>2</sup>,  
M. MCCracken<sup>3</sup>, M.R. MULVEY<sup>3</sup>, D.J. HOBAN<sup>1,2</sup>,  
G.G. ZHANEL<sup>2</sup>  
Health Sciences Centre/Diagnostic Services of Manitoba,  
Winnipeg, MB<sup>1</sup>, University of Manitoba, Winnipeg, MB<sup>2</sup>,  
National Microbiology Laboratory, Winnipeg, MB<sup>3</sup>

**P34****A Real-Time PCR Assay to Identify MRSA and CMRSA10 from Surveillance Samples**

G. RITCHIE\*, A. WONG, M. ROMNEY, S. CHAMPAGNE  
Division of Medical Microbiology, St. Paul's Hospital, Providence  
Health Care, Vancouver, BC

**P35****Surveillance for Methicillin-Resistant *Staphylococcus aureus* (MRSA) at a Toronto Community Shelter: Molecular and Antimicrobial Resistance Characteristics**

B.M. WILLEY<sup>1,2</sup>\*, B. BORGUNDAAG<sup>1,3</sup>, T. SVOBODA<sup>4</sup>,  
A. ROSIAS<sup>1</sup>, P. GNANASUNTHARAM<sup>1,3</sup>, M. LOFTUS<sup>1</sup>, A. TYLER<sup>1,3</sup>,  
V. PORTER<sup>1</sup>, N. KREISWIRTH<sup>1</sup>, L. LOUIE<sup>5</sup>, A. MCGEER<sup>1,2,3</sup>  
Mount Sinai Hospital, Toronto, ON<sup>1</sup>, University Health Network,  
Toronto, ON<sup>2</sup>, University of Toronto, Toronto, ON<sup>3</sup>, Centre for  
Research on Inner City Health, St Michael's Hospital, Toronto,  
ON<sup>4</sup>, Sunnybrook and Womens College Health Science Centre,  
Toronto, ON<sup>5</sup>

**P36****Epidemiology of Tinea Pedis (TP) and Toenail Onychomycosis (TO) in Saskatchewan (SK), Canada**

H. CONGLY\*  
Saskatchewan Disease Control Laboratory,  
Saskatchewan Health, Regina, SK

**P37****Another Letter in the Van Alphabet; Molecular Characterization of the Novel D-Alanine-D-Serine Operon VanL from a Vancomycin-Resistant *Enterococcus faecalis* Isolated in Canada**

D. BOYD<sup>1</sup>\*, B. WILLEY<sup>2</sup>, D. FAWCETT<sup>3</sup>, N. GILLAN<sup>3</sup>,  
M. MULVEY<sup>1</sup>  
Public Health Agency of Canada, Winnipeg, MB<sup>1</sup>,  
Mt. Sinai Hospital and University Health Network, Toronto, ON<sup>2</sup>,  
Rouge Valley Health Centre Centenary Site, Scarborough, ON<sup>3</sup>

**P38****Worms and War: a Case Report of Trauma and Tropical Disease Intersecting**

M. HAWKES<sup>1</sup>\*, C. MASUMBUKO<sup>2</sup>  
University of Toronto, Toronto, ON<sup>1</sup>, HEAL Africa, Goma,  
North Kivu, the Democratic Republic of the Congo<sup>2</sup>

**P39****Validation of RT-PCR Methods for Molecular Diagnostics and Epidemiology of Mumps Virus**

J. HIEBERT<sup>1</sup>\*, C. FUNG<sup>3</sup>, C. SEVENHUYSEN<sup>1</sup>, J. BEIRNES<sup>1</sup>,  
T. HATCHETTE<sup>2</sup>, G. TIPPLES<sup>1</sup>  
National Microbiology Laboratory, Public Health Agency of  
Canada, Winnipeg, MB<sup>1</sup>, Department of Pathology and  
Laboratory Medicine, QE II Health Science Center, Halifax, NS<sup>2</sup>,  
Biological Sciences, University of Alberta, Edmonton, AB<sup>3</sup>

**P40****Comparison of Vitek2 AST-YS01 Card, Sensititer YeastONE Broth Microdilution, Amphotericin Etest, Fluconazole Disk Diffusion (DD) with the CLSI Reference Method Broth Macrodilution (BMD) for Antifungal Susceptibility Testing of *Candida* spp**

S. CHAMPAGNE\*, S. PENGILLY, M. DUMOUCHELLE,  
M. ROMNEY  
Providence Health Care, Vancouver, BC

**P41****Assessment of QuikCult (IME Inc) (QC), a Rapid Culture-Based Screening Method for Urine Specimens (UR)**

K. TAN<sup>1,2</sup>, S. HARRISON<sup>1</sup>, J. REID<sup>1</sup>, D. ROSCOE<sup>1,2</sup>  
Vancouver General Hospital, Vancouver, BC<sup>1</sup>, Canada,  
University of British Columbia, Vancouver, BC<sup>2</sup>

# POSTER PRESENTATIONS

(Available as of time of printing)

**P42**

## **Molecular Epidemiology of a Multiclonal Outbreak of *K. pneumoniae* and *E. coli* Harboring Plasmid-Mediated DHA-1 and *QnrB4* from a Toronto Community Hospital**

D. BOYD<sup>1</sup>, B. WILLEY<sup>2\*</sup>, D. FAWCETT<sup>3</sup>, N. GILLAN<sup>3</sup>, M. MULVEY<sup>1</sup>  
Public Health Agency of Canada, Winnipeg, MB<sup>1</sup>, Mt. Sinai Hospital and University Health Network, Toronto, ON<sup>2</sup>, Rouge Valley Health Centre Centenary Site, Scarborough, ON<sup>3</sup>

**P43**

## **Fatal Cases of *Staphylococcus aureus* Pleural Empyema in Infants**

A. ROUGEMONT<sup>1</sup>, C. BUTEAU<sup>1</sup>, P. OVETCHKINE<sup>1</sup>, J.C. FOURNET<sup>1</sup>, C. BERGERON<sup>1</sup>, D. BOURON-DAL SOGLIO<sup>1</sup>  
CHU Sainte Justine, Montreal, QC

**P44**

## **Imported Cases of Chikungunya Virus-Associated Disease Among Canadian Travellers: 2005 - 2007**

K. MAKOWSKI<sup>1\*</sup>, M. ANDONOVA<sup>1</sup>, H. ARTSOB<sup>1</sup>, M. DREBOT<sup>1</sup>  
National Microbiology Laboratory, Winnipeg, MB

**P45**

## **Ongoing Control of *Haemophilus influenzae* b Infections in Canadian Children: 2004-2007**

D. SCHEIFELE<sup>1,2\*</sup>, S. HALPERIN<sup>1,2</sup>, B. LAW<sup>1,3</sup>, R. BORTOLUSSI<sup>1,2</sup>  
Canadian Immunization Monitoring Program, Active (IMPACT), Ottawa, ON<sup>1</sup>, Canadian Paediatric Society, Ottawa, ON<sup>2</sup>, Public Health Agency of Canada, Ottawa, ON<sup>3</sup>

**P46**

## **Cryptosporidiosis in Bears in Metro Vancouver Watersheds: What are the Public Health Implications?**

S. SHAY<sup>1</sup>, R. GROVER<sup>2</sup>, A. LI<sup>1</sup>, B. AUK<sup>1\*</sup>, J. FUNG<sup>1</sup>, J. ISAAC-RENTON<sup>1,2</sup>, C. ONG<sup>1,2</sup>  
Environmental Microbiology, BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC<sup>2</sup>

**P47**

## **Canavanine-Glycine-Bromothymol Blue Media Versus RFLP for the Identification of *C. neoformans* var. *gattii*, an Emerging Pathogen in British Columbia**

S. MITHANI<sup>1\*</sup>, M. LEE<sup>1</sup>, G. AL-RAWAH<sup>2</sup>, M. MORSHED<sup>1,3</sup>, J. ISAAC-RENTON<sup>1,3</sup>, L. HOANG<sup>1,3</sup>  
Laboratory Services, BC Centre for Disease Control, PHSA, Vancouver, BC<sup>1</sup>, Children's & Women's Health Centre of British Columbia, Vancouver, BC<sup>2</sup>, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC<sup>3</sup>

**P48**

## **First isolation of *Borrelia burgdorferi* from *Ixodes cookei* Removed From a Dog in Alberta**

K. FERNANDO<sup>1\*</sup>, M.-K. LEE<sup>1</sup>, Q. WONG<sup>1</sup>, K. BURGESS<sup>2</sup>, L. DURDEN<sup>3</sup>, M. MORSHED<sup>1,4</sup>  
BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, St. Albert Animal Clinic, St. Albert, AB<sup>2</sup>, Georgia Southern University, Statesboro, GA, United States<sup>3</sup>, University of British Columbia, Vancouver, BC<sup>4</sup>

**P49**

## **A Rare *Cryptosporidium hominis* Subtype Links Cryptosporidiosis Cases Associated with the Use of a Community Aquatic Centre**

C. PLOHMAN<sup>1</sup>, S. CHOW<sup>1</sup>, R. GUSTAFSON<sup>1,3</sup>, R. PARKER<sup>2</sup>, C. ONG<sup>1,3\*</sup>  
University of British Columbia, Vancouver, BC<sup>1</sup>, Fraser Health Authority, BC<sup>2</sup>, BC Centre for Disease Control, Vancouver, BC<sup>3</sup>

**P50**

## **Surveillance of Multi-resistant *Streptococcus pneumoniae* in Southern Saskatchewan**

E. NAGLE<sup>1\*</sup>, R. R. MCDONALD<sup>1</sup>, G. B. HORSMAN<sup>1</sup>, P. N. LEVETT<sup>1</sup>  
Saskatchewan Disease Control Laboratory, Regina, SK

**P51**

## **Genotyping of Measles Virus in Canada: 2002 - 2008**

J. HIEBERT<sup>1\*</sup>, J. BEIRNES<sup>1</sup>, G. TIPPLES<sup>1</sup>  
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

**P52**

## **Development of Canadian Clinical Preventive Guidelines for Newly Arriving Immigrants and Refugees: A National Collaboration to Improve the Health of Migrants**

H. SWINKELS<sup>1\*</sup>, J. FEIGHTNER<sup>2</sup>, L. J. KIRMAYER<sup>3</sup>, N. MACDONALD<sup>4</sup>, L. NARASIAH<sup>5</sup>, K. POTTIE<sup>6</sup>, M. RASHID<sup>7</sup>, V. ROBINSON<sup>8</sup>, P. TUGWELL<sup>9</sup>, C. GREENAWAY<sup>9</sup>  
Department of Health Care and Epidemiology and Department of Family Practice, University of British Columbia, Vancouver, BC<sup>1</sup>, Department of Family Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, Hamilton, ON<sup>2</sup>, Culture and Mental Health Research Unit, SMBD-Jewish General Hospital, Division of Social & Transcultural Psychiatry, McGill University, Montreal, QC<sup>3</sup>, Department of Paediatrics, IWK Health Centre, Dalhousie University, Halifax, NS<sup>4</sup>, Programme Régional d'Accueil et d'Intégration des Demandeurs d'Asile (PRAIDA), Montreal, QC<sup>5</sup>, Department of Family Medicine, Institute of Population Health and Elisabeth Bruyere Research Institute, University of Ottawa, Ottawa, ON<sup>6</sup>, Access Alliance Community Health Centre, Toronto, ON<sup>7</sup>, Institute of Population Health, University of Ottawa, Ottawa, ON<sup>8</sup>, Division of Infectious Diseases, SMBD-Jewish General Hospital, McGill University, Montreal, QC<sup>9</sup>



# P53

## Comparison Of *Campylobacter jejuni* Isolates From Human Cases And Chicken In Ontario By Fla Gene Sequencing

G. BROUKHANSKI<sup>1,2\*</sup>, R. ESHAGHI<sup>1</sup>, W. MEI<sup>3</sup>, J. LABELLE<sup>1</sup>, A. VALDIVIESO-GARCIA<sup>4</sup>, S. BROWN<sup>1</sup>, F. JAMIESON<sup>1,2</sup>  
Toronto Public Health Laboratories, Toronto, ON<sup>1</sup>, University of Toronto, Toronto, ON, BC<sup>2</sup> Centre for Disease Control, Vancouver, BC<sup>3</sup>, Public Health Agency of Canada, Guelph, ON<sup>4</sup>

# P54

## Characterization of Human Cefoxitin-resistant (FOX-R) *Salmonella* Isolates in Canada 2005-2006

L. MATASEJE<sup>1,2\*</sup>, J. XIAO<sup>4</sup>, S. KOST<sup>1</sup>, L.-K. NG<sup>1,2</sup>, K. DORE<sup>3</sup>, M. MULVEY<sup>1,2</sup>, and Canadian Integrated Program on Antimicrobial Resistance Surveillance (CIPARS)  
University of Manitoba, Winnipeg, MB<sup>1</sup>, National Microbiology Laboratory, Winnipeg, MB<sup>2</sup>, Laboratory for Foodborne, Waterborne and Zoonotic Infections Division, Guelph, ON<sup>3</sup>, Centre for Disease Control and Prevention, Shenzhen, Baoan, China<sup>4</sup>, CIPARS

# P55

## The Detection of West Nile Virus Infections in Humans and Horses From Cuba: 2003-2005

M. ANDONOVA<sup>1\*</sup>, M. PUPO<sup>2</sup>, M. GUZMAN<sup>2</sup>, R. LINDSAY<sup>1</sup>, H. ARTSOB<sup>1</sup>, M. DREBOT<sup>1</sup>  
National Microbiology Laboratory, Winnipeg, MB<sup>1</sup>, Tropical Medicine Institute "Pedro Kouri", Havana, Cuba<sup>2</sup>

# P56

## Evaluation and Comparison of Commercial Immunological Reagents for *Legionella* spp

K. BERNARD<sup>1,2</sup>, A. REIMER<sup>1\*</sup>, D. WIEBE<sup>1</sup>, T. BURDZ<sup>1</sup>, B. NG<sup>1</sup>  
Public Health Agency of Canada, Winnipeg, MB<sup>1</sup>, University of Manitoba, Winnipeg, MB<sup>2</sup>

# P57

## Investigation of an Unusual Gram-Negative Bacillus Recovered from Contaminated Toothpaste, Identified as a Member of the Genus *Halotalea*

K. BERNARD<sup>1,3\*</sup>, B. NG<sup>1</sup>, A. REIMER<sup>1</sup>, T. BURDZ<sup>1</sup>, D. WIEBE<sup>1</sup>, J. GAGNON<sup>2</sup>, C. COIGNAUD<sup>2</sup>, J. BELLEMARE<sup>2</sup>, G. GOVIN<sup>2</sup>, H. BOUCHER<sup>2</sup>  
National Microbiology Laboratory, Winnipeg, MB<sup>1</sup>, HPFBI, Longueuil, QC<sup>2</sup>, University of Manitoba, Winnipeg, MB<sup>3</sup>

# P58

## Foodborne Botulism in British Columbia: A 30 Year History

J. WONG<sup>1\*</sup>, J. FUNG<sup>1</sup>, J. ISAAC-RENTON<sup>1,2</sup>, L. MCINTYRE<sup>1</sup>, A. TRINIDAD<sup>1</sup>  
BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, University of British Columbia, Vancouver, BC<sup>2</sup>

# P59

## Reflections on HIV: Identifying Needs, Improving Learning, Optimizing Patient Care

C. TREMBLAY<sup>1\*</sup>, P. LIN<sup>2</sup>, M.-F. DESLAURIERS<sup>3</sup>  
University of Montreal Hospital Center, Montreal, QC<sup>1</sup>, Canadian Heart Research Centre, Toronto, ON<sup>2</sup>, Pfizer Canada Inc., Kirkland, QC<sup>3</sup>

# P60

## Serological Diagnosis of Syphilis: Enzyme-Linked Immunosorbent Assay to Measure Antibodies to Individual Recombinant *Treponema pallidum* Antigens

A. LAU<sup>1\*</sup>, I. MARTIN<sup>1</sup>, P. SAWATZKY<sup>1</sup>, R. TSANG<sup>1</sup>  
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

# P61

## Implementation and Analysis of an Updated MIRU-VNTR Method for Molecular Typing of *Mycobacteria tuberculosis* in Manitoba

S. CHRISTIANSON<sup>1\*</sup>, P. ORR<sup>2,3</sup>, E. BELLAMY<sup>1</sup>, J. WOLFE<sup>1</sup>, M. SHARMA<sup>1,3</sup>  
Public Health Agency of Canada, Winnipeg, MB<sup>1</sup>, Manitoba Health, Winnipeg, MB<sup>2</sup>, University of Manitoba, Winnipeg, MB<sup>3</sup>

# P62

## Use of Interferon-gamma Assays in a Selective Tuberculin Tested Population at a Vancouver TB Clinic

Y. SIMPSON<sup>1\*</sup>, M. MORSHED<sup>1,3</sup>, Q. WONG<sup>1</sup>, G. STARK<sup>2</sup>, V. COOK<sup>2</sup>, K. ELWOOD<sup>2</sup>, J. ISAAC-RENTON<sup>1,3</sup>  
Laboratory Services, BC Centre for Disease Control, Vancouver, BC<sup>1</sup>, TB Control Division, BC Centre for Disease Control, Vancouver, BC<sup>2</sup>, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC<sup>3</sup>

# POSTER PRESENTATIONS

(Available as of time of printing)

## FRIDAY, FEBRUARY 29

### Poster Presentations (P63-P80)

Pavilion Ballroom Foyer

Viewing: 1030 – 1100  
1200 – 1400  
1500 – 1630

#### P63

### Infection Control E-learning: An Assessment of the Effectiveness of an E-learning Module to Transfer Knowledge on the Proper Use of Personal Protective Equipment (PPE) Through Direct Observation

*E. BRYCE*<sup>1\*</sup>, *B. GAMAGE*<sup>2</sup>, *C. HON*<sup>1</sup>, *J. LOCHANG*<sup>3</sup>, *A. YASSI*<sup>3</sup>, *D. MAULTSAID*<sup>1</sup>, *S. YU*<sup>4</sup>

Vancouver Coastal Health, Vancouver, BC<sup>1</sup>, Provincial Health Services Authority, Vancouver, BC<sup>2</sup>, University of British Columbia, Vancouver, BC<sup>3</sup>, Occupational Health and Safety Agency for Healthcare, Vancouver, BC<sup>4</sup>

#### P64

### The Role of Torovirus in Nosocomial Viral Gastroenteritis at a Large Tertiary Paediatric Centre

*J. GUBBAY*<sup>1\*</sup>, *A. AL-REZQI*<sup>1</sup>, *M. HAWKES*<sup>1</sup>, *L. WILLIAMS*<sup>1</sup>, *S. RICHARDSON*<sup>2,3</sup>, *A. MATLOW*<sup>1</sup>

Department of Paediatrics, The Hospital for Sick Children and The University of Toronto, Toronto, ON<sup>1</sup>, Division of Microbiology, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, ON<sup>2</sup>, Department of Laboratory Medicine and Pathobiology, The University of Toronto, Toronto, ON<sup>3</sup>

#### P65

### The Stealthy Arrival of Super *Clostridium difficile* in Nova Scotia

*S. SMITH*<sup>1\*</sup>, *J. LEBLANC*<sup>2</sup>, *R. DAVIDSON*<sup>1,2</sup>, *K. FORWARD*<sup>1,2</sup>

Dalhousie University, Halifax, NS<sup>1</sup>, Department of Pathology and Laboratory Queen Elizabeth II HSC, Halifax, NS<sup>2</sup>

#### P66

### Evaluation of Chromogenic Screening Media for the Detection of Vancomycin Resistant Enterococci

*B. LUI*, *M. HARRIS*, *P. KASTNER*, *L. ROSMUS*, *J. FULLER*<sup>\*</sup>

Division of Medical Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Edmonton, AB

#### P67

### UV-visible Marker for Assessing Cleaning Compliance of Toilets: A Valuable Tool for Monitoring Cleaning Compliance of Toilets for Patients with *Clostridium difficile* Associated Diarrhea (CDAD)

*M. ALFA*<sup>1,3\*</sup>, *N. OLSON*<sup>2</sup>, *A. WALD*<sup>2</sup>

Dept. of Medical Microbiology, Winnipeg, MB<sup>1</sup>, St. Boniface Research Centre, Winnipeg, MB<sup>2</sup>, Diagnostic Services of Manitoba, Winnipeg, MB<sup>3</sup>

#### P68

### Soap and Water Are Superior to Alcohol Rub and Antiseptic Wipes for Removal of *Clostridium difficile* by Handwashing: A Randomized Controlled Trial

*M. OUGHTON*<sup>1\*</sup>, *V. LOO*<sup>2,3,4</sup>, *N. DENDUKURI*<sup>5</sup>, *S. FENN*<sup>4</sup>, *M. LIBMAN*<sup>2,3,4</sup>

Department of Medicine, McGill University, Montreal, QC<sup>1</sup>, Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, QC<sup>2</sup>, Department of Microbiology, McGill University, Montreal, QC<sup>3</sup>, McGill University Health Centre, Montreal, QC<sup>4</sup>, Department of Epidemiology and Biostatistics, McGill University, Montreal, QC<sup>5</sup>

#### P69

### *Pseudomonas* Blood Stream Infection (BSI); Epidemiology and Clinical Characteristics in One Institution Over a Seven Year Period

*A. ALJIFRI*<sup>\*</sup>

University of Alberta Hospital, Edmonton, AB

#### P70

### Low Concentrations of Herpes Simplex Virus Type 2 (HSV-2) Display Atypical Melting Temperature (T<sub>m</sub>) Profiles

*J. LEBLANC*<sup>\*</sup>, *S. CAMPBELL*, *J. PETTIPAS*, *T. HATCHETTE*, *R. DAVIDSON*

QEII Health Sciences Centre, Halifax, NS

#### P71

### The Utility of Nested PCR and Restriction Endonuclease Digestion for the Genotyping of Herpes Simplex Virus (HSV)

*S. CAMPBELL*<sup>\*</sup>, *J. LEBLANC*, *J. PETTIPAS*, *T. HATCHETTE*, *R. DAVIDSON*

QEII Health Sciences Centre, Halifax, NS

#### P72

### Uracil-DNA Glycosylase (UNG) Influences the Melting Temperature (T<sub>m</sub>) of Herpes Simplex Virus (HSV) Hybridization Probes

*J. LEBLANC*<sup>\*</sup>, *J. PETTIPAS*, *S. CAMPBELL*, *R. DAVIDSON*, *T. HATCHETTE*

QEII Health Sciences Centre, Halifax, NS

#### P73

### International Study of Inter-laboratory Variation of Cytomegalovirus Viral Load

*K. MARTIN*<sup>1\*</sup>, *J.K. PREIKSAITIS*<sup>1,2</sup>, *X.L. PANG*<sup>1,2</sup>, *J.D. FOX*<sup>1,3</sup>, *G. MILLER*<sup>4</sup>, *A. CALIENDO*<sup>5</sup>, *AST INFECTIOUS DISEASE COMMUNITY OF PRACTICE*

Provincial Public Health Laboratory (Microbiology), AB<sup>1</sup>, University of Alberta, Edmonton, AB<sup>2</sup>, University of Calgary, Calgary, AB<sup>3</sup>, Vanderbilt University, Nashville, Tennessee, United States<sup>4</sup>, Emory University School of Medicine, Atlanta, Georgia, United States<sup>5</sup>

# P74

## Evaluation of Trinity Biotech Captia™ IgG and Euroimmun IgG ELISA Assays for Determining Immunity to Varicella Zoster, Measles and Mumps Viruses

D.A. JOHNSON<sup>1,\*</sup>, S.E. DALE<sup>1,2</sup>, J.B. MAHONY<sup>1,2</sup>

McMaster University, Hamilton, ON<sup>1</sup>,  
St. Joseph's Healthcare, Hamilton, ON<sup>2</sup>

# P75

## Genomics-Based Methods for the Detection and Whole-Genome Sequencing of an Unknown Virus

D. EISLER<sup>1,\*</sup>, D. LAWRENCE<sup>1</sup>, R. GILLIES<sup>1</sup>, M. PETRIC<sup>1,2</sup>,  
P. TANG<sup>1,2</sup>

British Columbia Centre for Disease Control, Vancouver, BC<sup>1</sup>,  
University of British Columbia, Vancouver, BC<sup>2</sup>

# P76

## Comparison of the Qiagen QIAcube® and the Roche MagNA Pure Compact® for the Extraction of Viral Nucleic Acid

C. KERN, L. SHAW, T. KARNAUCHOW\*

Regional Virology Laboratory, Children's Hospital of Eastern  
Ontario, Ottawa, ON

# P77

## A Real-time PCR Assay for Detection of Herpes Simplex Virus in CSF Using the Spartan DX™, a New Real-time PCR Instrument

L. SHAW, A. ROGAEVA, C. HARDER, T. KARNAUCHOW\*

Regional Virology Laboratory, Children's Hospital of Eastern  
Ontario, Ottawa, ON

# P78

## Development of a Quantitative PCR Assay for Human Adenovirus

K. ADIE<sup>1,\*</sup>, A. MAK<sup>1</sup>, A. MCNABB<sup>1</sup>, M. PETRIC<sup>1,2</sup>, P. TANG<sup>1,2</sup>

British Columbia Centre for Disease Control, Vancouver, BC<sup>1</sup>,  
University of British Columbia, Vancouver, BC<sup>2</sup>

# P79

## A Comparison of Cell Culture Versus Real Time PCR (RT-PCR) for the Detection of HSV 1/2 from Routine Clinical Specimens

S. CAMPBELL<sup>1,\*</sup>, J. LEBLANC<sup>1</sup>, J. PETTIPAS<sup>1</sup>, T. HATCHETTE<sup>1,2</sup>,  
R. DAVIDSON<sup>1,2</sup>

Queen Elizabeth II Health Sciences Centre, Halifax, NS<sup>1</sup>,  
Dalhousie University, Halifax, NS<sup>2</sup>

# P80

## Clinical Concordance of the CDC and Siemens Medical Solutions Diagnostics Influenza A/B Virus Molecular Assays

N. KREISWIRTH<sup>1</sup>, B.M. WILLEY<sup>1,2</sup>, J. DETMER<sup>3</sup>, S. SANGHA<sup>3</sup>,

M. ALBALOS<sup>3</sup>, A. PETRICH<sup>4</sup>, S. CHONG<sup>4</sup>, K. LUINSTR<sup>4</sup>,

G. MOUSSA<sup>1</sup>, C. BUSH<sup>3</sup>, J. MAHONEY<sup>4</sup>, S. RICHARDSON<sup>5,6</sup>,

M. SMIEJA<sup>4</sup>, T. MAZZULLI<sup>1,2,6</sup>, A. TYLER<sup>1,\*</sup>

Mount Sinai Hospital, Toronto, ON<sup>1</sup>, University Health Network,  
Toronto, ON<sup>2</sup>, Siemens Medical Solutions Diagnostics,  
Tarrytown, New York, United States<sup>3</sup>, St. Josephs Hospital,  
McMaster University, Hamilton, ON<sup>4</sup>, Hospital for Sick Children,  
Toronto, ON<sup>5</sup>, University of Toronto, Toronto, ON<sup>6</sup>

# P81

## Detection of MRSA by the BD GenOhm MRSA Assay (BMA) from Flocked Swabs Transported in Liquid Amies (LA)

D. GOLDFARB<sup>3,\*</sup>, P. JESSAMINE<sup>1,2</sup>, A. BONNEAU<sup>1</sup>,

K. RAMOTAR<sup>1,2</sup>, M. DESJARDINS<sup>1,3</sup>

The Ottawa Hospital, Ottawa, ON<sup>1</sup>, The Ottawa Hospital  
Research Institute, Ottawa, ON<sup>2</sup>, Children's Hospital of Eastern  
Ontario, Ottawa, ON<sup>3</sup>

## FRIDAY, FEBRUARY 29

### CLINICAL VIGNETTE POSTERS

Pavilion Ballroom Foyer

Viewing: 1030 – 1100  
1200 – 1400  
1500 – 1630

### CVP1

#### The Case of the Floppy Baby

N. MORGAN\*, A. WADHWA

McMaster University, Department of Infectious Disease/  
Medical Microbiology

### CVP2

#### A Granulomatous Breast Mass

D.R. RICCIUTO\*, W.L. GOLD

University of Toronto, Toronto, ON

### CVP3

#### Case of *Bordetella bronchiseptica* and *Legionella pneumophila* Pneumonia in an Immunocompromised Patient

B. MEATHERALL\*, D. GREGSON, D. CHURCH

Department of Infectious Disease, University of Calgary,  
Calgary, AB

### CVP4

#### New Seizures in a Previously Healthy Young Man – An Unexpected Case of Neurocysticercosis

J. Y. GABOR\*, J. M. EMBIL

Department of Medicine and Medical Microbiology & Faculty of  
Medicine, University of Manitoba, Winnipeg, MB

### CVP5

#### Chronic Intermittent Hematuria in New Immigrant Child

A. HALEIS\*, M. ALFA, K. MANICKAM, A. RONALD

Department of Medical Microbiology and Infectious Diseases,  
Faculty of Medicine, University of Manitoba, Winnipeg, MB

### CVP6

#### First Case of Meningitis Caused by *Streptococcus suis* Serotype 14 in North America

A. HALEIS\*, M. ALFA, K. MANICKAM, A. RONALD

Department of Medical Microbiology and Infectious Diseases,  
Faculty of Medicine, University of Manitoba, Winnipeg, MB



# AUTHORS INDEX

Abood S	SP53	Carlson M	L1	Eisler D	C1,P15, P75	Isaac-Renton J	E6,02, SP37,
Ackerman M	B1	Carruthers S	M4	El-Helou P	SP14	Jamieson F	P46,P47 ,P58,P62
Adachi D	G1	Carson J	SP28	Ellis A	P13	Jang D	SP5,SP42,P1,P23,P53
Adam H	SP31,P29	Carson M	A1	Elwood K	SP47,P62	Jan L	G3,03
Adie K	P78	Castriciano S	B1,F1,M4	Embil J	H1,H2,I3, CVP4	Jessamine P	P31
Adonsu-Hoyi Y	N1	Chablit-Clark A	E5	Eshaghi R	P53	Jessop J	P81
Ahmed-Bentley J	P17	Chagla A	P23	Ewert R	O3	John M	P23
Akhavan P	SP53	Chagla Y	SP30	Fanella S	H2	Johnson C	SP2,SP30
Alawi M	SP13, SP20, P26	Chagla Z	SP30	Faremo A	E6	Johnson DA	E3
Albalos M	P80	Champagne S	I4, SP4, SP10, SP12, P34, P40	Fawcett D	P37,P42	Johnson HZ	P74
Al-Dabbagh M	B3			Feightner J	P52	Johnston G	P16
Alfa M	H4,04,P67,CVP5,CVP6	Chan D	O1	Fenn S	P68	Johnstone J	L1
Alipour M	SP9, P20	Chand C	O1	Fernando K	P48	Jones K	SP16
Aljifri A	P69	Chandran U	K4,SP28	Fisman D	B2,E3,SP5,SP42	Jorgensen D	SP42
Allen U	SP23	Chapman K	K2	Fitzgerald M	E5	Kadivar K	P15
Allen V	SP31	Chau A	A1,SP8	Forgetta V	SP19	Kajita K	N1
Al-Nakhli D	P12	Chaudhury A	P2	Forward K	D6, L3, P18, P65	Kalalinia BF	N2
Alqahtani M	SP23	Cheang M	H1	Fournet JC	P43	Kanji J	L2
Al-Rahani G	SP24	Chen R	O1	Fox J	D1, D4,SP16,P16, P73	Kapala J	SP14
Al-Rawahi G	SP51,P47	Chen Z	N3	Frenette C	M1	Karlowsky J	G3
Al-Rezqi A	P64	Cheng L	F6	Frost L	SP52	Karlowichow T	04,SP1
Amihod B	M1	Chernesky M	G3,03	Fuller J	C3,K4,SP32,P17, P66	Karnauchow T	P76, P77
Anderson M	SP22	Cheung C	SP36	Fung C	P39	Karunakaran K	SP56
Andonov A	N2	Cheung R	G1	Fung J	02,P46,P58	Kasman N	E5
Andonova M	P44,P55	Chiu N	P21	Gabor JY	CVP4	Kastner P	P66
Antonishyn N	K1,SP36, M2	Chiu T	K1,SP36	Gagnon J	P57	Katz K	SP31
Appleyard G	P16	Chong CY	P9	Galanis E	E6,K2,02	Kaur GJ	SP6
Arbour N	A4	Chong M	A1,A3	Gamage B	P63	Keller M	SP25
Arikan Y	F6	Chong S	D2,E6,G3,P80	Garcha H	P14	Kelly M	L3
Arora DS	SP6	Chong SA	M3	Geddes G	C1	Kendall P	A1
Artsob H	P44,P55	Choptany M	H1	Giambra A	F1	Kern C	P76
Asadipour A	L2	Chow R	N4	Gibson B	E5	Keynan Y	SP15
Auk B	01,P46	Chow S	P49	Gilbert M	N4	Khurana V	P16
Bacalso CM	M2	Christianson S	P61	Gillani N	P37,P42	Kidson P	L3
Bacha N	C2	Chui L	E2,K1,SP32,SP36	Gillies R	P75	Kim J	F4,N1,N3,SP46
Baker L	N4	Church D	F4,CVP3	Glover J	SP52	Kinlin L	E3
Barth C	P30	Ciccotelli W	SP23	Gnanasuntharam P	SP33,P35	Kirmayer LJ	P52
Baudry P	A2, SP1,SP7,SP44, P21	Claessens C	P11	Goh S	I4,01, P31,	Klein M	SP25
Beaulieu S	K3	Clay S	D6	Gold WL	CVP2	Kornherr P	P6
Bechar C	L3	Coignaud C	P57	Goldfarb D	P81	Kost S	P54
Behravan J	L2	Collins C	G1	Golding G	E4, F2, F5, I2, SP45, P32	Kraeker C	SP13
Beirnes S	P39,P51	Congly H	P36	Gouin G	P57	Krajden M	D5,N4,SP40,SP46,SP56
Bekal S	SP24	Conly J	F4	Gravel D	M1	Kreiswirth N	SP35,P35,P80
Belhaj A	SP26	Cook D	D5,N4,SP46	Green K	SP17,P3,P4	Kumar A	SP9, P20
Bellamy E	P61	Cook P	N4	Greenaway C	P52	Kunimoto D	E2
Bellemare J	P57	Cook V	SP47,P62	Gregson D	J3,CVP3	Labelle J	P53
Bergeron C	P43	Corbett C	P7	Gris M	P29	Lagacé-Wiens P	A2,I3,04,SP1, SP7,P21, P33
Bernard K	SP24,P56,P57	Couillard M	K3	Grover R	P46	Laing N	P21
Berry J	P7	Cox P	SP23	Grudeski E	N2	Lakhani A	F6
Bigham M	E6,SP49	Crozier NA	M2	Grunfeld A	F6	Lambert K	L3
Blais M	SP43	Cudek E	SP34,SP35	Gubbay J	P3,P4,P64	Lannigan R	SP2
Blondel-Hill E	A1	Currie A	SP31	Gunadasa K	D5	Larios O	04,SP15
Boehnke R	E5	Dale SE	P74	Gururajkumar A	P2	Lau A	P60
Boese D	P7	Dalton B	F4	Gustafson L	E6	Laupland K	J3,SP41
Bonneau A	P81	Daly P	E6,I4	Gustafson R	E6,P49	Lauzon D	SP24
Booth M	B1	Dasal A	SP19	Guzman M	P55	Laverdière M	L3
Borgundvaag B	SP31,P35	Davidson R	D6,E1,P8,P65, P70,P71,P72,P79	Haase D	E1	Lavoie S	N3
Boroumandi S	P29			Haider S	SP20	Law B	P45
Bortolussi R	P45	Dawar M	SP39	Haleis A	CVP5,CVP6	Lawrence D	P75
Borycheski L	P24	Decorby M	A2,SP1,SP3,SP7,P21, P33	Halperin S	P45	Leal J	SP41
Boucher H	P57	Delima C	P1	Halwani M	SP9, P20	Leblanc J	D6,P8,P65,P70, P71,P72,P79
Bouron-Dal Soglio D	P43	Dendukuri N	P68	Hammond G	H1	Leblanc L	P13
Bowie W	A1,K2	Deraps S	P11	Hansen TL	M2	Lebrihi A	C2
Boyd D	H4,P37,P42	Deschatelets J	N3	Harder C	A4,P77	Lee B	SP36
Boyington C	SP48	Desjardins M	P5, P18, P81	Harris M	L3, P66	Lee C	SP21,SP26
Brauer M	E5	Deslauriers M-F	P59	Harrison P	K2	Lee CH	F3
Breitkreutz L	C3	Detmer J	P80	Harrison RA	SP55, P17	Lee J	H3,J2
Brodin E	02	Dewar K	SP19	Harrison S	P41	Lee M	P47
Brosnikoff C	L3, P19, P28	Dhaliwal J	SP38	Harvey S-B	P5	Lee M-K	P15, P48
Broukhanski G	P53, B2	Dias J	SP19	Hatchette T	D6,E1,G2,P8,P39, P70,P71,P72,P79	Lee T	SP11,SP17
Brown E	SP5	Dibernardo A	B4			Leung B	D5
Brown P	L1	Diprima A	SP42	Haub K	SP19	Leung T	F6
Brown S	SP5,P1,P23,P53	Dirse K	L1	Hawkes M	P38,P64	Leung V	SP24
Brukner I	SP19	Dixit S	SP20	Hegglin K	P30	Leveque G	SP19
Brundage D	P30	Dobson S	A1,B3,P31	Henry B	A1	Levet P	F5, E4,M2,SP45,P32,P50
Brunstein J	B3,P22	Dolman S	SP5	Hewitt K	L3	Li A	SP22,P46
Bryce E	I2,P63	Dore K	P54	Hickenbotham M	SP19	Liao R	P27
Buracond S	G3,M3,M4	Doucette C	G3	Hilderman T	P39,P51	Libman M	P68
Burdz T	SP24,P56,P57	Dowhaniuk D	P6	Ho K	I3	Liboz T	C2
Burgess K	P48	Doyle P	SP11	Hoang L	D4	Light B	H1
Bush C	P80	Doyle-Waters M	E5	Hoban D	C1,E6,01,SP38,P31,P47	Limerick B	H1
Buteau C	P43	Drebot M	B4,P44,P55	Hoban DJ	A2,SP1	Lin P	P59
Buxton J	SP49	Dreher K	A1	Hon C	SP3,SP7,P18,P21,P33	Lindsay R	B4,P55
Buxton JA	SP40	Drews S	B2,P1,P4	Horsman G	P63	Liu L	G4
Calder-Kent B	N1	Dumouchelle M	P40	Hosselet A	F5, E4,M2,P50	Lloyd-Smith E	I4
Caliendo A	P73	Duncan C	P4	Huck P	P6	Locas MC	L3
Campbell J	I2, F2	Dunnett S	F3	Hull M	SP37	Lochang J	P63
Campbell K	P6	Durden L	P48	Hussain Z	I4,SP4,SP10	Loeb M	I2
Campbell N	E1	Eden S	M1	Irvine J	SP30		
Campbell S	P8,P70,P71,P72,P79	Edwards R	SP52		E4,F5,SP45,P32		

## AUTHORS INDEX

Loftus M	P35	Narasiah L	P52	Romney M	I4,SP4,SP10,P34,P40	Thomas E	B3,P22, P31
Long R	E2	Naus M	SP22	Ronald A	CVP5,CVP6	Thoon KC	P9
Loo V	SP19,P68	Nayan S	SP21	Roscoe D	SP11, SP13, SP51, P14, P18, P41	Tilley P	SP48, D4
Louie K	E6	Ndao M	J1			Tipples G	P39,P51
Louie L	I2,SP12, SP31,P35	Nelson J	SP19	Roscoe M	P29	Tokaryk K	D1
Louie M	SP44	Nelson N	SP35	Rosmus L	P66	Tokaryk KL	D4
Lovgren M	SP48,P10	Neumann N	SP44	Ross T	J3	Tomalty L	P27
Low D	A1,SP17,SP23,SP33, SP34,SP35, P3,P4	Neva F	J1	Rostas A	SP34,P35	Toye B	A4
		Ng B	SP25,P56,P57	Rougement A	P43	Tremblay C	P59
Lowe C	SP11	Ng L-K	P54, SP42	Roy PH	SP43	Trepman E	H1
Lu J	SP52	Ng-Brett V	E3	Rubinstein E	SP15	Trinidad A	P58
Lui B	P66	Nguyen H	SP45	Rutherford C	F3	Tsang P	N4,P23,P60
Luinstra K	B1,B4,M3,P12,P80	Nichol K	A2,SP3,SP7, P21,P33	Rzayev Y	SP33	Tugwell P	P52
Lum A	P22	Nicoll L	I3	Sader H	P18	Turnbull L	C3, L3, P19, P28
Lundy H	P25	Nishikawa J	G1	Salvadori M	SP30	Twele L	F4
Luong M	SP24	Nsungu M	F5	Sand C	C3	Tyler A	P35,P80
Lyn P	F3	Obariany AK	M2	Sangha S	P80	Tyndall M	I4,SP46
MacDonald K	H1	Ofner M	I2	Sarabia A	P24	Tyrrell G	E2,K1,SP38,SP48,P10
MacDonald N	P52	Ogilvie G	SP46	Sarsfield P	H1	Valdivieso-Garcia A	P53
MacDougall L	SP22, P13	Olson N	P67	Sarwal S	D6	Valupadas S	P6
MacEachern D	O3	Omri A	SP9, P20	Sauvé C	K3	Van Zuilen L	F3
MacLean D	J1	Ong C	J2,SP50, P13, P46,P49	Sauve L	B3	Varatharajulu R	J1
MacRitchie C	O3	Opavsky A	SP23	Sawatzky P	P60	Vashisht R	P21
Magrini V	SP19	Ormiston D	I3	Saxinger L	I1,K4,SP32,SP55, P17	Vasquez-Camargo F	J1
Mahony J	B1,D2,G4,M3, P74, P80	Orr P	P61	Scheifele D	P45	Vayalunkal J	M1
Main C	F3,SP26,SP27	Ota K	SP42	Schiffer J	P7	Vehyl J	F2
Majumdar S	SP16	Oughton M	SP19,P68	Schmidt L	P7	Villeneuve A	SP19
Majury A	P23	Ovetchkine P	P43	Schofield A	C3	Vinh D	SP24
Mak A	D5, SP25, P17, P78	Pabbaraju K	D1,D4	Seah C	P4	Vortel J	K2
Mak S	A3	Paccagnella A	O1,P31	Sebastian R	SP4	Vrbova I	A1,E5,SP8
Makowski K	P44	Padhi S	SP40	Semenova V	P7	Wadhwa A	CVP1
Maksymiw TA	M2	Paget J	SP26	Serhir B	K3	Wald A	P67
Malek S	SP33,SP35	Palefsky J	SP56	Sevenhuysen C	P39	Waldron B	L3
Malhotra S	SP47	Pang XL	P73	Sexsmith L	P25	Walker R	P14
Malloch L	N1	Papadopoulos F	P25	Shah L	P13	Walkty A	P21
Manchak J	SP52	Papneja T	SP20	Shahidi N	SP38	Wang C	H3
Manickam K	O4,CVP5,CVP6	Pappas P	H1	Shaikh N	P11	Ward B	J1
Mardis E	SP19	Parker R	P49	Sharma M	SP47,P61	Waters S	SP49
Markovic C	SP19	Patel J	G3	Sharp M	K2	Watson Creed G	D6
Marra F	A1,A3	Patrick D	A1,A3,E5,SP8,SP22, SP38,SP39,SP46	Shaw D	SP18	Watt C	I2,SP12
Marrie T	E1,SP16			Shaw L	P76, P77	Webby R	G2
Martin I	P23,P60	Pelletier M	K3	Shay S	P46	Webster D	E1
Martin K	P73	Pengilly S	P40	Shyng S	P13	Webster R	G2
Masumbuko C	P38	Persaud NC	SP45	Sill M	P23	Weir C	M1
Mataseje L	SP44,P54	Petric M	D3,SP56,P75,P78	Simor A	F2, I2, SP12, SP31	Weshnoweski B	P21
Mathieu F	C2	Petrich A	B1,B4,M3,P12,P80	Simpson Y	P62	White A	E3
Matlow A	I2, P64	Pettipas J	D6,E1,P8,P70,P71,P72,P79	Singh AE	SP48	Whitley A	P14
Maultsaid D	P63	Phillips P	H3, K2	Singhal N	SP13, SP21	Wiebe D	SP24,P56,P57
Mazzulli L	SP53	Phong Dao H	C2	Siu T	SP39	Wiebe L	H1
Mazzulli T	B2,P80	Pienaar C	P10	Skinner S	H2	Wierzbowski A	SP3, P21
McCracken M	P21,P33	Pillai D	SP23	Small G	SP53	Wilcox L	F3,SP26
McDonald R	F5,K1,SP36	Pisani C	K4	Smieja M	B1,G3,M3,M4,O3, P12,P26,P80	Willey B	SP31, SP33,SP34,SP35, SP53, P35, P37, P42, P80
McDonald RR	E4,M2,SP45,P32,P50	Plitt S	SP48			Williams L	P64
McGeer A	I2,M1,SP17,SP23, SP31,SP35,P3,P4,P35	Plohmman C	P49	Smith SW	P10	Williamson J	SP50
		Pong-Porter S	P3,P4,SP33	Smith S	P60	Willson P	G2
McIntyre C	SP22	Porter V	SP33,SP35,P35	So G	M4	Wiseman M	SP15
McIntyre L	E6,P58	Portillo E	G3,O3	Spain V	SP56	Witkowska M	SP2
McIvor M	SP22	Pottie K	P52	Spreitzer DJ	E3	Wolfe J	SP47,P61
McKnight D	SP11	Poutanen SM	SP23,SP33,SP35,SP53	Stark G	F2	Wong A	M1,P34
McLean D	P6	Power K	SP26	Stefanovic A	P62	Wong B	E6,O2
McNabb A	C1,O1,P78	Preiksaitis J	E2, P73	Steiner T	SP4	Wong E	SP46
McNeil S	SP18	Pritchard C	O3	Stephen C	K2	Wong J	O2,SP52,P58
McQueen R	P26	Prystajecy N	SP37	Stoakes L	E5	Wong Q	P15, P48,P62
Meatherall B	CVP3	Pulido K	N3	Stockdale D	SP53	Wong R	SP22
Mei W	D5,P53	Pupo M	P55	Stoltz J	F5	Wong S	D1,D4
Melano R	P4	Purych D	A1,F6,SP8	Stone J	P23	Woods S	F5
Messier N	SP43	Quinn B	F5	Sumner J	E6	Woolven R	P25
Mihowich J	N3	Quinn C	P7	Suntres ZE	G3	Wootton S	P31
Milburn S	SP2	Ramazani M	L2	Surynicz K	SP9, P20	Xiao J	P54
Miller G	P73	Ramotar K	A4,P5,P81	Sutherland K	F2	Xiong JH	SP43
Miller M	P27	Rashid M	P52	Svoboda T	SP48	Yamamura D	F3, L3, SP26
Minion J	SP32	Rau N	SP23	Smith S	P35	Yassi A	P63
Mithani S	C1,P47	Rawte P	SP5,P1	Smith SW	P65	Yau Y	P29
Momenkhan I	SP11	Raymondo D	P6	Swidinsky K	P10	Yea C	D3,G1
Montaner J	H3	Reid J	P14, P41	Swinkels H	N2	Yebio B	P20
Moore D	M1	Reimer A	SP24,P56,P57	Sy E	P52	Yoshida E	H3
Morbey M	N2	Rekart M	SP46	Ta B	SP12	Yost CK	E4
Morgan N	F3, CVP1	René P	SP25	Tailor F	L3	Yu A	SP40
Morshed M	P15,P47,P48,P62	Rennie R	C3,L3, P18,P19,P28	Tamari I	P21	Yu S	P63
Moussa G	P80	Reyes R	SP2	Tan DHS	SP42	Zhanel G	A2,SP1, SP3,SP7, SP44, P21,P33
Moussa M	SP34	Reynolds R	SP11	Tan K	SP53		
Moyen E	F4,F5,H4,I2,SP44,P4, P34,P39,P52	Ricci G	F3	Tang P	SP10,P41	Zhang K	F4
		Ricciuto DR	CVP2	Tang W	C1,SP47,P23,P75,P78	Zhang R	I4
Mulvey M	E4, F2, F5, H4, I2, SP44, SP45, P21, P32, P33, P37, P42, P54	Richardson D	F3	Taylor D	SP39	Zoutman D	P27
Murray R	H4	Richardson S	SP31,SP42,P1, P29,P64,P80	Taylor G	N4,SP46		
Nadarajah J	SP27	Ritchie G	P34	Tee NWS	M1,SP32,SP55, P10		
Nagle E	P50	Robinson V	P52	Tellier R	P9		
Nagy C	SP19	Rodriguez-Maynez L	E6	Thibert L	D3,G1		
Namoccatcat S	P14	Rogaeva A	P77	Thomas E	SP25		
					P30		



# And the beat goes on...

This goes out to all those cool daddy-os...the coolest of the coolest event not to be missed!

david  
wills  
AND THE  
**DYNAMICS**  
with the Dynagroove Horns

**Date:** Saturday,  
March 1, 2008

**Location:** Grand Ballroom

**Time:** Reception  
Host Wine & Specialty Cocktail  
1900 – 1930

**Gala**  
Cash Bar  
1930 – 2300

**Price:** \$65 (+ GST)  
Buffet Style Dinner

Entertainment  
sponsored by

**SIEMENS**





## SPEAKERS BIOS

### Jane L. Burns, MD

Dr. Burns received her M.D. from the University of Washington in 1978. She did her residency training at Children's Hospital & Regional Medical Center in Seattle and was chief resident there in 1981. Her fellowship was also at Children's Hospital & Regional Medical Centre in Seattle and she studied antibiotic resistance mechanisms with Dr. Arnold Smith. She began her research interest in cystic fibrosis lung infections in 1985 and has published more than 80 research articles on cystic fibrosis. She is currently a Professor of Pediatrics and Clinical Director in the Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Washington. She also serves as the Director of the Cystic Fibrosis Microbiology Laboratory and Therapeutics Development Network Core Microbiology Laboratory at Children's Hospital & Regional Medical Center in Seattle.

### Michael A. Drebot, PhD

Dr. Michael Drebot received his PhD in microbiology in 1988 from Dalhousie University and was then awarded a postdoctoral fellowship in genetics from the Hospital for Sick Children (Toronto, 1988-1991). In 1991 he joined the National Centre for Enteroviruses in Halifax where he conducted research on the molecular biology of polioviruses and various enteric pathogens. In 1997, Dr. Drebot was appointed as Chief of Viral Zoonoses within the Zoonotic Diseases and Special Pathogens (ZDSP) section of the National Microbiology Laboratory and in 2007 also became the Director of the Science Technology and Core Services program. As well, Dr. Drebot is an assistant professor adjunct within the Medical Microbiology department, University of Manitoba.

The focus of his program has been to work with colleagues at ZDSP and national / international collaborators on carrying out reference diagnostic services, surveillance, and the establishment of applied and basic research programs for various zoonotic disease agents including: arboviruses (such as West Nile virus) and rodent-borne pathogens such as hantaviruses. Ultimately the information gained from these three core activities are used to better define the risk factors, geographic distribution and intervention strategies available to minimize human exposure to these pathogens. In addition, Dr. Drebot has recently established a program dealing with the identification and characterization of antiviral candidates that are currently being assessed both in vitro and in vivo using various animal models of pathogenesis.

### John Embil, MD FRCPC

Dr. Embil is a specialist in Infectious Diseases and Internal Medicine. He undertook his undergraduate medical training at Dalhousie University in Halifax, Nova Scotia, and Internal Medicine and Infectious Diseases at the University of Manitoba, in Winnipeg.

He is the Director of the Infection Prevention and Control Unit at the Health Sciences Centre, Winnipeg, Manitoba, Canada, and he sits on several Public Health Agency of Canada committees which focus on Infection Prevention and Control.

He is an Associate Professor in the Department of Medicine, Section of Infectious Diseases and Medical Microbiology at the University of Manitoba. Dr. Embil has published nearly 200 articles in the fields of Infectious Diseases, Infection Control, and infections in persons with diabetes. He specializes in the treatment of all infectious diseases. His research interests include the epidemiology of hospital acquired infections, blastomycosis and the pathogenesis and epidemiology of ulcerations in the lower extremities in persons with diabetes. Dr. Embil's research unit is also actively involved in the evaluation of new antimicrobial agents in clinical settings.

### Todd Hatchette, MD

Dr. Hatchette earned his MD from Memorial University of Newfoundland in 1995. Following Internal Medicine training at Memorial University and a Fellowship in Infectious Diseases and Medical Microbiology at Dalhousie University, Dr. Hatchette completed postdoctoral research training in virology at St. Jude Children's Research Hospital in Memphis Tennessee under the supervision of Dr. Robert G. Webster, a world authority on influenza A. He is currently the Director of the Virology and Immunology section of the Division of Microbiology, QEII Health Science Center, and is an Assistant Professor in the Department of Pathology with a cross-appointment in the Department of Medicine where he is a consultant Infectious Diseases. As the Province's only clinical virologist, Dr. Hatchette has expertise in the clinical and laboratory diagnosis of viral infections and has given CME lectures to various health care professional and serves as an advisor on a number of local and provincial committees. In particular he is involved quite heavily in Pandemic Influenza Planning Committees.

## SPEAKERS BIOS

### **Jim Hutchinson, MD FRCPC**

Dr. Hutchinson earned his MD degree at the University of Alberta in 1985. After residency training in Medical Microbiology at the U of A and University of Calgary, he became a faculty member at Memorial University of Newfoundland Medical School in 1994. During his tenure at Memorial Dr. Hutchinson has developed a large interest in antibiotic utilization in hospital and the community locally, nationally and internationally with focus on application of the World Health Organization's ATC classification for measuring and comparing antibiotic use. Dr. Hutchinson has been the regional Medical Director of the Infection Control Service since his arrival in St. John's. He is active on several national committees including the Canadian Hospital Epidemiologic Committee (CHEC), the directing body of the Canadian Nosocomial Infection Surveillance Program (CNISP) of Health Canada and is also Chairman of the board of directors of the Canadian Committee on Antibiotic Resistance (CCAR) — a federally funded body working actively to improve all aspects of antibiotic utilization in human's and food animals in Canada.

### **Dennis Kunimoto, MD FRCPC**

Dr. Dennis Kunimoto is Professor in the Department of Medicine at the University of Alberta, Medical Director at Edmonton TB Clinic, and Deputy Director, Division of Infectious Diseases at the University of Alberta in Edmonton. Dr. Kunimoto is very active on several national and provincial associations including the Alberta Society for Infectious Diseases where he served as a Past President; he was Former President of the ID Section for the Alberta Medical Association, and Former Treasurer and Councillor for the Canadian Infectious Diseases Society (CIDS).

He completed his Clinical Training in medicine in 1980 from the University of Alberta; he did then his internal medicine residency from 1981 to 1983 at the University of Alberta, and specialized in Infectious Diseases from the University of Manitoba from 1983 to 1985.

Dr. Kunimoto has published articles in nearly 61 publications, and 72 abstracts in the fields of Immunology and Molecular biology of *M. tuberculosis*. He completed his research training in Immunology & Molecular Biology in the United States from 1985 to 1988.

### **Mark Loeb, MD MSc FRCPC**

Dr. Mark Loeb is Professor in the Departments of Pathology and Molecular Medicine and Clinical Epidemiology and Biostatistics at McMaster University. He graduated from McGill Medical School in 1990, then completed fellowships in Internal Medicine, Infectious Diseases and Medical Microbiology at the University of Toronto and McMaster University, and an MSc in Clinical Epidemiology at McMaster in 1997.

Dr. Loeb's research interests include emerging infectious diseases, respiratory infections, antimicrobial resistance, and hospital epidemiology. He is Principal Investigator of an NIAID Population Genetics Research Program on West Nile Virus and a CIHR New Emerging Team on antibiotic use and resistance in seniors. He has led CIHR funded multidisciplinary teams on pneumonia and SARS and is conducting a CIHR funded cohort study on West Nile virus.

Dr. Loeb has served on numerous national and international advisory committees. He is Associate Editor, ACP Journal Club and Evidence-Based Medicine and is Co-editor of the first textbook on Evidence-Based Infectious Diseases. Recent honours include the 2006 Gold Medal for Medicine from the Royal College of Physicians and Surgeons of Canada and the Society for Healthcare Epidemiology of America Investigator Award.

### **Paul Mead, MD MPH**

Dr. Mead is a Medical Officer and Chief of the Epidemiology and Surveillance Activity, Bacterial Diseases Branch, Division of Vector-borne Infectious Diseases, CDC. Dr. Mead received his Medical Doctorate from the University of Colorado and a Masters of Public Health degree from University of California, Berkeley. After medical school he completed Internal Medicine Residency at Dartmouth Hitchcock Medical Center and an Infectious Diseases Fellowship at the University of California, San Francisco. Dr. Mead joined CDC in 1994 as an Epidemic Intelligence Service Officer in the Foodborne and Diarrheal Diseases Branch in Atlanta. He transferred the Division of Vector-borne Infectious Diseases in 2003 and currently works on Lyme disease, plague, tularemia, and tick-borne relapsing fever.

**Kurt G. Naber, MD**

Dr. Naber is Associate Professor of Urology at the Technical University of Munich School of Medicine and from 1975-2006, he was Head of the Urologic Clinic, St Elisabeth Hospital in Straubing, a teaching hospital of the Technical University of Munich, Germany.

In 1966, he received his Doctor of Medicine degree from the University of Munich School of Medicine. In 1971, he was a research fellow at the Department of Urology of the Veterans Administration Hospital in Madison, Wisconsin, USA. In 1973, he finished his training as urologist at the University Hospital of Marburg and received his PhD (Habilitation).

Dr. Naber was President of the Paul Ehrlich Society for Chemotherapy (PEG) in Germany, and of the Federation of European Societies for Chemotherapy and Infection (FESCI). He was the President of the 2nd European Congress of Chemotherapy 1998 in Hamburg, Germany. He is currently the President of the International Society of Chemotherapy (ISC) for Infection and Cancer (2005-2009) and he is Chairman of the UTI Commission of the ISC.

Dr. Naber is the author of more than 540 scientific articles and medical textbooks, and serves on the editorial board of several journals. He is a member of numerous societies, including the German, European and American Urological Associations (AUA), the PEG, the German Society for Infection, and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID).

His research interests include urological infections, especially the microbiology and pharmacokinetics of antimicrobials for the treatment of UTI and prostatitis.

**Richard O'Brien, MD**

Dr. Richard O'Brien received his Bachelor of Science degree in Chemistry from Wheeling Jesuit College and his Doctor of Medicine degree from West Virginia University School of Medicine. In 1970, following his internship in medicine at the University of Maryland Hospital in Baltimore, Dr. O'Brien joined the United States Public Health Service. He completed his residency in internal medicine and his pulmonary fellowship at Emory University in Atlanta and postgraduate training in epidemiology at the London School of Hygiene and Tropical Medicine. In 1979, Dr. O'Brien joined the CDC Division of Tuberculosis Elimination (DTBE). From 1991-1996, he was detailed to the WHO Global Tuberculosis Programme in Geneva. Following his return

to CDC, as head of the TB Research Branch, he expanded research on new TB diagnostics and oversaw the establishment of the TB Trials Consortium (TBTC) for therapy trials of new TB drugs. In January 2004, Dr. O'Brien joined FIND as Head of Product Evaluation. In this capacity, he has primary responsibility for pivotal clinical trials and registration of new TB diagnostics.

**Mario Raviglione**

Mario Raviglione was appointed Director of the Stop TB Department in 2003.

He joined the World Health Organization in 1991 as an Associate Professional Officer sponsored by the Italian Government, to work on TB/HIV and TB epidemiology in Europe. Later, he became responsible for setting up the global drug-resistance surveillance project and the new TB surveillance and monitoring system. Between 1999 and 2003, he was Coordinator for Tuberculosis Strategy and Operations globally, taking charge particularly of surveillance and programme monitoring; operational research on community and private practitioner involvement in TB control; TB/HIV interaction; multi drug-resistance TB management in developing countries; and DOTS expansion worldwide. Currently, as Director of the Stop TB Department of WHO, he is responsible for strategies and policies and works through a network of TB experts at all levels of the Organization.

He has had more than 150 articles published in influential health journals and books including TB chapters in the last three editions of Harrison's Principles of Internal Medicine. As a leading expert in TB, he has served as a visiting professor in various medical schools and also lectures at international health conferences on global TB issues. He has been a member of the Stop TB Partnership Coordinating Board since its establishment in 2001. He graduated from the University of Turin in Italy in 1980, and later trained in internal medicine and infectious diseases in New York (where he also was Chief Medical Resident at Cabrini's Medical Centre) and Boston, where he was appointed an AIDS Fellow at Beth Israel Hospital, Harvard Medical School. He has recently received the Princess Chichibu TB Global Award for his achievements in TB control.



## SPEAKERS BIOS

### **Stephen Shafran, MD**

Stephen Shafran received his MD from the University of Toronto. He trained in Internal Medicine at the University of Toronto and in Infectious Diseases at the University of British Columbia. After an initial academic appointment at the University of Saskatchewan in 1986-1989, he moved to the University of Alberta in 1989 where he has remained. He has held positions of Director of the Infectious Diseases Training Program and Director of Undergraduate Education for the Department of Medicine. Since 1998, he has held the position of Professor and Director, Division of Infectious Disease, Department of Medicine. He has served the Canadian Infectious Disease Society in several capacities, including as President. He presently chairs the Safety and Efficacy Review Committee of the Canadian HIV Trials Network. He was a member of the organizing committee of both the 2004 and 2007 Canadian Consensus Conference on the Management of Viral Hepatitis. He has received teaching awards from the students and residents from both the University of Saskatchewan and the University of Alberta. He has received the publication award from the University of Alberta Department of Medicine and an award from the American Society for Microbiology for the best abstract at ICAAC in the area of antiviral therapy. His research activities focus on clinical trials of antiviral agents. His clinical practice is focused primarily on HIV and chronic viral hepatitis, including coinfection. He also provides HIV and hepatitis care in two prisons in the Edmonton area.

### **Cécile Tremblay, MD FRCPC**

Cécile Tremblay is an Infectious Disease specialist/virologist at the Centre Hospitalier de l'Université de Montréal, Hôtel-Dieu Hospital, and Director of the AIDS Research and Clinical Care Unit at the C.H.U.M.. She is Associate Professor in the Department of Microbiology and Immunology of the University of Montreal. Dr. Tremblay obtained her M.D. at University of Montreal in 1992. She completed her residency in microbiology and infectious disease at University of Montreal, and received her certification from the Royal College of the Physicians of Canada in Medical Microbiology in 1997. Thereafter, she pursued a post-doctoral fellowship on HIV research at Massachusetts General Hospital/Harvard Medical School. Upon her return to Montreal in 2001, she has established a research laboratory which focuses on the study of HIV-1 genetic evolution and pre-clinical development of antiretroviral drugs with a specific interest in viral entry inhibitors. Recently, in collaboration with a group of investigators from Quebec, she set-up a cohort of HIV infected subjects with slow disease progression (long-term non progressors). Her research program also includes the study of HIV-1 viral reservoirs under various immunotherapeutic interventions, and collaborative research with investigators from developing countries to study drug resistance and facilitate the management of HIV infection. Dr. Tremblay is a CIHR new investigator.

## A SPECIAL INVITATION

*Dear Colleagues,*

*On behalf of the Local Organizing Committee, I would like to invite you to AMMI Canada - CACMID's 2009 Annual Conference to be held with the 26th International Congress of Chemotherapy (ICC) in Toronto, June 18-21, 2009. Mark your calendars and be there!*

*The next ICC will be a blend of original, cutting edge science as well as clinical and scientific reviews by leading authorities. It will bring together physicians and scientists from around the world. It will be a prime venue to showcase your new work and an excellent venue to learn and network.*

*Toronto in June is a warm and exciting city. It is a cosmopolitan centre with direct air connections to most major cities in Canada and around the world. It features first rate restaurants and theatres, and is convenient to attractions such as Niagara Falls.*

*For more information, visit our web-site: [www.icc-09.com](http://www.icc-09.com).*

*If you would like to be on our Email information list, contact us at [icc09@congresscan.com](mailto:icc09@congresscan.com)*

*We look forward to seeing you in Toronto!*

*Ray*

**Ray Saginur, MD**  
President – 26th ICC

**26<sup>th</sup> ICC 2009 Toronto!**  
JUNE 18 - 21, 2009

Where the World's Experts  
in Clinical Microbiology  
and Infectious Diseases Meet

**ISC**  
International Society of Chemotherapy  
1000 University Ave., Suite 1000  
Toronto, Ontario M5G 1R7  
Tel: 416-593-9200

**AMMI Canada**  
Canadian Association of Medical Microbiologists and Infectious Diseases  
1000 University Ave., Suite 1000  
Toronto, Ontario M5G 1R7  
Tel: 416-593-9200

**CACMID**  
Canadian Society for Clinical Infectious Diseases  
1000 University Ave., Suite 1000  
Toronto, Ontario M5G 1R7  
Tel: 416-593-9200

[www.icc-09.com](http://www.icc-09.com)

26th ICC - International Congress of Chemotherapy and Infectious Diseases  
Toronto, Ontario, Canada — Sheraton Centre Toronto Hotel



# VANCOUVER

SURROUNDED BY SPECTACULAR VIEWS OF WATER AND mountains, Vancouver is a bustling city nestled in a beautiful setting.

Catering to any interest throughout the year, visitors can enjoy Vancouver's world class shopping, gourmet meals, outstanding live entertainment, sporting events, theatre, and outdoor adventures.

Vancouver was voted the "Best City in the Americas" for 2004, 2005 and 2006 by Condé Nast Traveler magazine, based on the categories of ambience, friendliness, culture and sites, restaurants, lodging, and shopping. It's no wonder this city was chosen to host the 2010 Olympic & Paralympic Winter Games!

## ACCOMMODATION

Located in the heart of Vancouver, the Sheraton Vancouver Wall Centre Hotel is surrounded by boutiques, outdoor markets, clubs, art galleries and theatres, along with a wide variety of local and international dining choices. In addition to spectacular views, the hotel offers a health club, pool, and spa. Guestrooms include high speed Internet, fax/data ports, in-room movies, personal voicemail, and multi-line telephones.



**Sheraton Vancouver  
Wall Centre Hotel**  
1088 Burrard Street  
Vancouver, British Columbia  
V6Z 2R9  
Phone: 604-331-1001  
Fax: 604-893-7200  
Reservations: 800-325-3535  
[www.sheratonvancouver.com](http://www.sheratonvancouver.com)



## RESTAURANTS AND BARS

There is a wide variety of dining and entertaining spots within the venue.

The casual Indigo Bar offers a tempting array of favourite malts and local brews, while Indigo Bistro Moderne serves a fresh seasonal menu in a playful, upbeat setting. Café One allows you to indulge in fine West Coast inspired cuisine with flare, while Bar One is ideal to relax with friends and satiate your palate with fine wines, single malt scotches and signature martinis.

There is also a Starbucks located on the lower level of the hotel.



**To find out what Vancouver holds in  
store for you, visit Tourism Vancouver at  
[www.tourismvancouver.com](http://www.tourismvancouver.com).**



# EDUCATION GRANTS

## AMMI CANADA ASSOCIATE MEMBERS

Financial support from industry allows AMMI Canada to offer educational grants to its Associate Members only (\$CAD).

**\$250** for Associates attending from British Columbia and Washington State

**\$500** for Associates attending from Alberta and Saskatchewan

**\$750** for Associates attending from Manitoba, Ontario, Quebec, NWT, Nunavut, Yukon, PEI, Newfoundland, New Brunswick, Nova Scotia and the USA.

**NB:** Associates attending from the city of Vancouver are ineligible for grants.

In order to apply for a grant, you must be an AMMI Canada Associate Member in good standing. You must register for the full conference, pay the registration fee, sign-in on site and submit a grant application form after the conference to the AMMI Canada Secretariat.

## CACMID EDUCATION GRANTS FOR TECHNICAL STAFF

### Eligibility

Applicants must be microbiology laboratory technologists or technicians and Active Members of CACMID. Each applicant is eligible for only one grant. To be eligible, the applicant must be the first author of the abstract and must be its presenter in an oral or poster session at the AMMI Canada – CACMID Annual Conference 2008.

### Application

An education grant application form will be available to those eligible at the registration desk during the conference or it can be downloaded from the CACMID website ([www.cacmid.ca](http://www.cacmid.ca)). This form is to be completed after the conference and either deposited at the registration desk or mailed to the CACMID Secretary Treasurer.

### Reimbursement (\$CAD)

**\$250** British Columbia and Washington State

**\$500** Alberta and Saskatchewan

**\$750** Manitoba, Ontario and Quebec

**\$1000** Nova Scotia, PEI, Newfoundland, New Brunswick, NWT, Nunavut, Yukon, and International.

**NB:** Technical staff attending from the city of Vancouver are ineligible for grants.

## Are you a member?

### To join AMMI Canada please contact:

Dr. Joanne Langley  
Secretary

c/o

Kimberley Wannamaker  
Administrative Assistant

101-298 Elgin Street

Ottawa, ON K2P 1M3

Tel: 1-866-467-1215 (toll free)

613-260-3233 x103

Fax: 613-260-3235

### For more

information on AMMI Canada  
please visit: [www.ammi.ca](http://www.ammi.ca)

### To join CACMID please contact:

Dr. Astrid Petrich  
Secretary and Treasurer

St Joseph's Healthcare

St Luke's Wing

Rm. L424

50 Charlton Ave. E.

Hamilton, ON L8N 4A6

Tel: 905-522-1155 x33270

Fax: 905-521-6083

### For more


information on CACMID  
please visit: [www.cacmid.ca](http://www.cacmid.ca)



# FLOOR PLANS


## LEVEL FOUR

North Tower




## LEVEL THREE

South Tower




## LOWER LOBBY LEVEL

North Tower




## GRAND BALLROOM LEVEL

North Tower



## LEVEL THREE

North Tower





WHERE CANADA'S EXPERTS IN CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES MEET  
POINT DE RENCONTRE DES EXPERTS CANADIENS EN MICROBIOLOGIE MÉDICALE ET INFECTIOLOGIE

AMMI Canada and CACMID are very grateful  
for the generous financial support of:

(Sponsors as of time of printing)

PLATINUM



*Life is our life's work*



GOLD



SILVER



BRONZE



COPPER




ZINC

Diagnostics



PATRON



VANCOUVER 2008